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Bovine pancreatic ribonuclease (RNase A) and its homologues are pyrimidine-
specific ribonucleases widely present in mammals, birds, amphibians, reptiles, 
and fish. RNases recognise a specific sequence – an adenosine 3' to a 
pyrimidine – on RNA, and cleave the molecule on the 3' side of the 3'-
phosphate of the pyrimidine base. Extensive studies have been carried out on 
the RNase A homologues, including eosinophil-derived neurotoxin (EDN; 
RNase 2), eosinophil cationic protein (ECP; RNase 3), and angiogenin (ANG; 
RNase 5), and revealed distinct biological functions: EDN and ECP are 
involved in neurotoxicity, and ANG possesses angiogenic activity. RNase 4, 
although being discovered for a long time, is not as well characterised as much 
as other RNases.  
 
RNase 4 has been found in several mammalian species including a few primates, 
porcine, bovine, and rodents. The mature protein of RNase 4 consists of 119 
amino acids, making it the shortest amongst all RNase A homologues. It has a 
higher inter-species similarity than its homologues, and such high evolutionary 
conservation suggests that RNase 4 has a more specialised function than RNA 
degradation. While RNase A, EDN, ECP, and ANG show cytidine preference, 
RNase 4 has a strong preference for uridine, which can be reversed back to 
cytidine by a single amino acid substitution of Asp-80, as shown by studies 
performed with porcine RNase 4 (also known as PL3).  
 
In this study, we used PL3 as a model to study the substrate specificity of RNase 
4, and have solved four structures, including PL3, PL3 D80A mutant, and these 
two proteins in complex with dUMP and dCMP respectively. PL3 adopts the 
classic kidney-shaped RNase A fold, and residues forming the substrate binding 
subsites occupy similar positions as those in human RNase 4 and the prototypic 
RNase A. The structure of PL3 D80A mutant resembles that of the wild type 
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PL3, and only hydrogen bond interactions between the side chains of Asp-80 
and Arg-101 are lost. 
 
The structure of PL3·dUMP complex revealed interactions between the dUMP 
and residues Arg-7, His-12, Thr-44 and Phe-117 of PL3, which were also 
observed in the structure of human RNase 4 in complex with dUp. The 
additional hydrogen bonds identified between dUMP and residues Gln-11, Lys-
40, Asn-43, and Lys-119 of PL3, as well as the absence of the interactions 
between Arg-101 of PL3 and the ligand that were present in the hRNase 4·dUp 
structure, could be due to the flexibility of the mononucleotide ligand.  
 
The crystal structure of PL3 D80A·dCMP complex presents a small number of 
hydrogen bond interactions between the protein and the dCMP ligand, which 
might be sufficient to stabilise the ligand in the B1 subsite, as the repulsion 
force on the dCMP ligand from the side chain of Arg-101 is absent in the PL3 
D80A mutant. This is because in the D80A mutant, Ala-80 cannot provide 
hydrogen bonding that would hold the side chain of Arg-101 towards the B1 
subsite.  
 
The activities of RNases can be inhibited by a 50 kDa cytosolic protein, the 
natural ribonuclease inhibitor (RI). RI binds to all the members of the RNase A 
superfamily, thus regulating the cytoplasmic RNA levels and protecting cells 
from inappropriately secreted RNases. The interactions between RNase and RI 
are tight, reversible, and in a 1:1 ratio. Several complex structures of RNase·RI 
from various species have been determined, and the residues in the interfaces 
between RNase and RI are conserved in all of the complexes. Studies revealed a 
17-fold tighter interaction between PL3 and human RI than RNase A, making it 
very interesting to study the structure of the PL3·RI complex and characterise 




To date, we have established purification protocols for both proteins, and the 
next step towards the structure of PL3·RI would be to prepare and purify the 
protein complex, subject the protein complex to crystallisation experiments, and 
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X-ray crystallography refers to the experimental science of the determination 
and analysis of three-dimensional structures of molecules. Max von Laue in 
1912, William L. Bragg and William H. Bragg in 1913 first shed light on X-ray 
diffractions of crystals (Bragg, 1914), and were recognized by Nobel Prizes in 
Physics in 1914 and 1915. A century later, to commemorate the enormous 
successes of crystallographic researches that had been achieved in almost every 
branch of science, the United Nations announced 2014 to be “the International 
Year of Crystallography”. 
 
The importance of X-ray crystallography in the area of Biochemistry is best 
reflected by its impact on the determination of macromolecule structures. After 
the intensive studies done on genomics, proteomics has become the next step in 
the study of biological systems. Proteins are the fundamental macromolecules 
of an organism and play crucial roles in biological processes. Interactions 
between proteins and other biomolecules have been identified in many cellular 
events, to name a few: cell growth and proliferation, differentiation and 
migration, structural and mechanical support, host immune defence, energy and 
nutrients storage, and enzymatic catalysis. The functions of proteins are defined 
by their physical features, thus the determination of protein structures is 
important and necessary for researchers to understand biological processes at 
the molecular level.  
 
In protein crystallography, the protein sample can either be obtained from other 
manufacturers, or be produced in one’s own laboratory. The production of 
protein often involves molecular cloning of the gene of interest, protein 
expression, and purification. The protein sample is crystallised and used in the 
collection of X-ray diffraction data of the crystals. The diffraction data are 
processed with the aid of computational programmes from where the three-
dimensional structure of a protein may be solved (Figure 1.1). This chapter will 
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discuss in general the methodologies involved in the determination of protein 
structures. 
 
Figure 1.1. Steps involved in protein structure determination using X-ray crystallography. 
 
1.2 Molecular cloning 
Molecular cloning refers to the experimental methods that researchers use to 
isolate the DNA sequence of interest from an organism, combine it into a small 
DNA molecule also known as a vector, and transfer the recombinant DNA 
molecule into a host cell where the DNA of interest can be expressed. 
Molecular cloning methods have a very wide application in modern 




The first step to a successful construction of a protein expression system is the 
identification and isolation of the DNA sequence of target protein. By the use of 
bioinformatics databases, the DNA sequence of target protein can be obtained 
and analysed. First, the DNA sequence of the target protein needs to be isolated 
from the chromosomal DNA and amplified by Polymerase Chain Reaction 
(PCR). The PCR product is subsequently treated with restriction endonuclease 
enzymes to create sticky ends or blunt ends; such treated DNA fragments are 
also known as inserts. In parallel, a selected DNA vector, often with additional 
features to ease subsequent purifications (such as affinity tags) and/or aid a 
better solubility (such as MBP-tag and Trx-tag) (Malhotra, 2009), is treated 
with the same enzymes to create a linear vector with complementary ends to 
those of the insert. The insert and linear vector are ligated with the presence of 
DNA ligase to produce a recombinant DNA molecule. This most common 
method was developed in early 1970s (Jackson et al., 1972; Cohen et al., 1973; 
Lobban and Kaiser, 1973), and more creative cloning techniques to assemble 
recombinant DNA molecules have been developed through the years. One of 
such techniques, ligation-independent cloning (LIC), was used in this project.  
 
In LIC cloning, no restriction endonucleases or DNA ligase are required, the 
creation of sticky ends is solely fulfilled by the 3’ to 5’ exonuclease activity of 
T4 DNA polymerase in the presence of dATP. Insert and linear vector with 
complementary sticky ends are mixed to allow annealing. The product – the 
annealed recombinant DNA plasmid – can be used in the subsequent 
transformation or transfection of host cells. 
 
1.3 Protein expression 
The recombinant DNA molecules need to be transfected into an appropriate 
host to aid protein expression. The choice of the host, also known as the 




If post-translational modifications (PTMs), such as glycosylation and 
phosphorylation, are required for the correct folding and activity of the 
recombinant protein, a eukaryotic expression system should be used. Yeast cells 
(for example Saccharomyces cerevisiae), insect cells, and mammalian cells are 
suitable candidates for this purpose. If these modifications are not required, a 
bacterial expression system will be the best choice, with Escherichia coli (E. 
coli) being the most commonly used amongst all.  
 
Often, the gene of the protein is carried into E. coli cells by an expression 
vector with a T7 promoter, and the protein expression is induced by the addition 
of a synthetic analogue of lactose, isopropyl-β-D-1-thiogalactopyranoside 
(IPTG). IPTG is able to initiate the transcription of the T7 gene that is anchored 
in the genome of E. coli, and the T7 RNA polymerase produced will start the 
transcription of the expression vector, hence the target gene. The T7 RNA 
polymerase is so selective that almost all the resources of the cells will be 
utilised in the expression of the protein of interest, resulting in a high yield of 
the protein within a few hours of induction.  
 
1.4 Protein purification 
Protein purification refers to the process of isolating the target protein from a 
natural source or a recombinant expression system. In protein crystallography, 
impurities often impede crystal growth. Although there is no clear cut on the 
requirement for the purity of protein samples, ~95% purity, represented by a 
single band on a well-loaded SDS-PAGE gel, is often considered to be a good 
starting point for protein crystallisation (Rupp, 2010).  
 
If the target protein is an extracellular protein, the tissue fluid or the supernatant 
of expression medium can be directly subjected to purification columns. 
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However, if the protein is expressed intracellularly, whether it is from a natural 
or a recombinant source, the first step in protein purification is to disrupt the 
cells and release the protein into solution. Cell disruption can be achieved either 
by physical force (namely mechanical disruption, liquid homogenisation, 
sonication, repeated freeze/thaw, and manual grinding) or the use of chemical 
cell lysis reagents. The choice of the technique mainly depends on the fragility 
and stability of the protein, and the amount of sample to be processed. If the 
protein of interest is soluble, it will be present in the supernatant after the 
centrifugation of the cell lysate; if the protein is in its insoluble form, also 
known as inclusion bodies, it will have to be solubilised and refolded prior to or 
during purification. 
 
Protein purification usually involves one or a few chromatographic techniques. 
In general, the sample containing the target protein is flowed through a column 
packed with materials designed for a specific type of chromatography. The type 
of chromatography used is dependent on the properties of the target protein 
being exploited, and is chosen so that the target protein interacts with the 
column material differently from other macromolecules, which leads to its 
separation from the mixture. Commonly used chromatographic techniques and 
the properties they are based on are listed in Table 1.1. Most of the listed 
chromatography techniques were employed in this study and will be discussed 
briefly below. 
 
Table 1.1 Chromatographic techniques commonly used in protein purification.  
Property Chromatographic techniques 
Charge Ion exchange chromatography 
Ligand specificity Affinity chromatography 
Hydrophobicity 
Hydrophobic interaction chromatography 
Reverse phase chromatography 
Size Size exclusion (also known as gel filtration) chromatography 
 
Ion exchange chromatography separates proteins based on their net surface 
charges (Figure 1.2a). The net surface charge of a protein molecule varies 
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according to the surrounding pH. If the pH is higher than the isoelectric point 
(pI) of the protein, the protein is net negatively charged, and will bind to a 
positively charged column (anion exchange column); if the pH is lower than its 
pI, the protein is net positively charged, and will bind to a negatively charged 
cation exchange column. Bound protein can be eluted either by altering the 
surrounding pH, or by increasing the ionic strength of the system.  
 
 
Figure 1.2. Separation principles of ion exchange chromatography and affinity 
chromatography. (a) In an anion exchange column, only negatively charged proteins bind 
to the positively charged column; (b) In an affinity column, only proteins with specific 
recognition towards the ligands bind to the column. 
 
Affinity chromatography is a very popular protein purification method. It traps 
target protein by specific biointeractions (Figure 1.2b). As mentioned in Section 
1.2, the chosen vector often adds additional features to the protein that enable 
the biointeractions to occur. These features are known as fusion tags, and they 
provide the recombinant protein with a specific ligand-binding affinity. 
Common tags include poly-histidine tag (His-tag), glutathione S-transferase tag 
(GST-tag), maltose binding protein tag (MBP-tag), and S-tag to name a few. 
 
Once highly purified protein sample is obtained, the fusion tags can be cleaved 
off from the protein by a specific protease, whose cleavage site is engineered in 
between the tag and the protein (Wilchek and Chaiken, 2000). If the target 
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protein is known to have a high-affinity binding partner that can be used to coat 
the matrix of the affinity column, it can be expressed without tags. Since the 
recombinant protein is usually the only one in the crude sample with the ligand 
binding affinity, the separation of the target protein with high purity can be 
achieved in a single step.  
 
Both hydrophobic interaction chromatography and reverse phase 
chromatography separate proteins according to their hydrophobicities (Figure 
1.3). In hydrophobic interaction chromatography, protein samples are loaded 
onto a column in a buffer with high salt concentration. The high salt 
concentration drives the interactions between the hydrophobic proteins and the 
alkyl- derivatised stationary phase. By gradually lowering the salt concentration, 
proteins can be eluted in order of hydrophobicity.  
 
Reverse phase chromatography utilises a more hydrophobic stationary phase, 
thus requiring organic solvents such as acetonitrile or methanol to elute the 
proteins. Most commonly, reverse phase chromatography is combined with 
high-performance liquid chromatography (HPLC), where a high pressure is 
applied to drive solutions move more quickly through the column to improve 
resolution (Regnier, 1983).  
 
Figure 1.3. Separation principles of (a) hydrophobic interaction chromatography and (b) 




Size exclusion chromatography, also known as gel filtration chromatography, 
separates protein samples based on their molecular weights (Porath and Flodin, 
1959; Eisenstein, 2006) (Figure 1.4). The matrix of a size exclusion column is 
made of porous particles, to which proteins do not bind but travel through. 
Large proteins can only travel through the spaces between the particles thus 
elute first, whereas small proteins can penetrate every region of the matrix and 
elute late. One advantage of size exclusion chromatography is that the buffer 
composition can be varied to suit the requirements for further purifications or 
analysis without altering protein separation. Because of this, size exclusion 
chromatography is often considered to be the final polishing step of protein 
purification. 
 
Figure 1.4. Separation principle of gel filtration chromatography. 
 
The purity of a purified protein is analysed by sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE), and its concentration can be 
determined by means of Bradford assay or absorbance of light at 280 nm. 
Biophysical (such as circular dichroism analysis, dynamic light scattering 
analysis, and mass spectrometry analysis) and biochemical characterisations of 
the protein should be performed to confirm the purified protein is mature, 
homogeneous and functionally active. If necessary, lyophilisation or 
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ultracentrifugation can be applied to the purified protein to obtain a more 
concentrated sample for subsequent protein crystallisation trials. 
 
1.5 Protein crystallisation 
In order to obtain diffraction data, the protein must be crystallised first. 
Crystallisation occurs when the concentration of the protein is greater than its 
solubility at that specific temperature, which is known as the supersaturation 
state. It is a non-equilibrium state and has a tendency to re-establish equilibrium 
by the formation and development of a solid state such as crystals (McPherson, 
2004). In principle, two major events happen during protein crystallisation: 
nucleation of the crystal, and crystal growth. Nucleation is a process where 
protein molecules aggregate into ordered and stable clusters in the current 
environment that serve as the nuclei. Crystal growth is the subsequent 
aggregation of protein molecules to the nuclei, during which the solid state 
becomes more attractive than the solution state (Figure 1.5).  
 
Figure 1.5. A phase diagram of crystallisation process. The precipitant represents the 




Although the principle of protein crystallisation is similar to that of the 
crystallisation of small molecules, it is more complicated in practice. There are 
various factors that can affect crystal growth, including  purity and 
concentration of protein,  buffer systems,  pH,  types and concentrations 
of salts and precipitants,  organic solvents,  detergents, and temperatures. 
Despite the huge amount of research done on protein crystallisation, it is still 
impossible to predict the perfect crystallisation condition for a protein. 
Hundreds or even thousands of conditions with various combinations of the 
factors mentioned above may need to be screened to identify the preferred 
conditions for crystallisation of a protein. Such screenings are often performed 
using pre-made, commercially available screens and are set up using automated 
crystallisation robots. Once initial hits are obtained, more subtle variations of 
the conditions can be made to optimise crystal growth. 
 
1.5.1 Methods of protein crystallisation 
There are three common methods of protein crystallisation: vapour diffusion, 
batch crystallisation and dialysis. The vapour diffusion method was used in this 
project, combined with a technique named seeding. 
 
1.5.1.1 Vapour diffusion 
Vapour diffusion is the most widely used method to produce protein crystals. A 
drop containing a mixture of protein and the crystallisation cocktail/precipitant 
is held together with the reservoir in a closed chamber. Since the precipitant is 
at a higher concentration in the reservoir than in the drop (adding the protein 
sample into the drop dilutes the precipitant), water (sometimes organic solvents) 
diffuses from the drop into the reservoir solution in order to reach equilibrium. 
As a result, the protein solution is gradually brought to supersaturation, where 
crystallisation occurs (Figure 1.6). The advantage of vapour diffusion method is 
that it is a reasonably slow process; therefore the system gradually reaches the 
nucleation zone rather than being quickly driven into the precipitation zone. 
This method is well suited for small sample volumes (0.05 – 2μl). The hanging 
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and sitting drop methods are frequently used techniques for crystallisation by 
vapour diffusion (Figure 1.6).  
 
Figure 1.6. A schematic representation of the most common vapour diffusion methods for 
protein crystallisation. (a): Hanging drop method; (b): Sitting drop method. 
 
Seeding 
Seeding is a technique where a small crystal seed is transferred into a pre-
equilibrated drop to allow free protein molecules in the solution to deposit on 
the surface of the seed and grow large crystals. The introduction of a crystal 
seed reduces random intermolecular interactions and drives such interactions to 
a more ordered form. Commonly, seeding can be achieved by two methods: 
micro-seeding and macro-seeding. In the former method, a dilution series of 
broken fragments of protein crystals is prepared and a portion of the diluted 
solution is added to a new crystallisation drop; in the latter method, a single and 
well-formed crystal (that is too small to directly collect data from) is used as 
seed. In both methods, the new crystallisation drop should be pre-equilibrated 
and the protein should be at a slightly lower concentration than the sample used 




1.5.1.2 Batch crystallisation 
Batch crystallisation is the classic technique of protein crystallisation. 
Relatively high concentrations of protein and crystallisation solution are mixed 
together so that supersaturation is reached immediately.  Batch crystallisation is 
simple to perform, and the development of micro-batch method allows the use 
of small sample volumes. 
 
1.5.1.3 Dialysis 
In dialysis, the protein solution is separated from the crystallisation solution by 
a semi-permeable membrane, which allows water and small molecules to be 
freely exchanged and at the same time prevents protein molecules from 
circulating. Although large volumes of protein samples are required, dialysis 
often gives rise to large crystals. 
 
1.6 Crystals and symmetry 
A crystal is a periodical arrangement of a regular repeating unit in all three 
dimensions. This repeating unit is known as the unit cell, and represents the 
basic building block of the crystal, from which the whole crystal can be built 
(Figure 1.7). A unit cell is defined by its three edges designated as a, b, and c, 
as well as three angles α (the angle between b and c), β (the angle between a 





Figure 1.7. Diagrammatic representation of the dimensions and angles of a unit cell 
(shaded grey), as well as the arrangement of unit cells in a crystal.  
 
Based on the type and property, a crystal can be grouped into one of the seven 
crystal systems (Blundell and Johnson, 1976; Blow, 2002; Rupp, 2010) (Table 
1.2). These seven systems are primitive lattices (designated by letter P), 
containing one point at each corner of the unit cell. In addition to these seven 
primitive lattices, Bravais discovered another seven non-primitive lattices. 
These non-primitive lattices can be categorised into three types: if there is an 
extra lattice point in the centre of the unit cell in addition to the points at the 
corners, it is classified as body centred and designated by letter I. If the cell has 
two extra lattice points in the centre of one pair of opposite faces, or in the 
centre of all lattice faces, it is classified as face centred, and designated by letter 
C or F respectively (Table 1.2). The seven primitive lattices together with the 
seven non-primitive lattices are called Bravais lattices (Blundell and Johnson, 
1976; Blow, 2002; Rupp, 2010).  
 
There are four types of symmetry operators in general: rotation, translation, 
mirror plane, and inversion, and the combination of these symmetry operators 
forms 32 crystallographic point groups. The 14 Bravais lattices together with 
the 32 point groups give rise to 230 space groups. For asymmetric, chiral 
molecules such as proteins, it is necessary to maintain their handedness, which 
eliminates mirror plane and inversion operations, resulting 65 chiral space 
groups (Blundell and Johnson, 1976; Rupp, 2010). 
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a ≠ b ≠ c 
α ≠ β ≠ γ ≠ 90° 
P None 
Monoclinic 
a ≠ b ≠ c 
α = γ = 90°, β ≠ 90° 
P 
C 
2-fold rotation axis 
parallel to b 
Orthorhombic 
a ≠ b ≠ c 






intersecting 2-fold axes 
Tetragonal 
a = b ≠ c 
α = β = γ = 90° 
P 
I 
4-fold rotation axis 
parallel to c 
Trigonal 
a = b ≠ c 
α = γ = 90°, β = 120° 
P 
3-fold rotation axis 
parallel to c 
Hexagonal 
a = b ≠ c 
α = γ = 90°, β = 120° 
P 
6-fold rotation axis 
parallel to c 
Cubic 
a = b = c 




Four 3-fold axes along 
space diagonals 
 
1.7 Data collection 
1.7.1 Cryo-protection of protein crystals 
Protein diffraction data collection is now routinely carried out under cryogenic 
conditions. This reduces radiation damage to the crystal, allows a complete 
dataset to be collected from a single crystal, and in turn lowers systematic errors 
and improves data quality (Rodgers, 1994). In cryo-crystallography, a protein 
crystal is mounted onto a litho-loop, flash-frozen with and kept in liquid N2 
until data collection. To prevent the formation of crystalline ice during flash 
cooling, one or more species of cryo-protectant is added to the drop prior to 
crystal mounting. In general, there are two types of cryo-protecting agents:  
cryo-protectants such as glycerol and ethylene glycol, can penetrate into the 
solvent channels of crystals, preventing the formation of crystalline ice;  
cryo-protectants, for example oil, that do not travel into the crystal but act as a 
barrier between the crystal and the surrounding environment (Garman and 
Owen, 2007). Some common cryo-protectants include glycerol, ethylene glycol, 
polyethylene glycol (PEG), methylpentanediol (MPD), and certain lithium and 




1.7.2 Diffraction data collection 
Flash-cooled protein crystals are now ready to be exposed to an X-ray source 
for data collection, which can be completed with either in-house X-ray sources 
or synchrotron radiation sources. In-house X-ray sources produce X-rays by 
bombarding high velocity electrons onto a metal target in vacuum. Copper is 
commonly used in the generation of X-rays, with a wavelength of 1.54 Å. If 
shorter wavelengths are required, molybdenum (wavelength = 0.71 Å) can be 
used (Blundell and Johnson, 1976). In-house X-ray sources are convenient to 
use; however, the intensity of the emitted beam is very low and diffraction 
images have to be recorded for a very long time. Nowadays, synchrotron 
radiation sources are more routinely used for X-ray diffraction data collections. 
 
In a synchrotron, electrons are produced in an electron gun, accelerated in a 
linear accelerator, boosted in energy, and fed into the storage ring. The 
electrons are forced to the circular orbit by a series of bending magnets. These 
magnets cause the electrons to lose energy in the form of light, which can be 
channelled out of the storage ring and into the experimental stations (Figure 
1.8). Synchrotron sources offer a wide range of wavelengths for different 
experiments, and thanks to the high-energy X-ray beams, diffraction data with 
high signal-to-noise ratio can be collected with shorter exposure times. 
 
1: electron gun 
2: linear accelerator 
3: booster 
4: storage ring 
5: beamline 
6: experimental stations 









1.8 Principles of X-ray diffraction 
More than 100 years ago, William Lawrence Bragg and William Henry Bragg 
proposed a theory that has now become the fundamental basis of X-ray 
crystallography (Bragg, 1914; Bragg, 1924). This is Bragg’s law, and refers to 
the simple equation:  
          
The Braggs modelled the crystal as a set of parallel planes that are defined by a 
set of indices (h k l), the Miller indices. These parallel planes are separated by a 
distance d. For two incident X-rays with an incidence angle θ to be still in phase 
after scattering, the extra distance travelled by the second wave must equal one 
or multiples of its wavelength that is denoted as nλ, where n is an integer 
(Figure 1.9). Such in phase waves would constructively interfere and produce a 
strong diffraction maximum.  
 
Figure 1.9. A schematic representation of Bragg’s Law. 
 
The structural information that one can obtain from X-ray diffraction data 
depends on the resolution of the data. Resolution is defined as the minimum 
interplanar spacing d for a particular set of X-ray diffraction intensities. The 
higher the resolution, the smaller the spacing, and the more detailed and 
accurate the structure is. Table 1.3 shows the level of detail of a structure one 




Table 1.3. Relationship between resolution and structural information obtained. 
Resolution Structural information obtained 
6.0 Å 
The outline of the molecule, the quaternary structure or the domain 
arrangement of a macromolecule can be resolved. Sometimes the 
secondary structures (α-helices and β-strands) are visible. 
3.0 Å 
Course of the polypeptide chain is traceable; the topology of the protein 
can be established. The side chains of residues can be built into the 
model with the aid of amino acid sequence. 
2.0 Å 
Main chain conformations of the molecule can be unambiguously 
established. Conformations of side chains, some bound water molecules 
or solvents are recognisable. 
1.5 Å Individual atoms are almost resolved. 
1.0 Å 
Hydrogen atoms may become visible; alternative conformations of side 
chains may become visible. 
 
The term structure factor (denoted as Fhkl) describes the resultant wave from all 
scattered waves produced by all atoms in the unit cell. For a unit cell containing 
j atoms, the structure factor is expressed as: 
         




The main objective of X-ray crystallography is to determine         , the 
electron density for all x, y, z coordinates in the unit cell. The electron density 
is the Fourier transformation of structure factors, and can be expressed as:  
         
 
 
         
 
                    
  
 
where V is the volume of the unit cell, (x, y, z) are the grid position coordinates, 
and h, k, l are the Miller indices. 
 
The amplitude of the structure factors        are directly related to the diffracted 
intensities:         
  therefore can be obtained directly from the experimental 
data. However, the phase of the structure factors      cannot be recorded, and is 
lost during data collection, without which the electron density map of the 
structure cannot be built. This is known as the phase problem. There are several 
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methods available for overcoming the phase problem, such as molecular 
replacement (MR) (Rossmann and Blow, 1962), isomorphous replacement (IR) 
(Green et al., 1954), and anomalous diffraction (Hendrickson, 1991). 
 
The raw diffraction data are processed with softwares to determine the space 
group and the unit cell parameters of the crystal, and to index, integrate, scale, 
and merge the reflections. The quality of the merged data can be assessed by 
the linear merging R-value Rmerge: 
       
                     
            
 
where        is the average intensity of each reflection. A good set of 
diffraction data should have an Rmerge value of ~4–5%; however, one needs to 
bear in mind that it is not the most useful indicator, as it does not take the 
redundancy of the diffraction data into account (lower redundancy will give 
lower Rmerge) (Wlodawer et al., 2008; Rupp, 2010). The signal-to-noise ratio 
(SNR)         provides an estimate for the usefulness of the data: usually 
the diffraction limit is set to a resolution where the SNR drops below 2.0. The 
redundancy and completeness are also useful indicators of the quality of the 
diffraction data. In principle, both high redundancy and high completeness are 
desirable, as the former improves the quality of the merged data, whereas the 
latter reduces the noise level and enhances the interpretability of calculated 
maps (Wlodawer et al., 2008; Rupp, 2010). 
 
Once the phases are obtained, an initial molecular model can be built into the 
calculated electron density map with the help of the amino acid sequence as 
well as any known structural characteristics of the target protein. The initial 
model is far from perfect, and it needs to be refined to improve the agreement 
between the experimental diffraction data and the calculated phases. The quality 
of the model is measured by calculating the R-factor, a measure of the level of 




                    
          
 
where |Fobs| is the amplitudes of the observed structure factor, and |Fcalc| is the 
amplitudes of the calculated structure factor of the model.  
 
The higher the agreement between the observed and calculated amplitudes, the 
closer the R factor is towards zero. However, the R-factor can be made small by 
increasing the number of model parameters, which would over-fit the 
diffraction data and result in a model that is physically incorrect (Rupp, 2010). 
To overcome this bias, an additional factor called Rfree is introduced (Brünger, 
1992). Rfree is calculated the same way as the R-factor using 5-10% of the total 
reflections that are excluded from refinement. Any over-fitting of the model is 














Chapter 2. Introduction to the ribonuclease A 





Early molecular biology studies revealed that biological information is stored in 
deoxyribonucleic acid (DNA) and fulfilled by proteins, with ribonucleic acid 
(RNA) serving as the link between these two types of molecules (Crick, 1970).  
                  
The essential flow of information through RNA is controlled by its synthesis or 
degradation. This involves two classes of enzymes. RNA polymerases catalyse 
the synthesis of RNA, whilst RNA degradation is achieved by the activities of 
RNA depolymerases, most commonly known as ribonucleases (RNases) 
(Raines, 1998).  
 
RNases catalyse the cleavage of the phosphodiester (P-O
5'
) bond of RNA, and 
depending on the binding position on the RNA molecule, RNases can be 
subcategorised into exo- and endo-ribonucleases. Exoribonucleases, for 
instance RNase D, carry out RNA degradation by removing nucleotides at 
either the 5' or the 3' end of the RNA molecule. In contrast, endoribonucleases, 
such as RNase A and RNase P, catalyse the cleavage of phosphodiester bonds 
within a polynucleotide RNA chain (Gegenheimer and Apirion, 1981).  
 
RNases are involved in the degradation of many RNA species, including the 
three most abundant RNA species in all organisms: ribosomal RNA (rRNA), 
messenger RNA (mRNA), and transfer RNA (tRNA). RNases have been found 
in all kingdoms of life, from microorganisms to mammals, demonstrating the 
importance of RNA regulation in cellular processes in all organisms. 
 
Extensive studies on RNases have provided researchers with extensive 
knowledge regarding their evolution, catalytic mechanisms, structures, and 
cellular functions. Interestingly, recent studies have also revealed special 
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biological properties of some RNases, such as cytotoxicity, the ability to induce 
and promote angiogenesis and neurogenesis, and roles in host defence. These 
make them potential targets for novel therapeutic agents. In this regard, our 
knowledge of bovine pancreatic ribonuclease (RNase A), the prototype of the 
RNase A superfamily, could be used to shed light on the physical, chemical and 
biological properties of these RNases. 
 
2.2 Bovine pancreatic ribonuclease (RNase A), the 
prototype of ribonucleases 
The study of the RNase A superfamily started with the discovery (Jones, 1920) 
and isolation (Dubos, 1937) of bovine pancreatic ribonuclease (EC = 3.1.27.5) 
in 1920 and 1937 respectively. The extensive studies on the folding, structure, 
and chemistry of RNase A that have followed have lead to the awarding of the 
Nobel Prize in Chemistry to four researchers in 1972 and 1984, thereby 
demonstrating the importance of this enzyme (Anfinsen, 1973; Moore and Stein, 
1973; Merrifield, 1986).  
 
The enzyme was given the name RNase A to refer to its predominant state in 
the pancreas of Bos taurus (Raines, 1998). RNase A is unmodified, whereas 
RNase B, C, and D, which are also isolated from bovine pancreas, are 
glycosylated at different sites (Plummer and Hirs, 1964; Plummer, 1968; 
Baynes and Wold, 1976; Liang et al., 1980; Rudd et al., 1992; Fu et al., 1994).  
 
RNase A is a secreted protein with a signal peptide of 26 amino acids, which is 
cleaved after secretion by the exocrine cells of the bovine pancreas. The mature 





2.2.1 Reaction catalysed by RNase A 
The depolymerisation of RNA catalysed by RNase A consists of two reactions: 
the transphosphorylation reaction and the hydrolysis reaction. During the first 
step (transphosphorylation), the phosphodiester bond is broken at the 5' position 
of one nucleotide, and the phosphate group is transferred to the 2' position of 
the adjacent nucleotide forming a 2',3'-cyclic phosphodiester intermediate 
product (Figure 2.1a). This intermediate is hydrolysed to a 3' nucleotide in the 
second step (hydrolysis) (Figure 2.1b) (Richards and Wyckoff, 1971; Eftink and 
Biltonen, 1987).  
 
Figure 2.1. Hydrolysis reaction of RNA. (a) The transphosphorylation reaction; (b) The 
hydrolysis reaction. 
 
2.2.2 Structure of RNase A 
The successful crystallisation of RNase A protein was first reported in the late 
1930s (Kunitz, 1939; Kunitz, 1940), and showed diffraction up to 2 Å 
(Fankuchen, 1941). The three-dimensional structure of RNase A was only the 
fifth protein structure to be solved using X-ray crystallography (Kartha et al., 
1967; Richards and Wyckoff, 1973), following myoglobin (Kendrew, 1963), 
haemoglobin (Perutz, 1963), lysozyme (Blake et al., 1965), and 




2.2.2.1 Structural features of RNase A 
The overall shape of RNase A resembles that of a kidney, with a predominant 
secondary structural feature of a four-stranded antiparallel β-sheet. The 
structure is stabilised by four disulphide bonds (formed between Cys-26 and 
Cys-84, Cys-40 and Cys-95, Cys-58 and Cys-110, and Cys-65 and Cys-72), two 
at each pole of the molecule. The active site residues are located in the cleft 
(Figure 2.2). 
 
Figure 2.2. Stereo view of the three-dimensional structure of bovine pancreatic 
ribonuclease A (RNase A) (PDB: 1AFU; Leonidas et al., 1997). Four pairs of cysteine 
residues involved in intra-molecular disulphide bonds are shown in pink; active site 
residues (Gln-11, His-12, Lys-41, and His-119) are shown as sticks. 
 
2.2.2.2 Catalytic mechanism of RNase A 
Researchers have proposed a few catalytic mechanisms for RNase A (Witzel, 
1963; Hammes, 1968; Wang, 1968), one of which is depicted in Figure 2.3. 
This mechanism, which is consistent with all known data from research 
performed on this enzyme, postulates that two histidine residues participate in 
the catalysis of RNA hydrolysis (Findlay et al., 1961). During the 
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transphosphorylation step, the side chain of His-12 acts as a base, abstracting 
the proton on the 2'-O of one nucleotide. The abstraction leads to further 
electron transfer along the nucleotide molecule, resulting in the attack of 2'-O 
on the phosphorus atom and the formation of the 2',3'-cyclic phosphodiester 
intermediate product (Usher et al., 1970; Usher et al., 1972; Sowa et al., 1997). 
The side chain of His-119 acts as an acid and facilitates the displacement of 5'-
O (Figure 2.3a). The second step, the slow hydrolysis of the 2',3'-cyclic 
phosphodiester occurs in a separate process that resembles the reverse of 
transphosphorylation (Cuchillo et al., 1993; Thompson et al., 1994). Here the 
roles of the histidines are reversed: the side chain of His-119 donates an 
electron to a water molecule, which subsequently passes the electron to the 
phosphorus atom and finally to the nitrogen atom of the side chain of His-12, 
producing the final reaction product (Figure 2.3b). DNA lacks the 2'-OH group, 
and therefore cannot be hydrolysed by RNases. 
 
Figure 2.3. Catalytic mechanism of RNase A. (a) The transphosphorylation step where an 
intermediate product, 2',3'- cyclic phosphodiester, is produced; (b) The hydrolysis 




Both the transphosphorylation and hydrolysis of RNA catalysed by RNase A 
occur via transition states having a pentavalent phosphorus atom (Raines, 1998). 
Uridine 2',3'-cyclic vanadate (UVC; Figure 2.4a), an analogue of the penta-
coordinate phosphorane bearing some resemblance to such a transition state 
(Lindquist et al., 1973), has been used to study the catalytic mechanism of 
RNase A (Borah et al., 1985; Ladner et al., 1997) (Figure 2.4b). Potential 
hydrogen bonds are identified between UVC and Gln-11, His-12, Lys-41, Thr-







Figure 2.4. Interactions between RNase A and uridine 2',3'-cyclic vanadate (UVC). (a) 
Chemical structure of UVC; (b) Stereo view of the structure of RNase A·UVC complex 
(PDB: 1RUV; Ladner et al., 1997); (c) Stereo view of the interactions between UVC and 
RNase A. UVC and the side chains of the residues involved in the recognition of UVC are 
shown as sticks; the N- and C- termini of RNase A are labelled as N and C respectively. 
Nitrogen and oxygen atoms are coloured in blue and red respectively; carbon atoms of 
RNase A and UVC are coloured in grey and green respectively; potential hydrogen bonds 






2.2.2.3 Catalytic site of RNase A 
The crystal structures of RNase A complexed with UVC have provided 
invaluable insight into the catalytic mechanism of RNase A, and revealed that 
the side chains of Gln-11, His-12, Lys-41, His-119 are proximal to the vanadyl 
group and therefore of catalytic importance (Wlodawer et al., 1983; Ladner et 
al., 1997) (Figure 2.4b).  
 
A close view of the active site is shown in Figure 2.5. His-12 and His-119 were 
identified as important catalytic residues from early work on RNase A, and 
their direct role in RNA degradation has been confirmed (Figure 2.3). As stated 
previously, His-12 acts as a base in the transphosphorylation reaction that 
abstracts a proton from the 2'-O of the ribose, thus favouring the attack of 2'-O 
on the phosphorus atom to give the pentacoordinate transition state (Cuchillo et 
al., 1997). His-119, on the other hand, acts as an acid in the 
transphosphorylation, protonating the 5'-OR leaving group and facilitating an 
in-line addition of 2'-O (Deakyne and Allen, 1979). Several crystallographic 
studies have shown that His-119 occupies predominantly two conformations 
(Richards and Wykoff, 1971; de Mel et al., 1994), and modelling studies have 
shown that His-119 is positioned equally well to participate in the RNA 
degradation reactions regardless of its conformation (de Mel et al., 1992). 
 
Figure 2.5. Close view of the active site of RNase A. Amino acid residues of catalytic 
importance are shown as sticks. Carbon, nitrogen and oxygen atoms are coloured in grey, 




Early chemical modification of Lys-41 suggested that it may contribute to the 
catalytic activity of RNase A (Hirs, 1962; Murdock et al., 1966), and this was 
later confirmed by site-directed mutagenesis studies on Lys-41. The K41A 
variant showed 1.9% activity with respect to the wild-type RNase A (Trautwein 
et al., 1991). 
 
The role played by Lys-41 in the catalytic activity of RNase is to stabilise the 
excess negative charge accumulated on the non-bridging phosphoryl oxygens in 
the transition state. A few hypotheses were made on the mechanism of this 
stabilisation (Roberts et al., 1969; Flogel et al., 1975; Trautwein et al., 1991), 
and a model where Lys-41 donates a single hydrogen bond to the transition 
state is supported by available data (Figure 2.6) (Raines, 1998). 
 
Figure 2.6. Putative structure of the transition state of the transphosphorylation of UpA 
by RNase A. Figure adapted from “Ribonuclease A” (Raines, 1998). 
 
Analysis of RNase A structures revealed that the side chain of Gln-11 can form 
a hydrogen bond to a substrate/substrate analogue (Figure 2.4c), phosphate ion 
or sulphate ion in the active site (Gilliland, 1997; Raines, 1998). Further 
mutagenesis and enzyme kinetic studies on Gln-11 revealed that a hydrogen 
bond formed between the side chain of Gln-11 and a phosphoryl oxygen 
prevents the substrate from binding in a non-productive mode, and enhances the 
catalysis of RNA hydrolysis (delCardayré et al., 1995; Raines, 1998).  
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2.2.2.4 Subsites of RNase A and substrate specificity 
Structural studies of RNase A not only revealed the primary active site 
consisting of amino acid residues Gln-11, His-12, Lys-41, and His-119, but also 
identified so called subsites that are involved in the recognition of other 
components of an RNA molecule in the catalytic cleft (Figure 2.7a). So far, 
three subsites denoted P0, P1, and P2 have been shown to be involved in the 
binding of phosphate groups of RNA, whereas two further subsites, B1 and B2, 
interact with the bases of the RNA (Parés et al., 1980; Parés et al., 1991; 
Nogués et al., 1995).  
 
As shown in Figure 2.7b, the P0 subsite consists of only one amino acid residue: 
Lys-66. The P1 subsite is the primary active site where residues Gln-11, His-12, 
Lys-41, and His-119 catalyse the degradation of RNA, whilst residues Lys-7 
and Arg-10 contribute to the binding of a phosphate group to the P2 subsite.  
 
The B1 subsite comprising residues Val-43, Asn-44, Thr-45, Phe-120, and Ser-
123 is a pyrimidine specific binding site, and it has been demonstrated that it 
has a 30-fold kinetic preference for cytosine over uracil (McPherson et al., 1986; 
Aguilar et al., 1992). In contrast, the B2 subsite with residues Asn-67, Gln-69, 
Asn-71, and Glu-111 prefers the binding of purines, specifically an adenine 
base (Katoh et al., 1986). The contributions of some amino acid residues to 
substrate binding and/or turnover have been verified by site-directed 
mutagenesis studies (Wlodawer et al., 1983; Trautwein et al., 1991; Tarragona-
Fiol et al., 1993; Thompson and Raines, 1994; delCardayré and Raines, 1994; 
Boix et al., 1994; delCardayré and Raines, 1995; delCardayré et al., 1995; 
Messmore et al., 1995; Thompson et al., 1995; Panov et al., 1996; Fisher et al., 








Figure 2.7. Subsites of RNase A involved in the binding of RNA. (a) Surface diagram of the three-dimensional structure of bovine RNase A showing the subsites 
involved in the recognition and degradation of RNA. B and P indicate the base and phosphate binding subsites respectively; (b) Schematic representation of the 
recognition of an RNA fragment (CpA) by RNase A. Residues in the different subsites are labelled. The phosphate group of the phosphodiester bond to be 




2.3 The RNase A superfamily 
2.3.1 Human RNase A homologues 
The analysis of human chromosome 14q11.2 revealed the complete 
identification of human RNase genes. A total of thirteen RNase genes were 
found, eight of which encode for the so-called canonical RNases (RNase 1-8). 
The remaining five, RNase 9-13, were named noncanonical RNases due to the 
lack of one or more catalytic residues (Cho et al., 2005). The major differences 
between the canonical and noncanonical RNases lie in the C-terminal regions 
(Castella et al., 2004; D'Alessio, 2011). As for their function, a couple of the 
noncanonical RNases (RNase 9 and 10) are expressed in mouse and porcine 
epididymis, suggesting they may play a role in the reproduction process of 
these species (Castella et al., 2004; Penttinen et al., 2003). 
 
The structures of RNase 1-5 and RNase 7 have been solved, all of which 
resemble that of RNase A, the typical kidney-shaped molecule (Figure 2.8). 
Multiple sequence alignments of mature human RNase 1-8 with bovine RNase 
A revealed highly conserved active site residues and cysteine residues involved 
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Figure 2.8. Structural similarity of human 
RNase A homologues – RNase 1 (hRNase 1; 
PDB: 2K11; Kövér et al., 2008), eosinophil 
derived neurotoxin (hEDN; PDB: 1GQV; 
Swaminathan et al., 2002), eosinophil cationic 
protein (hECP; PDB: 1QMT; Boix et al., 1999), 
RNase 4 (hRNase 4; PDB: 1RNF; Terzyan et al., 
1999), angiogenin (hANG; PDB: 1B1I; Leonidas 
et al., 1999a), and RNase 7 (hRNase 7; PDB: 






Figure 2.9. Comparison of the primary structures of human RNases 1-8. The sequence of 
bovine RNase A is shown for comparison. Conserved catalytic residues are coloured in 
red; cysteines involved in the formation of disulphide bonds are coloured in yellow. All 
sequences were obtained from UniProtKB database. The multiple sequence alignment was 
performed using Clustal Omega EMBL-EBI online server (Sievers et al., 2011; McWilliam 
et al., 2013). 
 
2.3.1.1 Human pancreatic RNase 1 (RNase 1) 
The expression of human RNase 1 has been identified in not only pancreas but 
also other tissues and organs, such as endothelial cells, dendritic cells, brain, 
liver and kidneys, to name but a few (Yasuda et al., 1993; Lapteva et al., 2001; 
Landré et al., 2002). Such wide existence over a variety of tissues has led to 
extensive research and subsequent discoveries of some of the novel roles of 
RNase 1. These include the ability to degrade HIV-1 RNA thus preventing 
foetus/neonate vertical transmission of HIV-1 (Bedoya et al., 2006), and 





2.3.1.2 Eosinophil derived neurotoxin (EDN; RNase 2) and Eosinophil 
cationic protein (ECP; RNase 3) 
Human RNase 2 and 3 are more commonly known as eosinophil derived 
neurotoxin (EDN) and eosinophil cationic protein (ECP) respectively (Figure 
2.8, Figure 2.10). EDN and ECP are two of the major secretory proteins of 
human eosinophil granules that were first isolated prior to their identification as 
members of the RNase A superfamily (Ackerman et al., 1983; Gleich et al., 
1986).  
 
Despite the first discovery in eosinophil granules and the initial characterisation 
as a neurotoxin (Durack et al., 1981; Fredens et al., 1982; Gleich et al., 1986), 
EDN is in fact expressed in spleen, liver, kidney, placenta, and body fluids 
(Beintema et al., 1988; Sorrentino et al., 1988; Mizuta et al., 1990; Yasuda et 
al., 1990; Shapiro and Vallee, 1991; Sorrentino et al., 1992). EDN displays a 
specific ribonucleolytic dependent antiviral activity against respiratory 
syncytial virus (RSV) and HIV (Domachowske, Bonville, et al., 1998; 
Domachowske, Dyer, et al., 1998; Rosenberg and Domachowske, 2001; 
Bedoya et al., 2006). Moreover, EDN is categorised as an alarmin, for its ability 
to activate and promote the chemotaxis of human dendritic cells in response to 
pathogen stimulation (Yang et al., 2003; Yang et al., 2004; Oppenheim and 
Yang, 2005; Acharya and Ackerman, 2014). 
 
Unlike EDN, ECP is solely expressed in eosinophils activated by inflammation. 
ECP is recognised to have bactericidal, antiviral, and antiparasitic activities, 
which are independent on its ribonucleolytic activity (Yazdanbakhsh et al., 
1987; Lehrer et al., 1989; Hamann et al., 1990; Domachowske, Dyer, et al., 
1998). Both the cytotoxicity and bactericidal activity of ECP are based on its 
ability to disrupt membranes (Carreras et al., 2003; Carreras et al., 2005; Boix 









Figure 2.10. Ligand recognitions of hEDN and hECP in stereo view. (a) Interactions 
between hEDN and adenosine 2',3'-diphosphate (ADP) (PDB: 1HI5; Leonidas et al., 2001); 
(b) interactions between hECP and adenosine 2',5'-diphosphate (A2P) (PDB: 1H1H; Boix 
et al., 1999a). ADP and A2P ligands as well as the side chains of residues interacting with 
the ligands are shown as sticks; the N- and C- termini of hEDN and hECP are labelled as 






EDN and ECP show unusual features relating to their catalytic properties. 
Neither EDN nor ECP hydrolyse the 2',3'-cyclic phosphodiesters produced in 
the first transphosphorylation reaction. Furthermore, despite the fact that EDN 
and ECP have the same base preference as the prototypic RNase A, their 
catalytic activities of CpA are significantly weaker than that of the RNase A 
(Boix et al., 1999b; Holloway et al., 2004; Shapiro and Vallee, 1991).  
 
2.3.1.3 Ribonuclease 4 (RNase 4) 
Initial characterisation of the members of the RNase 4 family revealed high 
degree of conservation, indicated by the high inter-species similarity between 
porcine, bovine, human, and rat enzymes. Such a level of conservation suggests 
a high evolutionary pressure to maintain the structure, which may imply a 
specialised function. RNase 4 is the shortest human canonical ribonuclease, 
with only 119 amino acid residues in the mature protein whereas its 
homologues have between 123 and 134 residues, yet its ribonucleolytic activity 
is close to that of RNase A. Unlike the other members in the RNase A 
superfamily, RNase 4 prefers uracil to cytosine as the base at the 3' side of the 
cleaved phosphodiester bond (Hofsteenge et al., 1998b; Seno et al., 1995; 
Shapiro et al., 1986; Terzyan et al., 1999; Vicentini et al., 1996, 1994; Zhou 
and Strydom, 1993) (Figure 2.11).  
 
Surprisingly, mutagenesis studies on its orthologue – porcine RNase 4 (pRNase 
4) suggested that such strong uracil preference could be reversed (to a cytosine 
preference) by a single amino acid substitution mutation of Asp-80 to alanine 
(Hofsteenge et al., 1998a). A recent discovery showed that human RNase 4 
(hRNase 4) is not only able to induce angiogenesis and the formation of 
neurofilaments – the intermediate filaments found in neurons that are essential 
for the development, maintenance and function of axons (Yuan et al., 2012), 
but also protects against hypothermia-induced neuron degeneration (Li et al., 





Figure 2.11. Stereo view of the structure of hRNase 4 in complex with 2'-deoxyuridine 3'-
monophosphate (dUp) (PDB: 2RNF; Terzyan et al., 1999). dUp as well as the side chains 
of residues interacting with the ligand are shown as sticks; the N- and C- termini of 
hRNase 4 are labelled as N and C respectively. 
 
2.3.1.4 Angiogenin (ANG; RNase 5) 
Angiogenin (ANG) is the most unusual member of the RNase A superfamily. 
ANG, originally isolated from tumour cell conditioned culture medium, 
possessed the ability to induce angiogenesis (the formation of new blood 
vessels) in vivo (Strydom et al., 1985; Fett et al., 1985). It exhibits a weak 
ribonucleolytic activity that is essential for angiogenesis (Shapiro et al., 1986). 
Structural studies on human (Acharya et al., 1994), bovine (Acharya et al., 
1995), and murine (Holloway et al., 2005; Crabtree et al., 2007) ANG revealed 
an overall structure similar to that of RNase A, and highlighted the less 
conserved B1 and B2 subsites, providing an explanation for the low level of 




Figure 2.12. The less conserved B1 and B2 subsites of human ANG (magenta) (hANG; PDB: 
1B1I; Leonidas et al., 1999a), bovine ANG (orange) (bANG; PDB: 1AGI; Acharya et al., 
1995), murine ANG-1 (cyan) (mANG-1; PDB: 2BWK; Holloway et al., 2005), and murine 
ANG-4 (green) (mANG-4; PDB: 2J4T; Crabtree et al., 2007) compared with those of 
RNase A (grey). 
  
The angiogenic activity of ANG is known to be associated with the pathology 
of cancers: the increased expression of ANG has been correlated with the 
formation of tumours in more than 20 clinical studies (Kao et al., 2002). Studies 
have shown that ANG antagonists could inhibit the establishment, progression, 
and metastasis of tumour xenografts in athymic mice (Kao et al., 2002; Olson et 
al., 1995, 1998, 2002; Piccoli et al., 1998). 
 
The biological role of ANG is not only found in angiogenesis, but also extends 
to the nervous system. ANG shows neuroprotective activity (Subramanian and 
Feng, 2007; Steidinger et al., 2011); however, some ANG mutants are cytotoxic 
towards motor neurons, leading to their degradation. A large number of ANG 
mutants have been identified to be associated with both familial and sporadic 
amyotrophic lateral sclerosis (ALS) (Conforti et al., 2008; Corrado et al., 2007; 
Fernández-Santiago et al., 2009; Gellera et al., 2008; Greenway et al., 2006, 
2004; Luigetti et al., 2011; Paubel et al., 2008; Seilhean et al., 2009; 
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Subramanian and Feng, 2007; Subramanian et al., 2008; Thiyagarajan et al., 
2012; van Es et al., 2009; Wu et al., 2007; Zou et al., 2012), as well as 
Parkinson’s disease (Rayaprolu et al., 2012; van Es et al., 2011). 
 
2.3.1.5 RNase 6 (RNase k6), RNase 7, and RNase 8 
RNase 6 was the sixth characterised member of the human RNase family. It 
was initially named as RNase k6 to indicate its relationship to the orthologous 
RNase k2 from bovine kidney. Despite its close sequence similarity to EDN 
and ECP, RNase 6 is expressed in most tissues, including lung, heart, brain, 
placenta, liver, kidney, pancreas, and skeletal muscle, but not in eosinophils 
(Rosenberg and Dyer, 1996). RNase 6 is likely to have a role in host defence 
due to the presence of RNase 6 encoding mRNA transcripts in neutrophils and 
monocytes (Sorrentino, 2010); however, no detailed information about this 
protein is presently available. 
 
The high amino acid sequence identity between RNase 7 and RNase 8 suggests 
that their genes are likely to have originated from a relatively recent gene 
duplication event (Sorrentino, 2010). However, the differences in the types of 
tissues expressing RNase 7 and RNase 8 may suggest that they possess different 
physiological functions. RNase 7 is found in epithelial tissues and several 
organs (Harder and Schroder, 2002; Zhang et al., 2003), while RNase 8 is 
uniquely expressed in the placenta (Zhang et al., 2002). Combining the fact that 
they both show bactericidal activity against several pathogenic bacteria, both 
Gram-positive and Gram-negative, the role of RNase 7 possibly lies in the 
antimicrobial defence of skin (Huang et al., 2007; Abtin et al., 2009; Torrent et 
al., 2010) while the function of RNase 8 is likely to be protecting the placenta 




2.3.2 Other vertebrate RNases  
Besides human RNases, homologues of RNase A have been discovered in many 
other vertebrate species, including mammals (for instance rodents) (Zhou and 
Strydom, 1993; Gupta et al., 1999; Dyer et al., 2004), birds (Cho et al., 2005; 
Nitto et al., 2006), reptiles (Zhao et al., 1994; Nitto et al., 2005), amphibians 
(Ardelt et al., 1991; Liao et al., 2000), and fish (Pizzo et al., 2006; Cho and 
Zhang, 2007; Kazakou et al., 2008; Pizzo et al., 2008; Pizzo et al., 2011). 
Despite their fundamental ribonucleolytic activity, some of these RNases 
possess more specialised functions, such as the anti-tumour activities of 
onconase (ONC) from Rana pipiens and RC-RNase from Rana catesbeiana, 
and the roles in host defence played by rodent eosinophil-associated 
ribonucleases (EARs) (Hooper et al., 2003; Ishihara et al., 2003; Garvey et al., 
2005), chicken RNase A-2, zebrafish and salmon RNases (Pizzo et al., 2006; 
Pizzo et al., 2008) to name but a few. Although of therapeutic value, these 
RNases are not the focus of this study, thus will not be discussed in more detail. 
 
2.4 Inhibitors of RNases 
Regulated RNase activity is crucial to organisms; uncontrolled RNA 
degradation might become cytotoxic and lead to cell death (Vescia et al., 1980; 
Wu et al., 1993; Leland et al., 1998; Suzuki et al., 1999). Research has revealed 
both natural and small molecule inhibitors that are capable of inhibiting RNases. 
 
2.4.1 The natural inhibitor of RNases – ribonuclease inhibitor (RI) 
The activities of members of the RNase A superfamily can be abolished by the 
cytosolic ribonuclease inhibitor (RI) (Beintema, Schüller, et al., 1988) (Figure 
2.13). RI is a 50 kDa protein that exists in the cytoplasm of all mammalian cells. 
The functions of RI can be categorised into three classes:  the regulation of 
cytoplasmic RNA level;  the prevention of secreted, non-cytoplasmic RNases 
from attacking the cytoplasm; and  the regulation of the activities of RNases 
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known to have physiological roles other than the degradation of RNA in the 
digestive system (Hofsteenge, 1994).  
 
Figure 2.13. Stereo view of the structure of porcine RI (pRI, coloured purple) in complex 
with RNase A (coloured green) (PDB: 1DFJ; Kobe and Deisenhofer, 1995). The N- and C- 
termini of both proteins are labelled as N and C respectively. 
 
The inhibition of RNases by RI is achieved via a two-step mechanism, where a 
rapid formation of an encounter enzyme-inhibitor complex (EI) occurs initially, 
followed by a slower isomerisation of EI to a tight complex EI
* 
(Lee et al., 1989; 
Lee and Vallee, 1989):  
           
RI forms a very tight but reversible, one-to-one complex with RNase. 
Dissociation constants (Ki) for RI complexed with RNase A (Lee et al., 1989a; 
Vicentini et al., 1990), ANG (Lee et al., 1989a, 1989b), EDN (Shapiro and 
Vallee, 1991) are all at femtomolar (fM) level, showing them to be amongst the 
strongest protein-protein interactions known. More details of RI will be 
presented in Chapter 4. 
 
2.4.2 Small molecule inhibitors of RNase A 
Early studies on the enzymatic mechanism of RNase A suggested that certain 
chemicals could inhibit the activity of RNase A (Barnard and Stein, 1960; 
Gundlach et al., 1959; Weil and Seibles, 1955). This led to investigations into 
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the possibility of using small molecules as RNase A inhibitors. Since the 
members of the RNase A family recognise their ligands all in a similar way, 
small molecule inhibitors of RNase A are likely to inhibit its homologues, some 
of which (for example RNase 4 and ANG) may be involved in disease 
conditions. 
 
Many such molecules have been characterised to date, such as haloacetates 
(Barnard and Stein, 1960; Gundlach et al., 1959), aribinonucleotides (Pollard 
and Nagyvary, 1973), ordinary nucleotides (Richards and Wyckoff, 1971; 
Eftink and Biltonen, 1987; Shapiro et al., 1989; D’Alessio et al., 1991; 
Sorrentino et al., 1992; Gilliland, 1997; Shapiro, 2001; Tsirkone et al., 2009) 
(Figure 2.14), nucleotide analogues (Shapiro et al., 1989; Nogués et al., 1998; 
Raines, 1998; Parmenopoulou et al., 2012) (Figure 2.15) and derivatives 
(Tarragona-Fiol et al., 1993; Gilliland, 1997; Leonidas et al., 1997; Leonidas et 
al., 1999b; Jardine et al., 2001; Shapiro, 2001). RNA based inhibitor design for 
RNase A has been the most common method used in this field (Russo et al., 
1997; Russo and Shapiro, 1999; Russo et al., 2001). 
 
Figure 2.14. Structures of RNase A in complex with uridine 5'-monophosphate (U5P, 
coloured green), and uridine 5'-diphosphate (UDP, coloured yellow) in stereo view (PDB: 
3DXG, 3DXH; Tsirkone et al., 2009). Residues interacting with U5P and UDP are 
coloured green and yellow respectively. Lys-41 is involved in the binding of UDP, which 






Figure 2.15. RNase A inhibition by triazole pyrimidine nucleosides. (a) Chemical structure 
of triazole pyrimidine nucleoside analogues; (b) Structures of RNase A in complex with 
triazole pyrimidine nucleosides 4a (cyan), 4b (orange), and 4e (grey) in stereo view (PDB: 
4G8V, 4G8Y, 4G90; Parmenopoulou et al., 2012). Residues interacting with 4a, 4b, and 4e 
are coloured cyan, orange, and grey respectively. Interactions between inhibitor molecules 
and His-12, Lys-41, Thr-45, and His-119 are observed in all three structures; Lys-7 
















Chapter 3. Molecular recognition of wild-type 
and mutant porcine ribonuclease 4 






3.1.1 RNase 4, a highly conserved member of the RNase A superfamily 
The discoveries of members of the RNase 4 family started with the isolation 
and characterisation of human RNase 4 (hRNase 4) rom the supernatant of 
human colon carcinoma conditioned medium (Fett et al., 1985; Shapiro et al., 
1986). Three years later, another RNase 4 was identified from porcine liver 
during the search for RNases that interact with porcine ribonuclease inhibitor 
(pRI), and was named PL3 (Hofsteenge et al., 1989). To date, the primary 
structure of RNase 4 from pig (Hofsteenge et al., 1989), cow (Hosoya et al., 
1990), human (Zhou and Strydom, 1993), and rat (Zhao et al., 1998) has been 
determined by protein sequencing, and that of mouse, chimpanzee, and 
Sumatran orangutan RNase 4 were deduced from their complementary DNA 
(cDNA) sequences.  
 
Figure 3.1. Comparison of the primary structures of porcine, bovine, mouse, rat, human, 
Sumatran orangutan, and chimpanzee RNase 4. All sequences were taken from 
UniProtKB database. The multiple sequence alignment with a conservation scoring was 
performed using Clustal Omega EMBL-EBI online server (McWilliam et al., 2013; Sievers 
et al., 2011). Conserved residues are highlighted yellow. 
 
Comparison of these primary structures revealed high interspecies similarity 
(~90%) (Figure 3.1), consistent with the early sequence analysis of porcine, 
bovine, human and rat RNase 4 (Hofsteenge et al., 1998b). The sequences of 
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RNase 4 differ only in 30 positions, 18 of which are conservative substitutions. 
The eight cysteine residues involved in disulphide bridging, the catalytic 
residues Gln-11, His-12, Lys-41, and His-119 (RNase A numbering), and 
several residues important for substrate binding are also conserved. Such high 
level of conservation suggests a strong evolutionary pressure to maintain its 
structure, which may in turn imply a more specialised function than RNA 
degradation in the digestive system (Zhou and Strydom, 1993).  
 
Molecular biology studies revealed that the messenger RNA (mRNA) of human 
RNase 4 (hRNase 4) is found in most tissues, liver being the most abundant 
source, but not brain (Rosenberg and Dyer, 1995; Futami et al., 1997). In 
porcine tissues, RNase 4 mRNA is present at high levels in liver and lung, and 
is detectable in brain but not in kidney, thymus or testis (Vicentini et al., 1994). 
 
Like all RNases in the RNase A superfamily, RNase 4 only cleaves RNA after 
pyrimidine bases (Shapiro et al., 1986). In contrast to the prototype RNase A 
that favours cytidine, RNase 4 has a salient feature of strong uridine preference 
(Vicentini et al., 1994). A comparison of the kcat/Km
*
 for the cleavage of 
uridylyl-3',5'-adenosine (UpA) and cytidylyl-3',5'-adenosine (CpA) by RNase A 
and RNase 4 (Table 3.1) suggested that the uridine specificity of RNase 4 
results from a suppression of the activity with cytidine-containing substrates 
(Hofsteenge et al., 1998b). 
 







RNase A hRNase 4 pRNase 4 (PL3) 
UpA 3.5   106 2.5   105 2.5   105 
CpA 4.5   106 6.3   102 6.7   102 
                                                 
*kcat/Km is a measure of how efficiently an enzyme converts a substrate into product. kcat, the turnover 
number, is the maximum number of substrate molecules converted to product per enzyme molecule per 





Residues 37-45 and 120-124 of RNase A contribute to its pyrimidine binding 
pocket, therefore these areas of PL3 were altered by site-directed mutagenesis to 
investigate the structural basis of the different substrate preferences between 
RNase A and RNase 4. By substituting residues 36-42 of PL3 with the 
corresponding ones of RNase A, Vicentini and colleagues observed a large 
preferential increase in the catalytic efficiency of the hybrid for cytidine-
containing substrates, suggesting the involvement of this region in the uridine-
preferring substrate specificity of PL3 (Vicentini et al., 1994). More site-
directed mutagenesis studies of PL3 suggested residues Asp-80 and Arg-101 
also contribute to the uridine preference. Furthermore, the substitution of Asp-
80 by alanine completely reversed such preference: the kcat/Km for UpA 
decreased 159-fold whereas the kcat/Km for CpA increased 233-fold (Hofsteenge 
et al., 1998a). 
 
The determination of the crystal structures of free hRNase 4 and in complex 
with deoxyuridine phosphate (dUp) with a resolution of 2.1 Å and 2.4 Å 
respectively, provided some structural insights of such substrate preference 
(Terzyan et al., 1999) (Figure 3.2). The overall structure of hRNase 4 displays 
the typical kidney-shaped RNase A fold common to all RNases. The P1 
catalytic site of hRNase 4 is similar to that of RNase A, and the residues of 
catalytic importance are conserved, namely Gln-11, His-12, Lys-40, and His-
116, equivalent to Gln-11, His-12, Lys-41, and His-119 of RNase A. The 
shortened C-terminus of RNase 4 causes structural rearrangement of the side 
chain of Arg-101 that penetrates the active site pocket and forms hydrogen 
bond with the O4 atom of uridine. In contrast, the equivalent residues in all 
other RNases of known structures are located at the surface and not engaged in 
substrate recognition. The structure of hRNase 4 also revealed that the presence 
of the side chain of Phe-42 forces Asp-80 to form a hydrogen bond with Thr-44 








Figure 3.2. Three-dimensional structures of free hRNase 4 and hRNase 4·dUp complex. (a) 
Superposition of the structures of hRNase 4 (light purple; PDB: 1RNF; Terzyan et al., 
1999) and RNase A (grey; PDB: 1AFU; Leonidas et al., 1997). Residues in P1 subsites of 
both proteins are shown as sticks; (b) structure of hRNase 4·dUp complex (PDB: 2RNF; 
Terzyan et al., 1999). Residues Arg-7, His-12, Thr-44, Arg-101 and His-116 interact with 
dUp ligand via hydrogen bonding, Phe-42 forces Asp-80 to hydrogen bond with Thr-44, 
which in turn interacts with dUp.  
 
Although with significantly different substrate specificity and possible novel 





studies. Only a few reports on the biological functions of RNase 4 have been 
published so far. Studies revealed that hRNase 4 is a component of the 
cytoplasmic granules of human peripheral blood monocytes, and this 
subcellular localisation of RNase 4 suggests that it may be involved in the 
degradation of polymeric RNA secreted by pathogens, as well as a role that is 
unique to monocyte-macrophage linkage (Egesten et al., 1997). Recent research 
suggested that RNase 4 is one of the two RNases secreted by CD8
+
 T cells that 
is involved in the inhibition of the X4 strains of HIV-1 (Cocchi et al., 2012). 
Besides its roles in host defence, hRNase 4 also showed angiogenic activities in 
in vitro, ex vivo, and in vivo assays, which requires a certain degree of 
ribonucleolytic activity. More surprisingly, hRNase 4 also showed neurogenic 
and neuroprotective activities, suggesting its involvement in neurodegeneration 
diseases such as amyotrophic lateral sclerosis (ALS) (Li et al., 2013). 
 
3.1.2 Rationale behind this study 
As stated, biochemical studies suggested that a single amino acid substitution of 
Asp-80, a highly conserved residue in not only the RNase 4 family but also all 
the orthologous RNase 1 and some other RNases, to alanine in pRNase 4 
completely reversed the substrate specificity from uridine-specific to cytidine-
specific. Although the crystal structures of unliganded hRNase 4 and hRNase 4 
complexed with d(Up) provided the explanation of the role Asp-80 plays in 
RNase 4 substrate specificity (Figure 3.2), the initial studies were carried out 
using porcine RNase 4 – PL3, whose crystal structure was yet to be solved. The 
focus of this study was the determination of four crystal structures:  wild type 
PL3 (wtPL3),  PL3 D80A mutant,  wtPL3 in complex with a uridine-
containing substrate, and  PL3 D80A mutant in complex with a cytidine-
containing substrate, hoping to provide more structural insights into the role 




3.2 Materials and Methods 
3.2.1 DNA sequencing of pYSBLIC-PL3 gene 
The pYSBLIC-PL3 construct was prepared by K. Kazakou, a previous PhD 
student in our laboratory, using the pET-YSBLIC vector to carry the PL3 gene 
and the E. coli BL21-CodonPlus (DE3)-RIL (BL21C
+
(DE3)-RIL) competent 
cells as the host (Kazakou, 2008). The pET-YSBLIC vector was a kind gift 
from Dr M. J. Fogg, University of York, UK. pET-YSBLIC vector is a pET-
28a(+) derivative that adds a noncleavable hexahistidine tag directly to the N-
terminal of the recombinant protein. 
 
DNA sequencing of the pYSBLIC-PL3 gene was performed to confirm the 
identity of the protein. The plasmid of pYSBLIC-PL3 was extracted from 10 ml 
of overnight culture using the Wizard plus SV Minipreps DNA purification 
system (Promega, USA); extraction protocol described in the Wizard plus SV 
Minipreps DNA purification system Technical Bulletin was followed. The 
plasmid DNA was sequenced by Eurofins MWG Operon, Germany. 
 
3.2.2 Expression and purification of pYSBLIC-PL3 
While waiting for the DNA sequencing result, an expression and purification 
trial of pYSBLIC-PL3 was carried out following the protocols described by 
Kazakou (2008). 1 L Terrific Broth (TB) medium (1.2% tryptone, 2.4% yeast 
extract, 72 mM K2HPO4, 17 mM KH2PO4 and 0.4% glycerol) supplemented 
with 50 μg/ml kanamycin, and 25 μg/ml chloramphenicol was inoculated with 
1 % overnight culture of BL21C
+
(DE3)-RIL-pYSBLIC-PL3 cells. The culture 
was incubated at 37 °C with shaking at 200 rpm, and subsequently treated with 
1 mM IPTG to induce protein expression when the cells were in their mid-
exponential phase of growth (indicated by OD600 ≥ 0.6). The induced cells were 
further incubated at 37 °C with shaking at 200 rpm for 3 hours, and harvested 
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by centrifugation at 15, 000 g (Beckman JLA 10.500 rotor) for 10 minutes. Cell 
pellets from 0.5 L culture were stored at -80 °C.  
 
The cell pellet from 0.5 L bacterial culture was resuspended in 50 ml lysis 
buffer (50 mM Tris-HCl, pH 8.0) and ruptured using the TS Series Benchtop 
cell disruptor (Constant Systems Ltd., Daventry, Northants, UK) at 24,000 psi. 
The lysate was centrifuged at 39,000 g (Beckman JLA 25.50 rotor) for 20 
minutes to harvest inclusion bodies (Kazakou, 2008). 
 
The inclusion body pellet was solubilised in 10 ml solubilisation buffer (7 M 
guanidine hydrochloride, 0.15 M reduced glutathione, 0.1 M Tris-HCl pH 8.0, 2 
mM EDTA) for 2 hours. The solubilised protein was separated from the solid 
matter by centrifugation at 70, 000 g for 30 minutes (Beckman JLA 25.50 rotor), 
and added dropwisely into 1 L refolding buffer (0.5 M L-arginine, 0.6 mM 
oxidized glutathione) with gentle stirring. After the addition of the protein 
sample, the refolding solution was left undisturbed at 4 °C overnight (Kazakou, 
2008). 
 
pYSBLIC-PL3 was purified by cation exchange chromatography. A self-packed 
column with SP-Sepharose Fast Flow beads (GE Healthcare, UK) was 
equilibrated with equilibration buffer (50 mM Tris-HCl pH 8.0, 100 mM NaCl). 
Precipitated protein was removed from the refolding solution by centrifugation 
at 15, 000 g for 30 minutes (Beckman JLA 10.500 rotor); soluble protein 
sample was diluted to 2.5 L with Milli-Q H2O and loaded onto the column. 
Subsequently the column was re-equilibrated with equilibration buffer (50 mM 
Tris-HCl pH 8.0, 100 mM NaCl). pYSBLIC-PL3 was eluted with an ascending 
NaCl gradient in equilibration buffer (from 0.1 M to 0.8 M NaCl). Fractions 




The protein sample was further purified using reverse phase chromatography. A 
Jupiter C4 column (Phenomenex, USA) was used. The column was washed 
with 95% buffer B (HPLC-grade acetonitrile with 0.08% trifluoroacetic acid 
(TFA)) and equilibrated with 95% buffer A (degassed HPLC-grade H2O with 
0.1% TFA) prior to protein loading. The column was re-equilibrated with buffer 
A after the protein was loaded; and the protein was eluted with an increasing 
Buffer B concentration. Fractions with raised UV trace were pooled and 
lyophilised overnight. The lyophilised protein sample was dissolved in HPLC-
grade H2O, and analysed by gel electrophoresis (Kazakou, 2008). 
 
3.2.3 Construction of BL21 Codon Plus-pET-46 Ek/LIC-PL3 strain 
The DNA sequencing of the pYSBLIC-PL3 gene indicated that the construct 
contained both the wild type PL3 and a mutant form of PL3 (details are provided 
in Section 3.3.1), therefore a new wild type PL3 construct was prepared using 
pET-46 Ek/LIC vector from Novagen, Germany. 
 
3.2.3.1 Primer Design 
Forward and reverse primers were designed to amplify the gene encoding for 
PL3 along with the overhanging bases for ligation-independent cloning (LIC), 
the codon at position 1 was corrected to encode amino acid residue glutamine, 
which was the first amino acid of the wild type PL3 protein (Table 3.2). The 
primers were synthesised by Invitrogen, USA. The melting temperatures were 
calculated using equation provided by Invitrogen: 
                         
   
             
 
 
Table 3.2 Primers for amplification of PL3 gene suitable for LIC cloning. 
Forward 
primer 
5’-GAC GAC GAC AAG ATG CAG GAT 
CGC ATG TAC CAA CGA TT-3’ 
TM = 62.6 °C 
%GC = 0.50 
Reverse 
primer 
5’-GA GGA GAA GCC CGG TTA CTA TTT 
GTC AAA GTG CAC AGG CAC CT-3’ 





3.2.3.2 Amplification of PL3 gene 
The plasmid extracted from the overnight culture of BL21C
+
(DE3)-RIL-
pYSBLIC-PL3 was used as the DNA template for the PCR reaction. The 
primers were dissolved in HPLC-grade H2O to produce 10 M stock solutions. 
The PCR reactions were prepared as shown in Table 3.3. A negative control 
with no DNA present was carried out. The effect of betaine on DNA 
amplification was tested. The PCR reaction was performed following the 
parameters shown in Table 3.4. 
 
Table 3.3. PCR reaction system for the amplification of PL3 gene.  
Forward primer (10 M) 1 μl 
Reverse primer (10 M) 1 μl 
Template PL3 DNA 0.5 μl 
dNTP mix (2 mM each) (Novagen) 5 μl 
25 mM MgSO4 (Novagen) 2 μl 
5 M betaine 0 or 10 μl 
10x PCR Buffer for KOD Hot Start DNA Polymerase (Novagen) 5 μl 
KOD Hot Start DNA Polymerase (Novagen) 1 μl 
H2O x μl 
TOTAL 50 μl 
 
Table 3.4. Cycling parameters for the amplification of PL3 gene. 
Segment Cycle(s) Temperature Time 
1 1 94 °C 1 minute 
2 2-18 
94 °C 1 minute 
58 °C 30 seconds 
72 °C 2 minutes 
3 1 72 °C 10 minutes 
4 1 4 °C - 
 
The PCR product was treated with 10 units DpnI restriction enzyme (Promega) 
at room temperature for 16 hours to remove the methylated template DNA. The 
DpnI treated PCR product was analysed by gel electrophoresis. The 400 bp 
band was cut off from the 1% agarose gel; the recovery of the PCR product was 
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performed following instructions from the Wizard SV gel and PCR Clean-up 
system (Promega).  
 
3.2.3.3 T4 Polymerase Treatment of target insert 
The PCR product was treated with T4 polymerase (Novagen) to produce sticky 
ends specifically for LIC cloning. The reactions were prepared as shown in 
Table 3.5; a negative and a positive control were used. The presence of dATP 
enabled the 3’ to 5’ exonuclease activity of T4 DNA polymerase, and produced 
specific single-strand overhangs. After 30 minutes incubation at 22 °C, the 
reactions were stopped by inactivating T4 DNA polymerase at 75 °C for 20 
minutes. 
 







T4 DNA polymerase 0.4 μl 0.4 μl 0.4 μl 
10  T4 DNA polymerase buffer 2 μl 2 μl 2 μl 
25 mM dATP 2 μl 2 μl 2 μl 
100 mM DTT 1 μl 1 μl 1 μl 
Control insert/PCR product 0 μl 4 μl 0.2 pmol
*
 
H2O 14.6 μl 10.6 μl 
Add H2O to 
20 μl 
*
 0.2 pmol of PCR product was required in the reaction, the volume of which can be calculated 
based on equation:              
                                              
                          
 
 
3.2.3.4 Annealing of the insert and pET-46 Ek/LIC vector 
The T4 polymerase treated insert was subsequently used to prepare the pET-46 
Ek/LIC-PL3 plasmid. 1 μl of pET-46 Ek/LIC vector from the pET-46 Ek/LIC 
vector kit (Novagen) and 2 μl T4 DNA polymerase treated PL3 gene insert 
(0.02 pmol) were mixed and incubated at 22 °C for 5 minutes. Subsequently, 1 




3.2.3.5 Preparation of pET-46 Ek/LIC-PL3 cloning strain 
The annealed pET-46 Ek/LIC-PL3 plasmid was used to prepare the plasmid-
amplifying strain. Top10 E. coli cells (Invitrogen) were used as the host. Top10 
cells inoculated with 2 μl pET-46 Ek/LIC-PL3 plasmid were incubated on ice 
for 5 minutes and heat-shocked at 42 °C for 90 seconds. The heat-shocked cells 
were kept on ice for 2 minutes before incubating with 500 μl LB broth at 37 °C 
for 1 hour. The cells were plated on an LB agar plate supplemented with 100 
μg/ml ampicillin and incubated at 37 °C with shaking at 200 rpm overnight. 10 
ml LB broth supplemented with 100 μg/ml ampicillin was inoculated with an 
isolated colony from the plate and incubated at 37 °C overnight. pET-46 
Ek/LIC-PL3 plasmid DNA was extracted from the cells using the Wizard plus 
SV Minipreps DNA purification system (Promega); the plasmid DNA was 
sequenced by Eurofins MWG Operon. 
 
3.2.3.6 Preparation of pET-46 Ek/LIC-PL3 expression strain 
The recombinant plasmid DNA was used to prepare the expression strain. 
BL21-CodonPlus (DE3)-RIPL (BL21C
+
(DE3)-RIPL) E. coli cells (Agilent 
Technologies, Santa Clara, California, USA) were used as the host; the same 
transformation protocol described in Section 3.2.3.5 was followed. A glycerol 
stock of this construct was prepared by mixing 200 μl of the overnight culture 
with 800 μl autoclaved 50% glycerol. The stock was stored at -80 °C after 
freezing in liquid N2. 
 
3.2.4 Expression and purification of wild type pET46-PL3 (wtPL3) 
The expression and purification protocols detailed in Section 3.2.2 were 
followed to express and purify wtPL3 from BL21C
+
(DE3)-RIPL-pET-46 
Ek/LIC-PL3 strain. Modifications were made to the protocols to optimise 
protein yield (the incubation time after induction was extended from 3 hours to 
16 hours; the volume of refolding buffer was reduced from 1 L to 500 ml), 
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which will be discussed in the Results section. Optimised expression and 
purification protocols were given in Appendix II. 
 
3.2.5 Mass spectrometry analysis of tagged wild-type pET46-PL3 
The identity of the tagged PL3 produced was verified by mass spectrometry. 
The experiment was carried out using an Agilent 6520 Accurate-Mass 
Quadrupole Time-of-Flight (Q-TOF) mass spectrometer (Agilent Technologies). 
The protein sample was in HPLC-grade H2O at a concentration of 10 mg/ml. 
Data acquisition and processing was controlled via Agilent MassHunter 
Workstation Software (Agilent Technologies). The mass spectrometry 
experiment was performed by Mr M. Lewis from the Department of Chemistry, 
University of Bath. 
 
3.2.6 His-tag cleavage of wtPL3 by Enterokinase  
3.2.6.1 Pilot study of His-tag cleavage of wtPL3 by enterokinase 
EnterokinaseMax (EKMax) from Invitrogen and recombinant enterokinase (rEk) 
from New England BioLabs (NEB), USA were used in the pilot study of PL3 
tag cleavage. The preparation of the pilot reactions were based on the 
instruction described in the EKMax User Manual (Invitrogen).  
 
The reactions contained 20 μg PL3 protein, 3 μl 10  EKMax Buffer (500 mM 
Tris-HCl, pH 6.5, 10 mM CaCl2, 1% Tween-20 (v/v)), and six different 
amounts of EKMax (0 unit
†
 as negative control, 0.001 unit, 0.01 unit, 0.1 unit, 1 
unit, and 4 units) (Table 3.6). 1  EKMax Buffer was used for the negative 
control, and to prepare the 10-fold serial dilutions of EKMax; 4 µl of undiluted 
EKMax was used for the 4 units of EKMax. The rEk was diluted with 1  
                                                 
†1 unit of EKMax is the amount of enzyme required to digest 20 µg of a thioredoxin-CAT fusion protein 
to 90% completion in 16 hours at 37°C.  
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EKMax Buffer to prepare an enzyme solution with a concentration of 0.00016 
μg/μl, which is equivalent to 1 unit/μl according to the unit definition provided 
in the datasheet. 
 
Table 3.6. Small-scale optimisation for enterokinase treatment. 
PL3 protein 20 μg 
10  EKMax Buffer 3 μl 
EKMax (or 1  EKMax Buffer for the negative control) 1 μl or 4 μl 
Deionized H2O x μl 
Total volume 30 μl 
 
PL3 protein used in this study was purified by ion exchange chromatography 
followed by reverse phase chromatography, lyophilised and re-suspended in 
HPLC-grade H2O. The concentration of the PL3 sample was measured by 
NanoDrop 2000c spectrophotometer (Thermo Scientific, USA) using the 
entered Abs 1%
‡




. The reactions were incubated at room 
temperature for 16 hours. The efficiency of the enterokinase cleavage was 
analysed by SDS-PAGE. 
 
3.2.6.2 Scale-up of Enterokinase cleavage reaction 
The pilot study showed that EKMax and rEk had similar levels of activity, and 
1 unit of enterokinase gave complete cleavage of 20 g PL3 protein in 1  
EKMax Reaction Buffer after 16 hours at room temperature.  
 
For large-scale enterokinase cleavage reactions, rEK was used; 10  EKMax 
Reaction Buffer (500 mM Tris-HCl, pH 6.5, 10 mM CaCl2, 1% Tween-20 (v/v)) 
was prepared as instructed in the EKMax User Manual. The reaction system 
using 1 unit of enterokinase was scaled up in a linear manner to suit the amount 
                                                 
‡ Abs 1% is calculated using the equation:           
 
  
, where   is the molar extinction coefficient 
of the protein;   is the molecular weight of the protein. 
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of PL3 to be treated. No dilution was made to the PL3 sample prior to the rEk 
treatment to achieve better cleavage results. 
 
3.2.7 Purification of untagged wtPL3 by affinity chromatography 
The rEk was removed from the PL3 sample by affinity chromatography. A 1 ml 
HiTrap Benzamidine FF (High Sub) column (GE Healthcare) was used to trap 
the rEk protease; all operations were performed with a syringe and a luer 
adapter provided. The rEk treated PL3 sample was loaded onto the column that 
had been equilibrated with 5 column volumes of equilibration buffer (50 mM 
Tris-HCl, pH 8.0, 1 mM CaCl2), and the column was subsequently washed with 
5 column volumes of equilibration buffer and 5 column volumes of wash buffer 
2 (50 mM Tris-HCl, pH 8.0, 100 mM NaCl). Untagged PL3 did not interact 
with benzamidine, and would be present in the flow through of the loading and 
first washing steps. Bound EKMax was eluted from the column with 5 column 
volumes of elution buffer (50 mM Tris-HCl, pH 8.0, 1 M NaCl). Fractions from 
loading and first wash step were collected in separate tubes and analysed by 
SDS-PAGE. 
 
3.2.8 Purification of untagged wtPL3 by reverse phase chromatography 
The untagged PL3 protein was further purified using reverse phase HPLC 
chromatography. The purification protocol described in 3.2.2 was followed. 
 
3.2.9 Construction of pET46-PL3 D80A mutant 
3.2.9.1 Primer Design 
A set of primers was designed for the site-directed mutagenesis of wild type 
PL3 DNA to produce PL3 D80A mutant (Table 3.7). The primers were 
manufactured by Eurofins MWG Operon. The melting temperatures were 




Table 3.7. Primers for amplifying PL3 D80A mutant by site-directed mutagenesis. 
Forward 
primer 
5’- GTG GTG AAG GTC ACA GCG TGC 
AGG GAG ACA GGA AG -3’ 
TM = 65.2 °C 
%GC = 0.60 
Reverse 
primer 
5’- CTT CCT GTC TCC CTG CAC GCT 
GTG ACC TTC ACC AC -3’ 
TM = 65.2 °C 
%GC =0.60 
 
3.2.9.2 PCR Site-directed mutagenesis of wtPL3 to produce PL3 D80A DNA 
The plasmid DNA extracted from the overnight culture of BL21C
+
(DE3)-RIPL-
pET-46 Ek/LIC-PL3 was used as the template DNA. The primers were 
dissolved in HPLC-grade H2O to produce 10 M stock solutions. The PCR 
recipe in Table 3.2 was followed. 2 l of PL3 template DNA was used instead 
of 0.5 l. The PCR reactions were carried out following the parameters shown 
in Table 3.3. Time for annealing and elongation was set to 30 seconds and 6 
minutes respectively. 
 
3.2.9.3 Preparation of pET46-PL3 D80A cloning strain 
The PCR product was treated with 10 units DpnI restriction enzyme at room 
temperature for 2 hours to digest methylated template DNA and subsequently 
used in the preparation of the cloning strain of pET-46 Ek/LIC-PL3 D80A. 
Top10 E. coli competent cells were used as the host; the transformation 
protocol described in Section 3.2.3.5 was followed. pET-46 Ek/LIC-PL3 D80A 
plasmid DNA was extracted from the cells using the Wizard plus SV Minipreps 
DNA purification system (Promega); the plasmid DNA was sequenced by 
Eurofins MWG Operon. 
 
3.2.9.4 Preparation of pET46-PL3 D80A expression strain 
Once the DNA sequencing result was confirmed correct, the recombinant 
plasmid DNA of pET46-PL3 D80A was used to prepare the expression strain. 
BL21C
+
(DE3)-RIPL E. coli cells (Agilent Technologies) were used as the host; 
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the same transformation protocol described in Section 3.2.3.6 was followed. A 
glycerol stock of the BL21C
+
(DE3)-RIPL-pET-46 Ek/LIC-PL3 D80A construct 
was prepared by mixing 200 μl of the overnight culture with 800 μl autoclaved 
50% glycerol. The stock was stored at -80 °C after freezing in liquid N2. 
 
3.2.10 Expression and purification of pET46-PL3 D80A mutant 
The optimised expression and purification protocols of wtPL3 protein 
(Appendix II) were followed to express and purify the PL3 D80A mutant.  
 
The N-terminal hexahistidine tag of the PL3 D80A mutant protein was removed 
by enterokinase following the protocol described in Section 3.2.6.2. 
 
3.2.11 Mass spectrometry analysis of wtPL3 and PL3 D80A mutant 
samples 
Identity of the three PL3 samples (namely untagged wtPL3, tagged and untagged 
PL3 D80A mutant) was verified by mass spectrometry. The experimental 
procedure described previously in Section 3.2.5 was followed. All three PL3 
samples were in HPLC-grade H2O with a concentration of 10 mg/ml. 
 
3.2.12 Ribonucleolytic activity assay of wtPL3 and PL3 D80A mutant 
samples 
The RNase assay protocol described by Shapiro et al. (1987), which was 
originally designed to assess the ribonucleolytic activity of hANG, was carried 
out to test the activities of wtPL3 and PL3 D80A mutant samples; human 




The assays contained 10 mg/ml yeast tRNA, 1 mg/ml bovine serum albumin 
(BSA), and six concentrations of PL3 samples (0-500 nM) in RNase assay 
buffer (0.1 M NaCl, 0.1 M HEPES pH 7.0) (Table 3.8). All assays were carried 
out in duplicate. Reactions were terminated by the addition of 700 l ice-cold 
3.4% perchloric acid after 2 hours incubation in 37 °C water bath. The mixtures 
were spun down at 16,100 g (Eppendorf Microcentrifuge 5415D) for 10 
minutes at 4 °C and the absorbance at 260 nm (A260) of the supernatants were 
used as a measure of the ribonucleolytic activity of test proteins. The 
magnitudes of the A260 values in the quasilinear portion of each plot (300-500 
nM for hANG, 0.3-0.5 nM for test samples) were used in the calculation of 
relative activities. 
 
Table 3.8. RNase activity assay reaction system. 
Assay mixture Concentration of protein sample (μM) 
blank 0.05 0.1 0.2 0.3 0.4 0.5 
Sep-pak water
*
 (μl) 110 105 100 90 80 70 60 
RNase assay buffer (μl) 100 100 100 100 100 100 100 
1 mg/ml BSA (μl) 30 30 30 30 30 30 30 
40 μg/ml test protein (μl) 0 5 10 20 30 40 50 
10 mg/ml tRNA (μl) 60 60 60 60 60 60 60 
Total (μl) 300 300 300 300 300 300 300 
*
Prepared using Sep-Pak Classic cartridges (Waters, USA). 
 
3.2.13 Crystallisation of wtPL3 and PL3 D80A mutant 
The 4 protein samples listed in Table 3.9 were used in the pre-crystallisation 
tests (PCTs) and initial screenings of crystallisation conditions. 
 
Table 3.9. Proteins used in the PCT tests and screening of crystallisation conditions. 




tagged PL3 D80A mutant 




3.2.13.1 Pre-crystallisation Tests (PCTs) 
A PCT test was performed with samples listed in Table 3.9 to establish a 
starting concentration for the subsequent screenings of crystallisation conditions. 
The PCT reagents (Table 3.10) were self-prepared in the laboratory, and the 
experimental protocol described in the PCT User Guide by Hampton Research 
was followed with minor alterations as detailed below. All samples were diluted 
with HPLC-grade H2O to a concentration of 10 mg/ml.  
 
1 ml of PCT reagent A1 was pipetted into the well A1 of a Nunclon multidish 
4-well plate. 1 l of protein sample was pipetted onto the centre of a glass cover 
slide (Hampton Research), and an equal volume of reagent A1 from the well 
was pipetted into the protein drop without mixing. The cover slide was inverted 
over well A1, which was sealed with vacuum grease (Dow Corning
®
). The 
procedure was repeated for reagents A2, B1, and B2. The plate was incubated at 
16 °C for 30 minutes prior to results examination. 
 






0.1 M Tris-HCl pH 8.5, 2.0 M (NH4)2SO4 
Reagent 
A2 
0.1 M Tris-HCl pH 8.5, 1.0 M (NH4)2SO4 
Reagent 
B1 
0.1 M Tris-HCl pH 8.5, 0.2 M MgCl26H2O, 30% w/v PEG 4000 
Reagent 
B2 
0.1 M Tris-HCl pH 8.5, 0.2 M MgCl26H2O, 15% w/v PEG 4000 
 
3.2.13.2 Screening for crystallisation conditions for wtPL3 and PL3 D80A 
mutant 
Protein samples listed in Table 3.9 (tagged wtPL3, untagged wtPL3, tagged PL3 
D80A, and untagged PL3 D80A) were diluted with HPLC-grade H2O to 10 
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mg/ml, which was determined to be an appropriate starting concentration for 
crystallisation by PCT tests.  
 
Crystallisation screens Structure screen I & II HT-96, PACT premier HT-96, 
JCSG-plus HT-96, and Morpheus HT-96 (Molecular Dimensions) were used to 
set up the initial screenings. The screenings were set up in 96-well Intelli 
crystallisation plates (Art Robbins Instruments, California, USA) by Phoenix 
protein crystallisation robot (Art Robbins Instruments). Equal volumes (0.15 l) 
of protein samples and reservoir solutions were added to the drop wells to give 
a final protein concentration of 5 mg/ml. All plates were incubated at 16 °C. 
 
3.2.13.3 Optimisation of crystallisation conditions for wtPL3 and PL3 D80A 
mutant 
Microcrystals of wtPL3 and PL3 D80A mutant were observed in several 
crystallisation conditions from Structure screen I & II HT-96, JCSG-plus HT-
96, and Morpheus HT-96. Crystallisations were repeated using the hanging 
drop vapour diffusion method in 24-well XRL plates (Molecular Dimensions) 
with increased or decreased salt and/or precipitant concentrations to optimise 
protein crystallisation.  
 
3.2.14 Crystallisation of wtPL3·dUMP and PL3 D80A·dCMP complexes 
3.2.14.1 Soaking tagged wtPL3 crystals with (UpA)5 and dUMP ligands 
Crystallisation of tagged wtPL3 was repeated using condition Morpheus – E10 
(0.1 M Morpheus Buffer System 3 pH 8.5, 0.12 M Monosaccharides, 30% v/v 
EDO_P8K) in 24-well XRL plates by hanging drop vapour diffusion method, 




Initial attempt of wtPL3 ligand recognition was carried out using a RNA 
oligonucleotide (UpA)5 synthesised by Eurofins MWG Operon. The wtPL3 
protein crystals were soaked with 2 mM (UpA)5 solution for 5 minutes, 1 hour, 
and 6 hours at room temperature respectively, flash-frozen with liquid nitrogen 
using the reservoir solution as cryo-protectant and transported to Diamond 
Light Source (DLS; Didcot, Oxfordshire, UK) for data collection. 
 
The mononucleotide ligand 2'-deoxyuridine-5'-monophosphate (dUMP) was 
also used in the soaking experiment. The soaking experiments were performed 
with two final concentrations of dUMP, 16.7 mM and 33.3 mM respectively, 
and four concentrations of ethylene glycol ranging from 16.7% to 28.3% as a 
cryo-protectant. Three sets of soaking experiments were set up 3 days, 2 days, 
and 1 day prior to crystal harvesting. Soaked wtPL3 crystals were flash-frozen 
with liquid nitrogen and transported to DLS, UK for data collection. 
 
3.2.14.2 PCT tests for co-crystallisations of PL3 and their ligands 
Due to the fact that soaking wtPL3 crystals with uridine-containing ligand failed 
to produce complex crystals, and PL3 D80A crystals grew as clusters that were 
not suitable for soaking experiments, the method of co-crystallisation was 
pursued. The ligands used were 2'-deoxyuridine-5'-monophosphate (dUMP) 
and 2'-deoxycytidine-5'-monophosphate (dCMP).  
 
PCT tests were performed with both the wtPL3·dUMP and PL3 D80A·dCMP to 
establish a starting concentration for subsequent crystallisation trials; the PCT 
protocol described in Section 3.2.13.1 was followed. Four protein samples 
listed in Table 3.9, namely tagged wtPL3, untagged wtPL3, tagged PL3 D80A, 
and untagged PL3 D80A proteins were used. Protein samples of wtPL3 and PL3 
D80A were mixed with dUMP and dCMP respectively in a 1:1.2 molar ratio, 




3.2.14.3 Screening for crystallisation conditions for wtPL3·dUMP and PL3 
D80A·dCMP complexes 
It was established from the PCT tests that a 9 mg/ml protein sample with 1.2  
ligand in molarity was an appropriate starting point for the initial screenings. 
Crystallisation screens Structure Screen I & II HT-96, PACT premier HT-96, 
JCSG-plus HT-96, ProPlex HT-96, Stura Footprint + MacroSol HT-96, 
Morpheus HT-96, and MIDAS HT-96 (Molecular Dimensions) were used to set 
up the initial screenings. Protocol described in Section 3.2.13.2 was followed.  
 
Additive screenings for PL3 D80A·dCMP crystallisation conditions were also 
carried out. 90% of Structure Screen I & II – A7 was used as the main 
crystallisation condition, to which 10% Silver Bullets (Hampton Research), 
Structure screen I & II HT-96, or MIDAS HT-96 was added. The additive 
screenings were performed using Phoenix protein crystallisation robot (Art 
Robbins Instruments) following the protocol described in Section 3.2.13.2. 
 
3.2.14.4 Optimisation of crystallisation conditions for wtPL3·dUMP and PL3 
D80A·dCMP complexes 
Microcrystals of wtPL3·dUMP and PL3 D80A·dCMP were observed in several 
crystallisation conditions from Structure Screen I & II HT-96, PACT premier 
HT-96, JCSG-plus HT-96, and Stura Footprint + MacroSol HT-96. 
Crystallisations were repeated using the hanging drop vapour diffusion method 
in 24-well XRL plates (Molecular Dimensions) with increased or decreased salt 




3.2.15 Data collection and structure solution of wtPL3, PL3 D80A mutant, 
wtPL3·dUMP and PL3 D80A·dCMP complexes 
3.2.15.1 Data collection and structure solution of wtPL3 
Tagged wtPL3 protein crystals obtained from condition Morpheus – F10 were 
flash-frozen with liquid nitrogen using the reservoir solution as cryo-protectant 
and transported to DLS, UK for data collection. X-ray diffraction data for 
wtPL3 were collected from a single crystal with 0.1° oscillation using a Pilatus3 
6M detector at beamline I24 with 0.02 second exposure time. 
 
The diffraction data were automatically indexed and integrated with XDS 
(Kabsch, 2010) and xia2 (Winter et al., 2013), and scaled to 1.25 Å using 
AIMLESS from the CCP4 programme suite (Evans, 2006, 2011; Winn et al., 
2011). Initial phases were obtained by molecular replacement using Phaser MR 
from the CCP4 programme suite (McCoy et al., 2007; Winn et al., 2011). 
Structure of human RNase 4 ( PDB: 1RNF; Terzyan et al., 1999) was used as a 
the search model. Isotropic and anisotropic structural refinements (the latter is 
often used on structures with higher resolutions) were performed using 
REFMAC5 from the CCP4 programme suite (Murshudov et al., 1997; 
Murshudov et al., 2011; Winn et al., 2011) and COOT version 0.7.1 (Emsley et 
al., 2010). The alternative conformations of residues and ethylene glycol 
molecules were added manually, and water molecules were added to the model 
using COOT (Emsley et al., 2010) at positions where mFo – DFc electron 
density peaks exceeded 3σ. PROCHECK (Laskowski et al., 1993; Vaguine et 
al., 1999) and MolProbity (Davis et al., 2007; Chen et al., 2010) were used for 
structure validation. Figures were drawn with PyMOL (DeLano, 2002). 
 
3.2.15.2 Data collection and structure solution of PL3 D80A mutant 
Tagged PL3 D80A protein crystals obtained from condition JCSG-plus – E1 
were flash-frozen by liquid nitrogen with 25% glycerol as cryo-protectant and 
transported to DLS, UK for data collection. X-ray diffraction data for PL3 
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D80A were collected from a single crystal with 0.5° oscillation using a Pilatus 
6M-F detector at beamline I04. 
 
The protocol described in Section 3.2.15.1 was followed to solve and refine the 
structure of PL3 D80A mutant. Integrated diffraction data were scaled to 2.9 Å, 
and the structure of wtPL3 was used as a search model in molecular 
replacement. Structure refinements were performed isotropically, as the 
resolution of the dataset was not high enough for anisotropic refinement. 
Automatically generated local non-crystallographic symmetry (NCS) restraints 
were used in refinements. 
 
3.2.15.3 Data collection and structure solution of wtPL3·dUMP complex 
Untagged wtPL3·dUMP crystals obtained from condition ProPlex – E7 were 
flash-frozen with liquid nitrogen with 25% glycerol as cryo-protectant and 
transported to DLS, UK for data collection. X-ray diffraction data for 
wtPL3·dUMP were collected from a single crystal with 0.1° oscillation using a 
Pilatus 2M detector at beamline I04-1. 
 
The protocol described in Section 3.2.15.1 was followed to solve and refine the 
structure of the wtPL3·dU5P complex. Integrated diffraction data were scaled to 
2.28 Å, and the structure of wtPL3 was used as a search model in molecular 
replacement. Structure refinements were performed isotropically. 
 
3.2.15.4 Data collection and structure solution of PL3 D80A·dCMP complex 
Tagged PL3 D80A·dCMP crystals obtained from modified condition Structure 
Screen I & II – A9 were flash-frozen with liquid nitrogen with 25% glycerol as 
cryo-protectant and transported to DLS, UK for data collection. X-ray 
diffraction data for PL3 D80A·dCMP were collected from a single crystal with 




The protocol described in Section 3.2.15.1 was followed to solve and refine the 
structure of PL3 D80A·dCMP complex. Integrated diffraction data were scaled 
to 2.6 Å, and the structure of wtPL3 was used as a search model in molecular 
replacement. Structure refinements were performed isotropically. Automatically 







There were two PL3 constructs available in the laboratory at the time, ptRP-PL3 
and pYSBLIC-PL3. The ptRP-PL3 construct was obtained from our collaborator 
Dr Jan Hofsteenge from Basel, Switzerland. The pYSBLIC-PL3 construct was 
prepared by K. Kazakou, a previous member of our laboratory.  
 
ptRP-PL3 would produce PL3 protein without N- or C-terminal tags. However, 
the lack of a detailed vector map of the self-synthesised ptRP vector, as well as 
the prolonged timespan of expression had made the pYSBLIC-PL3 construct the 
ideal choice. 
 
3.3.1 DNA sequencing of pYSBLIC-PL3 gene, expression and purification 
of pYSBLIC-PL3 
The plasmid DNA of pYSBLIC-PL3 was extracted using the Wizard plus SV 
Minipreps DNA purification system (Promega) and sequenced by Eurofins 
MWG Operon to confirm the DNA sequence. An expression and purification 
trial of pYSBLIC-PL3 was carried out following the expression and purification 
protocols described in Section 3.2.2.  
 
Pure pYSBLIC-PL3 could be purified following the purification protocol at a 
concentration of ~10 mg/ml. However, the DNA sequencing detected a Gln to 
Asn substitution at position 1 of the mature protein. Such mutation was not 
detected after the initial construction of this strain. Hence, a new construct for 






(a) (a) Chromatogram of cation 
exchange purification;  
 
(b) Chromatogram of reverse 
phase HPLC purification; 
 
(c) 15% SDS-PAGE gel of 
purified pYSBLIC-PL3 
samples.  
Lane 1: low molecular weight 
marker (Sigma); 
Lane 2 – 4: fractions of PL3 






Figure 3.3. Results of pYSBLIC-PL3 purifications. (a) Chromatogram of cation exchange 
purification of pYSBLIC-PL3; (b) Chromatogram of reverse phase HPLC purification of 
pYSBLIC-PL3; (c) 15% SDS-PAGE gel of purified pYSBLIC-PL3 samples. 
 
3.3.2 Construction of BL21C+-pET-46 Ek/LIC-PL3  
The protocol described in Section 3.2.3 was followed to prepare the 
BL21C
+
(DE3)-RIPL-pET-46 EK/LIC-PL3 construct. DpnI was used to remove 
methylated template DNA, and tThe DpnI treated PCR products were analysed 
by gel electrophoresis (Figure 3.4). Lane 1 and 2 are the negative controls 
without and with betaine, which reduces secondary structure formation in GC-
rich regions (Rees et al., 1993); lane 3 and 4 are the PL3 PCR products without 
and with betaine respectively. The 400 bp band in both PCR samples matches 





Lane M1: 1,000 bp DNA ladder 
Lane M2: 100 bp DNA ladder 
Lane 1: Negative control 1 
              (without betaine) 
Lane 2: Negative control 2 
              (with 1 M betaine) 
Lane 3: PCR product 1 
              (without betaine) 
Lane 4: PCR product 2 
              (with 1 M betaine) 
Figure 3.4. DpnI treated PCR products on a 1% agarose gel. Neither of the negative 
controls contained DNA; both of the PCR products showed a single band of DNA at 400 
bp, which matched the size of the PL3 gene. 
 
The DNA of PL3 gene was recovered from the gel and inserted into the pET-46 
Ek/LIC vector. The pET-46 Ek/LIC-PL3 plasmids were transformed into, and 
extracted from the overnight cultures of Top 10 and BL21 Codon Plus 
(BL21C
+
(DE3)-RIPL) competent cells respectively. The plasmid DNA was 
sequenced, and the results were aligned with the wild type PL3 DNA obtained 
from the NCBI database (Gene ID: 396976) (Figure 3.5). 
 
The alignment confirmed that the pET-46 Ek/LIC-PL3 plasmid as well as the 
BL21C
+






Figure 3.5. Sequence alignments between the sequences of the cloning plasmid, the 
expression plasmid, and the PL3 gene sequence obtained from NCBI database (Gene ID: 
396976). Alignment was performed using Clustal W2 (Larkin et al., 2007). Sequence 
coloured in blue and red represent the sequences of pET-46 Ek/LIC vector and the 
primers used in the PCR reaction respectively. Coloured sequences are not part of the 
native PL3 gene; they were included in the alignment to ensure the correctness of the 
remainder of the target sequence.  
CLUSTAL 2.1 multiple sequence alignment 
 
cloning      AGGAGATATACCATGGCACATCACCACCACCATCACGTGGATGACGACGACAAGATGCAG 60 
express      ------------ATGGCACATCACCACCACCATCACGTGGATGACGACGACAAGATGCAG 48 
PL3          ------------ATGGCACATCACCACCACCATCACGTGGATGACGACGACAAGATGCAG 48 
                         ************************************************ 
 
cloning      GATCGCATGTACCAACGATTCCTGCGGCAACACGTGGACCCTGATGCGACAGGTGGCAAT 120 
express      GATCGCATGTACCAACGATTCCTGCGGCAACACGTGGACCCTGATGCGACAGGTGGCAAT 108 
PL3          GATCGCATGTACCAACGATTCCTGCGGCAACACGTGGACCCTGATGCGACAGGTGGCAAT 108 
             ************************************************************ 
 
cloning      GATGCCTACTGCAACTTGATGATGCAAAGACGGAAGATGACTTCACATTATTGCAAGCGC 180 
express      GATGCCTACTGCAACTTGATGATGCAAAGACGGAAGATGACTTCACATTATTGCAAGCGC 168 
PL3          GATGCCTACTGCAACTTGATGATGCAAAGACGGAAGATGACTTCACATTATTGCAAGCGC 168 
             ************************************************************ 
 
cloning      TTCAACACTTTCATTCATGAAGACATTTGGAACATTCGTAGTATCTGCAGCACCTCCAAT 240 
express      TTCAACACTTTCATTCATGAAGACATTTGGAACATTCGTAGTATCTGCAGCACCTCCAAT 228 
PL3          TTCAACACTTTCATTCATGAAGACATTTGGAACATTCGTAGTATCTGCAGCACCTCCAAT 228 
             ************************************************************ 
 
cloning      ATTCAGTGCAAGAATGGCCAGATGAACTGCCATGAGGGCGTGGTGAAGGTCACAGACTGC 300 
express      ATTCAGTGCAAGAATGGCCAGATGAACTGCCATGAGGGCGTGGTGAAGGTCACAGACTGC 288 
PL3          ATTCAGTGCAAGAATGGCCAGATGAACTGCCATGAGGGCGTGGTGAAGGTCACAGACTGC 288 
             ************************************************************ 
 
cloning      AGGGAGACAGGAAGTTCCAGGGCTCCCAACTGCAGATACCGGGCCATGGCCAGCACTAGA 360 
express      AGGGAGACAGGAAGTTCCAGGGCTCCCAACTGCAGATACCGGGCCATGGCCAGCACTAGA 348 
PL3          AGGGAGACAGGAAGTTCCAGGGCTCCCAACTGCAGATACCGGGCCATGGCCAGCACTAGA 348 
             ************************************************************ 
 
cloning      CGGGTTGTCATTGCCTGTGAGGGTAATCCAGAGGTGCCTGTGCACTTTGACAAATAGTAA 420 
express      CGGGTTGTCATTGCCTGTGAGGGTAATCCAGAGGTGCCTGTGCACTTTGACAAATAGTAA 408 
PL3          CGGGTTGTCATTGCCTGTGAGGGTAATCCAGAGGTGCCTGTGCACTTTGACAAATAGTAA 408 
             ************************************************************ 
 
cloning      CCGGGCTTCTCCTCAAATCTCGAGTCTGGTAAAGAAACCGCTGCTGCGAAATTTGAACGC 480 
express      CCGGGCTTCTCCTCAAATCTCGAGTCTGGTAAAGAAACCGCTGCTGCGAAATTTGAACGC 468 
PL3          CCGGGCTTCTCCTCAAATCTCGAGTCTGGTAAAGAAACCGCTGCTGCGAAATTTGAACGC 468 
             ************************************************************ 
 
cloning      CAGCACATGGACTCGTCTACTAGCGCAGCTTAATTAACCTAGGCTGCTGCCA-CCGCTGA 539 
express      CAGCACATGGACTCGTCTACTAGCGCAGCTTAATTAACCTAGGCTGCTGCCA-CCGCTGA 527 
PL3          CAGCACATGGACTCGTCTACTAGCGCAGCTTAATTAACCTAGGCTGCTGCCAACCGCTGA 528 
             **************************************************** ******* 
 
cloning      GCAATAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTGCTGAA 599 
express      GCAATAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTGCTGAA 587 
PL3          GCAATAACTAGCATAACCCCT--------------------------------------- 549 
             *********************                                        
 
cloning      A----------- 600 
express      AGGAGGAACTAT 599 
PL3          ------------ 
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3.3.3 Expression and purification of wild-type pET46-PL3 
The expression and purification protocol described in Section 3.2.2 was 
followed to express and purify wtPL3 from the BL21C
+
(DE3)-RIPL-pET-46 
Ek/LIC-PL3 strain.  
 
3.3.3.1 Optimisation of the expression condition for pET46-PL3 
No significant expression of PL3 could be observed 3 hours after IPTG 
induction (Figure 3.6a). To increase the protein yield, the time for protein 
expression was extended: induced culture was incubated at 16 °C for 16 hours. 
Protein yield was improved (Figure 3.6b). 
 
(a) Level of PL3 expression after 3 hour induction at 37 °C. 
Lane 1: low molecular weight marker (Sigma); 
Lane 2: cell culture before induction; 
Lane 3: cell culture after 3-hour induction. 
 
(b) Level of PL3 expression after 16 hour induction at 16 °C. 
Lane 1: low molecular weight marker (Sigma); 
Lane 2: cell culture after 16-hour induction. 
Figure 3.6. 15% SDS-PAGE gel of samples taken during the expression of wtPL3 showing 
the levels of expression after (a) 3 hour induction at 37 °C, and (b) 16 hour induction at 
16 °C. Proteins were electrophoresed under reducing and denaturing conditions prior to 
staining with Coomassie brilliant blue R-250. 
 
The optimised expression condition was followed for all subsequent expression 
trials, and the same purification protocol described in Section 3.2.2 was 
followed. Surprisingly, very low level of wtPL3 could be eluted from the 
column. Instead, a large amount of protein was eluted during the column wash 
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step with 1 M NaOH (Figure 3.7). Since ion exchange chromatography 
depended the net surface charge of the protein which could be different if the 
protein was not correctly folded, the next step was therefore try to optimise the 
refolding condition. 
 (a) 
(a) Chromatogram of the 
elution step. The peak 
has a maximum UV 








(b) Chromatogram of the 
NaOH washing step. 
The peak has a 
maximum UV 





Figure 3.7. Chromatograms of (a) the elution step, and (b) the NaOH washing step of the 
initial cation exchange purification of wtPL3. Purification only produced a small amount 
of correctly folded PL3; a large amount of incorrectly folded PL3 was eluted during the 
NaOH column washing step. 
 
3.3.3.2 Optimisation of the purification condition for pET46-PL3 
The protocol as described in Section 3.2.2 was followed for the preparation and 
solubilisation of wtPL3 inclusion bodies.  
 
The volume of the refolding buffer (0.5 M L-arginine, 0.6 mM oxidized 
glutathione) was reduced from 1 L to 500 ml to increase the concentration of 
wtPL3, which may assist correct protein refolding. Subsequent cation exchange 




The yield of wtPL3 protein from this purification was significantly improved 
compared with the original protocol; however, the elution of wtPL3 only began 
when the concentration of NaCl was close to 0.8 M. To further optimise the 
purification protocol, the maximum NaCl concentration was increased to 1.5 M 
during the elution step, whilst the optimised solubilisation and refolding steps, 
as well as the subsequent HPLC purification protocol were followed. Pure 
wtPL3 was obtained at the end of the two-step purification (Figure 3.8), 
approximately 20 mg of wtPL3 per 1 L of bacterial culture.  
 (a) 
(a) Chromatogram of cation 
exchange purification; 
 
(b) Chromatogram of 
reverse phase HPLC 
purification; 
 
(c) 15% SDS-PAGE gel of 
purified wtPL3. 
Lane 1: low molecular 
weight marker (Sigma); 
Lane 2: wtPL3 purified 






Figure 3.8. Results of the purifications of wtPL3 from the BL21C
+
(DE3)-RIPL-pET-46 
Ek/LIC-PL3 strain. Protein sample was electrophoresed under reducing and denaturing 
conditions prior to staining with Coomassie brilliant blue R-250. Both (a) the cation 
exchange purification and (b) the reverse phase HPLC purification showed good 
separation of the target PL3 protein. Significant quantities of pure wtPL3 were obtained at 




3.3.4 Mass spectrometry analysis of tagged wild type pET46-PL3 
A single species with a molecular weight of 15539.53 Da was detected by mass 
spectrometry (Figure 3.9). This value matches the theoretical molecular weight 
(15539.4 Da) of the tagged PL3 with the methionine from the tag being 
removed.  
 
Figure 3.9. Result of the mass spectrometry analysis of wtPL3 sample. A single species 
with a molecular weight of 15539.53 Da was detected, matching the expected molecular 
weight of tagged wtPL3. 
 
3.3.5 His-tag removal of wtPL3  
Prior to proceeding with the following experiments, the tagged wtPL3 was used 
in the formation of PL3pRI complex where precipitation was observed (Section 
4.3.2). Considering the N-terminal hexahistidine tag of PL3 could hinder the 
formation of PL3pRI complex, experiments were carried out in order to remove 
the N-terminal hexahistidine tag by enterokinase. Two enterokinase enzymes 




3.3.5.1 His-tag cleavage by EKMax  
A pilot study was carried out to determine the appropriate concentration of 
EKMax needed for tag cleavage. SDS-PAGE analysis of the pilot study of His-
tag cleavage by EKMax is shown in Figure 3.10. All concentrations of EKMax 
used showed a certain level of digestion; and 0.1 unit of EKMax was the 
minimal amount tested that was sufficient to completely digest 20 μg of PL3 
protein in 16 hours.  
 
Lane 1: tagged PL3 with 0 unit of 
EKMax; 
Lane 2: tagged PL3 with 0.001 unit 
of EKMax; 
Lane 3: tagged PL3 with 0.01 unit of 
EKMax; 
Lane 4: tagged PL3 with 0.1 unit of 
EKMax; 
Lane 5: tagged PL3 with 1 unit of 
EKMax; 
Lane 6: tagged PL3 with 4 unit of 
EKMax; 
Lane 7: PageRuler Plus Prestained 
Protein Ladder (Thermo 
Scientific). 
Figure 3.10. 15% SDS-PAGE gel of samples of the pilot study of His-tag cleavage by 
EKMax. Protein samples were electrophoresed under reducing and denaturing conditions 
prior to staining with Coomassie brilliant blue R-250. 0.1 unit of EKMax was the minimal 
amount tested that was sufficient to completely digest 20 μg of PL3 protein in 16 hours. 
 
3.3.5.2 Purification of EKMax digested wtPL3 by affinity chromatography 
The reaction of the His-tag cleavage of wtPL3 with 0.1 unit of EKMax was 
scaled up in a linear fashion to produce more untagged wtPL3. A total amount 
of 9.2 mg of wtPL3 was digested with 46 unit of EKMax for 16 hours at room 
temperature. The EKMax was removed from the PL3 sample by affinity 
chromatography with a 1 ml HiTrap Benzamidine FF (High Sub) column from 
GE Healthcare. Flow through from all steps were collected and analysed by 
SDS-PAGE (Figure 3.11). Untagged PL3 did not show sign of interaction with 






Lane 1: flow through of the loading 
step; 
Lane 2: flow through of the first 
washing step; 
Lane 3: flow through of the second 
washing step; 
Lane 4: eluate; 
Lane 5: PageRuler Plus Prestained 
Protein Ladder (Thermo 
Scientific). 
Figure 3.11. 15% SDS-PAGE gel of samples collected during the benzamidine affinity 
chromatography purification of EKMax digested PL3. Protein samples were 
electrophoresed under reducing and denaturing conditions prior to staining with 
Coomassie brilliant blue R-250. Untagged PL3 was present in the fractions of loading and 
the first washing steps. The calculated molecular weight of EkMax is 26.3 kDa; however, 
it appears on SDS-PAGE gels as 46 kDa due to glycosylation (LaVallie et al., 1993). 
 
3.3.5.3 His-tag cleavage by rEK 
Due to a short-term discontinuation of EKMax, rEK from NEB was used 
instead in future experiments. Another pilot study was carried out using rEK to 
ensure a similar efficiency as EKMax could be achieved by rEK. SDS-PAGE 
analysis of the pilot study of His-tag cleavage by rEK is shown in Figure 3.12. 
All concentrations of rEK used showed a certain level of digestion. 0.1 unit of 
rEK could cleave the majority of the 20 μg PL3, indicated by the very weak 
band corresponding to the tagged PL3 and a lower strong band of untagged PL3 
protein. The results suggested that 1 unit of rEK was the minimal amount tested 
that was sufficient to completely digest 20 μg of PL3 protein in 16 hours.  
 
Lane 1: tagged PL3 with 0 unit of rEK; 
Lane 2: tagged PL3 with 10
-3
 unit of 
rEK; 
Lane 3: tagged PL3 with 10
-2
 unit of 
rEK; 
Lane 4: tagged PL3 with 10
-1
 unit of 
rEK; 
Lane 5: tagged PL3 with 1 unit of rEK; 
Lane 6: tagged PL3 with 4 unit of rEK; 
Lane 7: PageRuler Plus Prestained 
Protein Ladder (Thermo 
Scientific). 
Figure 3.12. 15% SDS-PAGE gel of samples of the pilot study of His-tag cleavage of wtPL3 
by rEK. Protein samples were electrophoresed under reducing and denaturing conditions 
prior to staining with Coomassie brilliant blue R-250. 1 unit of rEK was the minimal 





3.3.5.4 Purification of rEK digested wtPL3 by affinity chromatography 
The reaction of the His-tag cleavage of wtPL3 with 1 unit of rEK was scaled up 
in a linear fashion to produce more untagged wtPL3. A total amount of 7.75 mg 
of wtPL3 was digested with 387.5 unit of rEK for 16 hours at room temperature. 
The rEk was removed from the PL3 sample by benzamidine affinity 
chromatography. Flow through from all steps was collected and analysed by 
SDS-PAGE (Figure 3.13). Untagged PL3 was mainly present in the fractions of 
loading and the first washing steps. 
 
 
Lane 1: flow through of the 
loading step; 
Lane 2: flow through of the first 
washing step; 
Lane 3: flow through of the 
second washing step; 
Lane 4: eluate; 




Figure 3.13. 15% SDS-PAGE gel of samples collected during the benzamidine affinity 
chromatography purification of rEK digested PL3. Protein samples were electrophoresed 
under reducing and denaturing conditions prior to staining with Coomassie brilliant blue 
R-250. Untagged PL3 was present mainly in the fractions of loading and the first washing 
steps. The calculated molecular weight of rEk is 26.3 kDa; however, it appears on SDS-
PAGE gels as 31 kDa (NEB P8070S). 
 
3.3.5.5 Purification of rEK digested wtPL3 by reverse phase HPLC 
chromatography 
Fractions of the first two steps of the benzamidine affinity chromatography 
purification were pooled and further purified by reverse phase HPLC 






Figure 3.14. Chromatogram of reverse phase HPLC purification of untagged PL3 showing 
good separation of the untagged PL3 protein.  The peak has a maximum UV absorbance of 
~2700 mAU. 
 
3.3.6 Mass spectrometry analysis of untagged wtPL3 
The untagged PL3 protein sample (10 mg/ml) was analysed by mass 
spectrometry. The abundant species detected had a molecular weight of 
13957.95 Da, which was consistent with that of the untagged (Met-0) PL3. 
Another species weighed 15539.53 Da could be detected weakly, which 
corresponds to that of the tagged PL3 (Figure 3.15). 
 
Figure 3.15. Result of the mass spectrometry analysis of untagged wtPL3 sample. The 
abundant species detected had a molecular weight of 13957.95 Da, consistent with the 
expected molecular weight of untagged (Met-0) PL3. Another species weighed 15539.53 Da 
could be detected weakly, which corresponds to the molecular weight of tagged PL3. 
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3.3.7 Construction of PL3 D80A mutant 
3.3.7.1 First attempt 
The protocol described in Section 3.2.9 was followed to prepare the pET-46 
Ek/LIC-PL3 D80A construct using the gene of wtPL3. However, the DNA 
sequencing result of the ET-46 Ek/LIC-PL3 D80A plasmid suggested that the 
constructed mutant was D80M rather than the desired D80A mutant. 
 
3.3.7.2 Second attempt 
In the second attempt, two parameters of the PCR recipe were modified: betaine 
was removed from the recipe to prevent it from over-reducing primer binding to 
the template; PfuUltra II Fusion HS DNA Polymerase was used (Table 3.11). 
Unfortunately, the mutation from the second attempt was still D80M; therefore 
it was likely that the primers had the wrong sequence. 
 






Forward primer (10 M) 1.5 μl 
Reverse primer (10 M) 1.5 μl 
Template PL3 DNA 2 μl 
dNTP mix (2 mM each) 5 μl 
25 mM MgSO4 2 μl 
10  PCR Buffer for KOD Hot Start DNA Polymerase 5 μl 
KOD Hot Start DNA Polymerase 1 μl 
H2O 32 μl 







Forward primer (10 M) 1 μl 
Reverse primer (10 M) 1 μl 
Template PL3 DNA 1 μl 
dNTP mix (2 mM each) 5 μl 
10  PfuUltra II Reaction Buffer 5 μl 
PfuUltra II Fusion HS DNA Polymerase (Agilent Technologies) 1 μl 
H2O 36 μl 
Forward primer (10 M) 1 μl 
TOTAL 50 μl 
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3.3.7.3 Third attempt 
A fresh set of primers (same sequences as shown in Table 3.7) was ordered 
from Eurofins MWG Operon, and the protocol described in Section 3.2.9 was 
followed. The plasmid DNA was sequenced, and the result was aligned with the 
native PL3 DNA obtained from the NCBI database (Gene ID: 396976) (Figure 
3.16). The alignment confirmed that the pET-46 Ek/LIC-PL3 D80A plasmid 
was successfully constructed and transformed into Top 10 cells. The plasmid 
was then used to prepare the expression strain. 
 
Figure 3.16. Sequence alignment of PL3 gene from the cloning strain of pET-46 Ek/LIC-
PL3 and the PL3 gene sequence obtained from NCBI database (Gene ID: 396976). 
Alignment was performed using Clustal Omega online server (Sievers et al., 2011; 
McWilliam et al., 2013). Bases coloured in red indicate the mutation sites. GAC in the 
sequence of wild type PL3 codes for aspartic acid (Asp or D); GCG in the sequence of PL3 
D80A codes for alanine (Ala or A). 
 
CLUSTAL O(1.2.0) multiple sequence alignment 
(Clustal Omega) 
 
wtPL3     ------------------------------------------------------------ 
PL3D80A-2 GAATAATTTTGTTTAACTTTAAGAAGGAGATATACCATGGCACATCACCACCACCATCAC 
                                                                             
 
wtPL3     ---------------------CAGGATCGCATGTACCAACGATTCCTGCGGCAACACGTG 
PL3D80A-2 GTGGATGACGACGACAAGATGCAGGATCGCATGTACCAACGATTCCTGCGGCAACACGTG 
                               *************************************** 
 
wtPL3     GACCCTGATGCGACAGGTGGCAATGATGCCTACTGCAACTTGATGATGCAAAGACGGAAG 
PL3D80A-2 GACCCTGATGCGACAGGTGGCAATGATGCCTACTGCAACTTGATGATGCAAAGACGGAAG 
          ************************************************************ 
 
wtPL3     ATGACTTCACATTATTGCAAGCGCTTCAACACTTTCATTCATGAAGACATTTGGAACATT 
PL3D80A-2 ATGACTTCACATTATTGCAAGCGCTTCAACACTTTCATTCATGAAGACATTTGGAACATT 
          ************************************************************ 
 
wtPL3     CGTAGTATCTGCAGCACCTCCAATATTCAGTGCAAGAATGGCCAGATGAACTGCCATGAG 
PL3D80A-2 CGTAGTATCTGCAGCACCTCCAATATTCAGTGCAAGAATGGCCAGATGAACTGCCATGAG 
          ************************************************************ 
 
wtPL3     GGCGTGGTGAAGGTCACAGACTGCAGGGAGACAGGAAGTTCCAGGGCTCCCAACTGCAGA 
PL3D80A-2 GGCGTGGTGAAGGTCACAGCGTGCAGGGAGACAGGAAGTTCCAGGGCTCCCAACTGCAGA 
          *******************. *************************************** 
 
wtPL3     TACCGGGCCATGGCCAGCACTAGACGGGTTGTCATTGCCTGTGAGGGTAATCCAGAGGTG 
PL3D80A-2 TACCGGGCCATGGCCAGCACTAGACGGGTTGTCATTGCCTGTGAGGGTAATCCAGAGGTG 
          ************************************************************ 
 
wtPL3     CCTGTGCACTTTGACAAATAG--------------------------------------- 
PL3D80A-2 CCTGTGCACTTTGACAAATAGTAACCGGGCTTCTCCTCAAATCTCGAGTCTGGTAAAGAA 
          *********************                                        
 




3.3.8 Expression and purification of tagged PL3 D80A mutant 
PL3 D80A was expressed and purified from inclusion bodies following the 
optimised protocol outlined in Appendix II (Figure 3.17). 
 (a) 
(a) Chromatogram of cation 
exchange purification of 
PL3 D80A mutant. The 
peak has a maximum UV 
absorbance of ~470mAU. 
 
(b) 
(b) Chromatogram of reverse 
phase HPLC purification 
of PL3 D80A mutant. The 
peak has a maximum UV 
absorbance of ~2700 
mAU. 
 
Figure 3.17. Chromatograms of (a) cation exchange purification, and (b) reverse phase 
HPLC purification of PL3 D80A mutant, showing good separation of PL3 D80A protein.  
 
3.3.9 Mass spectrometry analysis of tagged PL3 D80A mutant 
The tagged PL3 D80A protein sample (8.9 mg/ml) was analysed by mass 
spectrometry. A single species with a molecular weight of 15495.58 Da was 
detected (Figure 3.18). This value matches the theoretical molecular weight 
(15495.4 Da) of the tagged PL3 D80A mutant with the methionine from the tag 




Figure 3.18. Result of the mass spectrometry analysis of tagged PL3 D80A mutant sample. 
A single species with a molecular weight of 15495.58 Da was detected, corresponding to 
the calculated molecular weight of tagged PL3 D80A.  
 
3.3.10 His-tag removal of PL3 D80A mutant 
3.3.10.1 His-tag cleavage by rEK 
Following the protocol outlined in Section 3.2.6, rEK was used to cleave the 
His tag from purified PL3 D80A. SDS PAGE analysis confirmed that cleavage 
was successful, as shown in Figure 3.19. All concentrations of rEK used 
showed a certain level of digestion. Similar to the results of His-tag cleavage of 
wtPL3 by rEK, 0.1 unit of rEK could cleave the majority of the 20 μg PL3 
D80A protein, and 1 unit of rEK was the minimal amount tested that was 





Lane 1: low molecular weight 
marker (Sigma); 
Lane 2: tagged PL3 D80A with 0 
unit of rEK; 
Lane 3: tagged PL3 D80A with 
10
-3
 unit of rEK; 
Lane 4: tagged PL3 D80A with 
10
-2
 unit of rEK; 
Lane 5: tagged PL3 D80A with 
10
-1
 unit of rEK; 
Lane 6: tagged PL3 D80A with 1 
unit of rEK; 
Lane 7: tagged PL3 D80A with 4 
unit of rEK. 
Figure 3.19. 15% SDS-PAGE gel of samples of the pilot study of His-tag cleavage of PL3 
D80A mutant by rEK. Protein samples were electrophoresed under reducing and 
denaturing conditions prior to staining with Coomassie brilliant blue R-250. 1 unit of rEK 
was the minimal amount tested that was sufficient to completely digest 20 μg of PL3 D80A 
protein in 16 hours. 
 
3.3.10.2 Purification of rEK digested PL3 D80A mutant by affinity 
chromatography 
A total amount of 10.12 mg of concentrated PL3 D80A sample was digested by 
rEk, which was subsequently removed from the protein sample by benzamidine 
affinity chromatography. Flow through from all steps were analysed by SDS-
PAGE (Figure 3.20). Untagged PL3 D80A protein did not show sign of 
interaction with benzamidine, and was present mainly in the fractions of 
loading and the first washing steps. 
 
Lane 1: low molecular weight marker (Sigma); 
Lane 2: flow through of the loading step; 
Lane 3: flow through of the first washing step; 
Lane 4: flow through of the second washing step; 
Lane 5: eluate. 
Figure 3.20. 15% SDS-PAGE gel of samples collected during the benzamidine affinity 
chromatography purification of rEK digested PL3 D80A mutant. Protein samples were 
electrophoresed under reducing and denaturing conditions prior to staining with 
Coomassie brilliant blue R-250. Untagged PL3 D80A was present mainly in the flow 
through of loading and the first washing steps. The calculated molecular weight of rEk is 




3.3.10.3 Purification of rEK digested PL3 D80A mutant by reverse phase HPLC 
chromatography 
Fractions collected from the first two steps of the benzamidine affinity 
chromatography purification were pooled and further purified by reverse phase 
HPLC chromatography. Untagged PL3 D80A protein elution started with ~50% 
acetonitrile·TFA (Figure 3.21).  
 
Figure 3.21. Chromatogram of reverse phase HPLC purification of untagged PL3 D80A 
mutant showing good separation of the untagged PL3 D80A protein. The peak has a 
maximum UV absorbance of ~2700 mAU. 
 
3.3.11 Mass spectrometry analysis of untagged PL3 D80A mutant 
The untagged PL3 D80A protein sample (10.5 mg/ml) was analysed by mass 
spectrometry. A single species with a molecular weight of 13913.94 Da was 
detected (Figure 3.22), which was consistent with the theoretical molecular 




Figure 3.22. Result of the mass spectrometry analysis of untagged PL3 D80A mutant 
sample. A single species with a molecular weight of 13913.94 Da was detected, matching 
the calculated molecular weight of the untagged (Met-0) PL3 D80A mutant. 
 
3.3.12 Ribonucleolytic activity assay of wtPL3 and PL3 D80A mutant 
The ribonucleolytic activities of tagged and untagged wtPL3 and PL3 D80A 
protein samples were analysed by conducting the tRNA cleavage assays as 
described by Shapiro et al. (1987). This assay was originally performed to 
measure the ribonucleolytic activity of hANG, and has been widely used as a 
‘robust method’ to assess the activities of other RNase A homologues, 
especially those purified from inclusion bodies. Since ANG possesses 
ribonucleolytic activity, it was used as a control to assess the relative 
ribonucleolytic activity of PL3 and PL3 D80A mutant proteins. 
 
The result of the initial RNase assay experiment revealed that native PL3 
protein is more active than native hANG with the same concentration. The four 
PL3 samples used in the subsequent assay experiments were therefore diluted to 
0.04 g/ml whilst the concentration of hANG was kept as 40 g/ml, which 




The absorbance readings of all protein samples were plotted on the same graph 
(Figure 3.23). The relative activity of each test sample was calculated using the 
method described by Crabtree et al. (2007). 
 
The results (Figure 3.23) showed that all four PL3 samples were active towards 
tRNA; and both tagged and untagged wtPL3 were more active towards tRNA 
than the two PL3 D80A protein samples. The relative activities of test proteins 
suggested that the D80A substitution slightly reduced the ribonucleolytic 
activity of PL3. However, since the nucleic acid composition of the yeast tRNA 
was not specified, more analyses need to be performed in order to draw a solid 
conclusion on the effect of the D80A mutation on the general ribonucleolytic 
activity of PL3. 
 
Figure 3.23. Ribonucleolytic activities of PL3 and PL3 D80A samples. Y-axis is the 
absorbance of the supernatant of the reaction sampless at 260 nm; x-axis is the protein 
concentration at nM, values in blue are the concentrations of hANG, values in black are 
the concentrations of PL3 and PL3 D80A samples. All PL3 samples showed ribonucleolytic 
activity towards yeast tRNA. The activities for 0.3 nM to 0.5 nM of each test protein were 
multiplied 1,000-fold, divided by the activity of hANG, and averaged to give the final 
relative activity. Wild type PL3 samples were ~1000  more active than hANG, whilst PL3 
D80A samples were ~500  more active than hANG. 



























Protein Concentration (nM) 










Relative activity to hANG 
tagged wtPL3                 1081.78 
untagged wtPL3             994.15 
tagged PL3 D80A           689.66 
untagged PL3 D80A      489.19 
  
115 
3.3.13 Crystallisation of wtPL3 and PL3 D80A mutant 
Four protein samples, namely tagged wtPL3, untagged wtPL3, tagged PL3 D80A, 
and untagged PL3 D80A were used in the screening for crystallisation 
conditions.  
 
3.3.13.1 PCTs and initial screening for crystallisation conditions 
PCTs were first performed, the results of which suggested that 10 mg/ml was an 
appropriate starting concentration for all four samples tested. Microcrystals 





Table 3.12. Initial crystallisation conditions of wtPL3 and PL3 D80A mutant. 
tagged wtPL3 
Structure screen I & II – C3 
0.1 M sodium HEPES pH 7.5, 
1.5 M lithium sulphate 
Structure screen I & II – E5 0.1 M Tris pH 8.4, 25% v/v tert-butanol 
Structure screen I & II – E9 0.1 M Tris pH 8.5, 20% v/v ethanol 
Structure screen I & II – H3 
0.1 M sodium acetate pH 4.6,  
0.2 M ammonium sulphate,  
30% w/v PEG 2000 MME 
JCSG-plus – C7 
0.1 M sodium acetate pH 4.5,  
0.2 M zinc acetate dihydrate,  
10% w/v PEG 3000 
Morpheus – E11 
0.1 M Buffer System 3
1
 pH 8.5, 






Morpheus – F10 







Morpheus – F11 
0.1 M Buffer System 3 pH 8.5, 
0.12 M Monosaccharides, 
30% v/v GOL_P4K 
untagged wtPL3 
JCSG-plus – E7 
0.1 M sodium cacodylate pH 6.5, 
0.2 M zinc acetate dihydrate,  
10% v/v 2-Propanol 
tagged PL3 D80A mutant 
Structure screen I & II – A3 
0.1 M sodium acetate pH 4.6, 
0.2 M ammonium sulphate, 25% v/v PEG 4000 
Structure screen I & II – A7 
0.1 M sodium citrate pH 5.6, 
0.2 M ammonium acetate, 30% v/v PEG 4000 
Structure screen I & II – H3 
0.1 M sodium acetate pH 4.6, 
0.2 M ammonium sulphate,  
30% v/v PEG 2000 MME 
Structure screen I & II – H12 1.6 M sodium citrate pH 6.5 
JCSG-plus – E1 
0.1 M sodium cacodylate pH 6.5, 
1.0 M sodium citrate tribasic dihydrate 
untagged PL3 D80A mutant 
Structure screen I & II – B7 
0.1 M sodium cacodylate pH 6.5, 
0.2 M zinc acetate, 18% PEG 8000 
Structure screen I & II – E8 0.1 M Tris pH 8.5, 50% v/v MPD 
JCSG-plus – A6 
0.1 M phosphate/citrate pH 4.2, 
0.2 M lithium sulphate, 20% PEG 1000 
1
 Composition of Buffer System 3: Tris (base) and Bicine; 
2
 Composition of Ethylene Glycols: di-ethyleneglycol, tri-ethyleneglycol, tetra-ethyleneglycol, 
and penta-ethyleneglycol;  
3
 Composition of GOL_P4K: glycerol and PEG 4000;  
4
 Composition of Monosaccharides: D-glucose, D-mannose, D-galactose, L-fucose, D-xylose, 
and N-Acetyl-D-glucosamine;  
5




3.3.13.2 Optimisation of crystallisation conditions for wtPL3 and PL3 D80A 
Larger crystals of tagged wtPL3 and tagged PL3 D80A could be obtained from 
the optimised crystallisation conditions listed in Table 3.13. Examples of these 
crystals are shown in Figure 3.24. 
 
Table 3.13. Optimised crystallisation conditions of wtPL3 and PL3 D80A. 
tagged wtPL3 
0.1 M Tris pH 8.5, 20 – 10% v/v ethanol 
0.1 M sodium acetate pH 4.5, 0.2 M zinc acetate dihydrate, 15% w/v PEG 3000 
0.1 M Morpheus Buffer System 3 pH 8.5, 0.12 M Monosaccharides,  
30% – 15 v/v EDO_P8K 
tagged PL3 D80A mutant 
0.1 M sodium cacodylate pH 6.5, 1.0 M sodium citrate tribasic dihydrate 
 
  
(a) – (c) crystals 





(d) crystals of 
tagged PL3 D80A 
protein. 
  







3.3.14 Crystallisation of wtPL3·dUMP and PL3 D80A·dCMP complexes 
3.3.14.1 Soaking tagged wtPL3 crystals with (UpA)5 and dUMP ligands 
(UpA)5 oligonucleotide was initially used in the soaking experiment, as UpA 
was used in the substrate preference experiments of RNase 4. However, 
preliminary analysis on the datasets suggested no ligand was bound in the 
crystals. 
 
Considering the fact that (UpA)5 is a hydrolysable ligand of PL3, the likelihood 
of successfully co-crystallising PL3 with this ligand would be low. A group of 
non-hydrolysable ligands commonly used in the studies of RNases is the 2'-
deoxy-2'-fluorouribose substrate analogues, such as 2'-deoxy-2'-fluorouridylyl-
3',5'-adenosine (2'-F-dUpA). As these substrates would have to be specially 
synthesised, a commercially available mononucleotide 2'-deoxyuridine-5'-
monophosphate (dUMP) was firstly chosen. 
 
Datasets were collected using dUMP soaked wtPL3 crystals; however, analyses 
of the datasets suggested that the crystals were ligand-free. As soaking 
experiments did not produce complex crystals, co-crystallisation was then 
performed. 
 
3.3.14.2 PCTs and initial screenings for crystallisation conditions 
To study the structural basis of RNase 4 substrate recognition, especially the 
role Asp-80 plays, we chose dUMP and dCMP as the ligands for wtPL3 and PL3 
D80A respectively. 
 
PCTs were first performed using protein samples (tagged wtPL3, untagged 
wtPL3 tagged PL3 D80A and untagged PL3 D80A) mixed with their 
corresponding ligands in a 1:1.2 molar ratio. The results of PCT suggested that 
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a final concentration of 9 mg/ml was an appropriate starting point for all four 
samples tested. Microcrystals were observed in several conditions from the 
subsequent 96-well screenings (Table 3.14). 
 
Table 3.14. Initial crystallisation conditions of wtPL3·dUMP and PL3 D80A·dCMP. 
tagged wtPL3·dUMP 
PACT permier – A5 0.1 M SPG buffer pH 8.0, 25% w/v PEG 1500 
JCSG-plus – C7 
0.1 M sodium acetate pH 4.5, 0.2 M zinc acetate, 
10% w/v PEG3000 
JCSG-plus – D4 
0.1 M sodium acetate pH 4.5, 
0.2 M lithium sulphate, 30% w/v PEG8000 
JCSG-plus – E7 
0.1 M sodium cacodylate pH 6.5,  
0.2 M zinc acetate dihydrate, 10% v/v 2-propanol 
untagged wtPL3·dUMP 
JCSG-plus – E7 
0.1 M sodium cacodylate pH 6.5,  
0.2 M zinc acetate dihydrate, 10% v/v 2-propanol 
ProPlex – E7 0.1 M sodium phosphate pH 6.5, 12 % PEG 8000 
Stura + MacroSol – G7 0.2 M ammonium sulphate, 24% w/v PEG 8000 
tagged PL3 D80A·dCMP 
Structure screen I & II – A7 
0.1 M sodium citrate pH 5.6, 
0.2 M ammonium acetate, 30% v/v PEG 4000 
Structure screen I & II – A9 
0.1 M sodium citrate pH 5.6,  
20% v/v 2-propanol, 20% w/v PEG4000 
Structure screen I & II – B7 
0.1 M sodium cacodylate pH 6.5,  
0.2 M zinc acetate, 18% PEG8000 
ProPlex – B5 
0.1 M sodium HEPES pH 7.5, 
0.1 M magnesium chloride, 10% w/v PEG 4000 
 
Additive screenings 
Since the crystals of tagged PL3 D80A·dCMP initially observed in the 
conditions listed in Table 3.14 were thin needle shaped, which could be 
different to fish out from the drops and more easily broken by high energy X-
rays, therefore additive screenings were also performed for the tagged PL3 
D80A·dCMP complex. A few conditions from the additive screenings produced 
crystals; however they still showed morphology of thin and long needles, 




3.3.14.3 Optimisation of crystallisation conditions for wtPL3·dUMP and PL3 
D80A·dCMP complexes 
Crystals of untagged wtPL3·dUMP and tagged PL3 D80A·dCMP complexes 
could be obtained from the optimised crystallisation conditions listed in Table 
3.15. Examples of these crystals are shown in Figure 3.25. 
Table 3.15. Optimised crystallisation conditions of wtPL3·dUMP and PL3 D80A·dCMP. 
untagged wtPL3·dUMP 
0.1 M sodium phosphate pH 6.5, 12 – 8% PEG 8000 
tagged PL3 D80A·dCMP 
0.1 M sodium citrate pH 5.6, 20 –15% v/v 2-propanol, 20 – 15% w/v PEG4000 
0.1 M sodium citrate pH 5.6, 0.2 M ammonium acetate, 26 – 20% v/v PEG 4000 
 
  






(b) – (d) crystals of 
tagged PL3 D80A·dCMP 
  
Figure 3.25. Examples of wtPL3·dUMP and PL3 D80A·dCMP protein crystals obtained 






3.3.15 Data collection and structure solutions of wtPL3, PL3 D80A mutant, 
wtPL3·dUMP and PL3 D80A·dCMP complexes 
3.3.15.1 Data collection and structure solutions of wtPL3 and PL3 D80A 
The crystals of tagged wtPL3 and tagged PL3 D80A shown in Figure 3.24c and 
Figure 3.24d diffracted to 1.17 Å (Figure 3.26) and ~2.8 Å (Figure 3.27) 
respectively. 
 
The structure of wtPL3 was solved in space group I2 (given by AIMLESS, 
equivalent to space group C2) at 1.25 Å with one molecule in the asymmetric 
unit (ASU); and the structure of PL3 D80A was solved in space group P1 at 2.9 
Å with four molecules in the ASU. Data collection and refinement statistics are 
shown in Table 3.16; Ramachandran plots of both structures are shown in 







Figure 3.26. Crystals and X-ray diffraction picture of wtPL3. (a) Diffraction image of a 
wtPL3 crystal showing diffractions at 1.17 Å; (b) the PL3 crystal mounted for data 









Figure 3.27. Crystals and X-ray diffraction picture of PL3 D80A mutant. (a) Diffraction 
image of a PL3 D80A mutant crystal showing diffractions at 2.9 Å; (b) the PL3 D80A 






Table 3.16. Data collection and refinement statistics of wtPL3 and PL3 D80A. 
 wtPL3 PL3 D80A mutant 
A. Data Collection Statistics 
Space Group I2 P1 
Cell 
a = 36.29 Å, 
b = 38.19 Å, 
c = 86.92 Å 
α = γ = 90°, 
β = 97.68° 
a = 30.83 Å, 
b = 61.82 Å, 
c = 68.89 Å 
α = 92.04°, β = 101°, 
γ = 101.2° 
No. of molecules in the ASU 1 4 








I/σ(I) 15.9 (4.4)* 8.0 (2.0)* 










B. Refinement Statistics 
Resolution range (Å) 50 – 1.25 50 – 2.90 
No. of reflections 215315 12420 
Unique No. of reflections 32743 7962 
Rcryst
b
 0.13 0.21 
Rfree
c
 0.15 0.28 
Number of non-H atoms:   
    Protein 1017 3853 
    Ligand 2 ethylene glycol 0 
    Water 130 0 
Average temperature factor (Å
2
) 19.5 65.8 
RMSD for bond lengths (Å) 0.01 0.009 
RMSD for bond angles (°) 1.45 1.28 
*
 Values in parentheses are for the outer shells, which is 1.27 – 1.25Å, and 3.08 – 2.90Å 
respectively. 
a
      
                
         
, where       and      are the i
th
 and the mean measurements of the 
intensity of reflection h, respectively. 
b
        
         
    
, where    and    are the observed and calculated structure factor amplitudes 
of reflection h, respectively. 
c






Figure 3.28. Ramachandran plot of wtPL3 structure, which has one molecule in the ASU. 
96.7% of the residues are lying in the most favoured regions. The Ramachandran plot was 





Figure 3.29. Ramachandran plot of PL3 D80A mutant structure, which has four molecules 
in the ASU. 94.5% of the residues are lying in the most favoured regions. The 





3.3.15.2 Data collection and structure solutions of wtPL3·dUMP and PL3 
D80A·dCMP complexes 
The crystals of untagged wtPL3·dUMP and tagged PL3 D80A·dCMP shown in 
Figure 3.25a and Figure 3.25d diffracted to ~2.1 Å (Figure 3.30) and ~2.25 Å 
(Figure 3.31) respectively. 
 
The structure of wtPL3·dUMP was solved in space group P212121 at 2.28 Å 
with four molecules in the ASU; and the structure of PL3 D80A·dCMP was 
solved in space group P1 at 2.6 Å with four molecules in the ASU. Data 
collection and refinement statistics are shown in Table 3.17; Ramachandran 







Figure 3.30. Crystals and X-ray diffraction picture of wtPL3dUMP complex. (a) 
Diffraction image of a wtPL3dUMP crystal showing diffractions at 2.2 Å; (b) the 










Figure 3.31. Crystals and X-ray diffraction picture of PL3 D80A·dCMP complex. (a) 
Diffraction image of a PL3 D80A·dCMP crystal showing diffractions at 2.25 Å; (b) The 
PL3 D80A·dCMP crystal mounted for data collection, the size of the red square is 
100μm 100μm. 





Table 3.17. Data collection and refinement statistics of wtPL3·dUMP and PL3 D80A·dCMP. 
 wtPL3·dUMP PL3 D80A·dCMP 
A. Data Collection Statistics 
Space Group P212121 P1 
Cell 
a = 76.19 Å, 
b = 91.32 Å, 
c = 93.43 Å 
α = β = γ = 90° 
a = 30.96 Å, 
b = 62.51 Å, 
c = 70.22 Å 
α = 89.78°, β = 79.21°, 
γ = 78.90° 
No. of molecules in the ASU 4 4 








I/σ(I) 14.7 (2.2)* 27.0 (10.7)* 










B. Refinement Statistics 
Resolution range (Å) 50 – 2.28 50 – 2.60 
No. of reflections 126853 43228 
Unique No. of reflections 29780 14168 
Rcryst
b
 0.23 0.25 
Rfree
c
 0.29 0.30 
Number of non-H atoms:   
    Protein 3840 3864 
    Ligand 4 dUMP, 2 PO4
3-
 4 dCMP 
    Water 83 0 
Average temperature factor (Å
2
) 48.3 46.1 
RMSD for bond lengths (Å) 0.01 0.01 
RMSD for bond angles (°) 1.41 1.51 
*
 Values in parentheses are for the outer shell, which is 2.34 – 2.28Å, and 2.72 – 2.60Å 
respectively. 
a
      
                
         
, where       and      are the i
th
 and the mean measurements of the 
intensity of reflection h, respectively. 
b
        
         
    
, where    and    are the observed and calculated structure factor amplitudes 
of reflection h, respectively. 
c





Figure 3.32. Ramachandran plot of wtPL3dUMP complex structure, which has four 
molecules in the ASU. 98.1% of the residues are lying in the most favoured regions. The 






Figure 3.33. Ramachandran plot of the refined PL3 D80A·dCMP complex structure, 
which has four molecules in the ASU. 94.9% of the residues are lying in the most favoured 
regions. The Ramachandran plot was calculated using PROCHECK (Laskowski et al., 




3.4 Structural analysis 
3.4.1 Structures of wtPL3 and PL3 D80A mutant 
3.4.1.1 Overall structures 
Structure of wtPL3 
The crystal structure of wtPL3 was determined at 1.25 Å resolution with well 
defined electron density (Figure 3.34). There is one molecule in the ASU. The 
final model comprises residues -2 – 119 with 6 side chains in alternative 
conformations, 2 ethylene glycol molecules, and 130 water molecules. 
Ramachandran plot revealed that 96.7% of the residues in the structures are in 
the most favourable regions with the remainder in the allowed regions (Figure 
3.28 in Section 3.3.15.1). 
 
The structure of wtPL3 adopts the characteristic α/β fold of RNase A, with three 
α helices and four β strands (Figure 3.35; Table 3.18). The structure is stabilised 
by four disulphide bonds (Figure 3.35). The main chain is well ordered apart 
from residues 84 – 86 in the L5 loop linking β2 and β3. High flexibility of 
corresponding regions is a characteristic feature of members of the RNase A 
superfamily, and is poorly defined in crystal structures of hEDN (Leonidas et 
al., 2001; Mosimann et al., 1996; Swaminathan et al., 2002), hECP (Boix et al., 
1999a), hANG (Leonidas et al., 1999a), and murine ANG-1 (mANG-1) 
(Holloway et al., 2005).  
 
The RNA binding subsites are also identified in the structure of PL3 (Figure 
3.36). Subsite P0 has only one residue, Lys-65; the catalytic subsite P1 consists 
of Gln-11, His-12, Lys-40, and His-116; Arg-7 and Arg-10 contribute to subsite 
P2. The subsite B1 consists of residues Phe-43, Asn-43, Thr-44, and Phe-117, 
and has a preference for uracil base; residues Asn-66, Gln-68, Asn-70, and Glu-






Figure 3.34. 2Fo-Fc electron density maps (contoured at 1.0σ) of the crystal structure of 
wtPL3: (a) the catalytic histidine at position 12; (b) the disulphide bond formed by Cys-64 
and Cys-71; (c) residue Ser-55 in alternative conformations; (d) the water network near 






Table 3.18. Secondary structure elements of wtPL3.  
α helices β strands Loops 
α1 Gln-1 – His-12 β1 Phe-42 – Ile-46 L1 Val-13 – Asn-21 
α2 Asp-22 – Arg-31 β2 Cys-71 – Glu-83 L2 Arg-32 – Arg-41 
α3 Ile-50 – Ile-56 β3 Tyr-94 – Glu-108 L3 His-47 – Asp-49 
 β4 Val-113 – Phe-117 L4 Cys-57 – Asn-70 
  L5 Thr-84 – Arg-93 
  L6 Gly-109 – Glu-112 
  L7 Asp-118 – Lys-119 
All elements are defined by PROCHECK (Laskowski et al., 1993; Vaguine et al., 1999; Winn 
et al., 2011); the three residues from the N-terminal tag are excluded. 
 
 
Figure 3.35. Cartoon representation of the structure of wtPL3 in stereo view. Disulphide 
bond forming cystines are labelled and shown in violet; α helices, β strands and loop 








Figure 3.36. Subsites of PL3 involved in the binding of RNA. (a) Surface diagram of the three-dimensional structure of PL3 showing the subsites involved in the 
recognition and degradation of RNA. B and P indicate the base and phosphate binding subsites respectively; (b) Schematic representation of the recognition of an 
RNA fragment (UpA) by PL3. Residues in the different subsites are labelled. The phosphate group of the phosphodiester bond to be hydrolysed by the enzyme 




Structure of PL3 D80A mutant 
The crystal structure of PL3 D80A was determined at 2.9 Å resolution with four 
molecules in the ASU (Figure 3.37). The final model of PL3 D80A includes 
residues 0 – 119 in molecule A, 1 – 119 in molecule B, -1 – 119 in molecules C 
and D. Ramachandran plot suggests that 95.1% of the residues in the structures 
of PL3 D80A are in the most favourable regions with the remaining 4.9% in the 
allowed regions (Figure 3.29 in Section 3.3.15.1).  
 
PISA analysis (http://www.ebi.ac.uk/pdbe/prot_int/pistart.html) (Krissinel and 
Henrick, 2007) of the structure suggests none of the potential dimers in the 
ASU appears to be biologically relevant. PISA server calculates a complexation 
significance score (CSS) based on the molecular contacts at the interface, 
indicating the likelihood for a packing interface observed in a crystal structure 
to be also observed in solution. Although there are one or two hydrogen bonds 
identified between A-D and B-C dimers (Table 3.19), the CSS scores for all the 
potential dimers are 0, suggesting the arrangement of the molecules in the ASU 
is a result of crystal packing. 
 
Figure 3.37. Arrangement of the four molecules of PL3 D80A in the ASU. The P0, P1, P2, B1, 




Table 3.19. Potential hydrogen bonds at various dimer interfaces within the ASU of the 
PL3 D80A structure. 
Hydrogen bond 
(donor – acceptor) 
Distance (Å) 
DVal-75 N – A Gly-67 O 3.17 
B Val-75 N – C Gly-67 O 3.05 
C Gln-63 NE2 – B Glu-73 O 3.14 
Potential hydrogen bonds shorter than 3.3 Å with D-H…A angle > 120° identified by HBPLUS 
(McDonald and Thornton, 1994) are shown. 
 
The four molecules of PL3 D80A mutant in the ASU are highly similar: 
superposition of molecules B, C, and D with molecule A reveals an rmsd value 
of 0.1 Å, 0.04 Å, and 0.1 Å for C
α
 atoms respectively. The average B-factor of 
molecule C is the lowest amongst all, suggesting it is the most ordered molecule 
in the ASU. Hence it will be used as a reference for all further discussion. The 
position of Ala-80 is well defined in the electron density maps, an example is 
shown in Figure 3.38. 
 
Figure 3.38. Stereo view showing the 2Fo-Fc electron density map (contoured at 1.0σ) of 
the refined model of PL3 D80A mutant in the region where the D80A mutation lies. 
 
3.4.1.2 Comparison of PL3 with hRNase 4 
The comparison of wtPL3 and hRNase 4 structures will be the main focus on 
here, as wtPL3 has the most similar conformation as that of hRNase 4 within the 
RNase A superfamily. The levels of similarity between the structures of wtPL3 
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and RNase A, hEDN, hECP, hRNase 4, and hANG were analysed by DaliLite 
(Holm and Park, 2000; McWilliam et al., 2013) pairwise three-dimensional 
structure alignments.  
 
Least-square superposition of wtPL3 with hRNase 4 (Figure 3.39) yields an rms 
deviation of 0.398 Å for C
α
 atoms, indicating wtPL3 is structurally very similar 
to hRNase 4. The secondary structure elements of wtPL3 and hRNase 4 mostly 
coincide, with two minor differences in the lengths of α2 (Ile-50 – Ile-56 in 
wtPL3 and Ile-50 – Ser-58 in hRNase 4) and β4 (Val-113 – Phe-117 in wtPL3 
and Val-113 – Gly-119 in hRNase 4). This is not at all surprising, as RNase 4 
proteins are highly conserved, and wtPL3 and hRNase 4 have a primary 
structure identity of 87.4%. 
 
Figure 3.39. Superposition of the structure of PL3 with that of hRNase 4 (PDB: 1RNF; 
Terzyan et al., 1999). PL3 and hRNase 4 are coloured in marine and grey respectively. 
Subsites P0, P1, P2, B1, and B2 are marked by green, red, yellow, cyan, and pink circles; 









The locations and residue compositions of the different RNA binding subsites 
of PL3 are almost identical to those of hRNase 4 (Figure 3.39). Like hRNase 4, 
the conserved residues Gln-11, His-12, Lys-40, and His-116 comprise the P1 
catalytic site of PL3; and side chain orientations of these residues are highly 
similar to those of the hRNase 4 (Figure 3.40).  
 
Figure 3.40. The P1 active sites of PL3 and hRNase 4 (PDB: 1RNF; Terzyan et al., 1999). 
PL3 and hRNase 4 are coloured in marine and grey respectively. 
 
The P0, P2, B1, and B2 subsites are highly conserved between PL3 and hRNase 4 
(Figure 3.41-3.42); and the side chain orientations are highly similar. The less 
well superposed P0 and B2 subsites of PL3 and hRNase 4 are likely due to the 
fact that they are located at loop regions with higher flexibility. 
Amongst the four subsites, there is a single amino acid difference at position 68 
in the B2 subsite: residue lysine in hRNase 4 is substituted with glutamine in 
PL3 (Figure 3.42b). B2 subsite is where the recognition of the adenine base 3' to 
the phosphodiester bond being hydrolysed occurs, with one of the four residues 
being substituted, the tightness of the binding between the ligand and the 
protein could be slightly affected, which may in turn affects the turnover rate of 
RNA molecules. However, we still need coupled catalytic activities data of PL3 






Figure 3.41. The (a) P0 and (b) P2 subsites of PL3 and hRNase 4 (PDB: 1RNF; Terzyan et 




Figure 3.42. The (a) B1 and (b) B2 subsites of PL3 and hRNase 4 (PDB: 1RNF; Terzyan et 
al., 1999). PL3 and hRNase 4 are coloured in marine and grey respectively. Glu-108 of PL3 
at the B2 subsite is in two alternative conformations. 
 
3.4.1.3 Comparison of PL3 and the prototypic RNase A 
Despite the different residue numbering, the catalytic residues Gln-11, His-12, 
Lys-40, and His-116 in the P1 subsite of PL3 are conserved in the structure of 
RNase A (Figure 3.43a). Such conservation is important for the ribonucleolytic 
activity of PL3. The residue compositions of other subsites are highly similar in 
the structure of PL3 and RNase A except for the B1 pyrimidine-binding pocket 
(Figure 3.43b): Val-43 in RNase A is substituted with a phenylalanine residue 
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in PL3 at position 42. Both site-directed mutagenesis studies on PL3 (Vicentini 
et al., 1996), and structural studies of hRNase 4 (Terzyan et al., 1999) have 
revealed that Phe-42 along can change the cytidine/uridine specificity of RNase 
4.  
 
Another significant difference observed in the B1 subsites of PL3 and RNase A 
is that PL3 lacks the corresponding residue of Ser-123 in RNase A. This early 
termination of peptide chain is also characterised in the structure of hRNase 4, 
and is considered to be involved in the substrate specificity of RNase 4 
(Terzyan et al., 1999). 
(a) (b) 
  
Figure 3.43. The (a) P1 and (b) B1 subsite of PL3 and RNase A (PDB: 1AFU; Leonidas et 
al., 1997). PL3 and RNase A are coloured in marine and pale yellow respectively.  
 
3.4.1.4 Difference in the interactions of wtPL3 and PL3 D80A mutant at the 
region of mutagenesis 
On average, the Cα atoms of the mutant molecules deviate only 0.55 Å (rms) 
from those of PL3, suggesting the aspartate to alanine substitution does not 
significantly affect the overall structure of the protein. Because the B1 subsite of 
RNases determines their substrate preference, and the PL3 D80A mutant is 
known to have different substrate specificity from PL3, the interactions between 





In the structure of PL3, 10 potential hydrogen bonds are identified involving 
either Asp-80 or residues in the B1 subsite. 4 of the hydrogen bonds are side 
chain-side chain interactions, whereas the remainder involve main chain atoms 
(Figure 3.44, Table 3.20). The interactions involving the side chain of Asp-80 
are lost in the structure of PL3 D80A; the remaining hydrogen bonds identified 
in the structure of PL3 are also observed in PL3 D80A structure (Figure 3.44, 





Figure 3.44. Comparison of the interactions at the B1 subsite of PL3 and PL3 D80A mutant. 
Nitrogen, oxygen, and sulphur atoms are coloured in blue, red, and dark yellow 
respectively; carbon atoms of PL3 and PL3 D80A are coloured in yellow and cyan 
respectively. Residues of PL3 are labelled in black, and residues of PL3 D80A are labelled 
in blue. Potential hydrogen bonds are shown as yellow (PL3) and blue (PL3 D80A) dashed 
lines. 
 
Table 3.20. Potential hydrogen bonds at the B1 subsite of PL3 and its D80A mutant. 
Hydrogen bond 
(donor – acceptor) 
Distance (Å) 
PL3 D80A 
 A B C D 
Asn-43 ND2 – Gln-11 O 2.88 2.76 2.77 2.75 2.75 
His-12 ND1 – Thr-44 O 2.96 2.87 2.89 2.88 2.90 
Lys-40 NZ – Asn-43 OD1 2.88 3.00 3.00 2.99 2.99 
Asn-43 N – Cys-81 O 2.95 2.77 2.80 2.78 2.79 
Cys-81 N – Asn-43 O 2.80 2.64 2.68 2.66 2.67 
Thr-44 OG1 – Asp-80 OD1 2.69     
Arg-101 NH2 – Asp-80 OD1 2.92     
Arg-101 NE – Asp-80 OD2 2.92     
Asp-80 N – Met-97 O 2.90     
Met-97 N – Asp-80 O 2.87     
Ala-80 N – Met-97 O  2.77 2.78 2.78 2.79 
Met-97 N – Ala-80 O  2.86 2.87 2.85 2.85 
Potential hydrogen bonds shorter than 3.3 Å with D-H…A angle > 120° identified by HBPLUS 





3.4.2 Structure of wtPL3·dUMP complex 
3.4.2.1 Overall structure of wtPL3·dUMP complex 
The crystal structure of wtPL3·dUMP complex was determined at 2.28 Å 
resolution, with four molecules in the ASU (Figure 3.45). The final model 
includes 4 wtPL3 molecules with residues 1 – 119, 4 dUMP molecules, 2 
phosphate ions, and 83 water molecules. As suggested by the Ramachandran 
plot, all residues are either in the most favourable regions (98.1%) or in the 
allowed regions (1.9%) (Figure 3.32 in Section 3.3.15.2).  
 
The CSS scores calculated by PISA server (Krissinel and Henrick, 2007) for all 
the potential dimers are 0 except those for molecules A-C (0.21) and B-C (0.03). 
With the highest CSS score (0.21) being much closer to 0 and the inconsistency 
in the residues involved in all potential dimerisations, the arrangement of the 
wtPL3·dUMP molecules in the ASU is not biological. The interactions at 







Figure 3.45. Arrangement of the four wtPL3·dUMP molecules in the ASU. dUMP ligands are shown in stick representation; the P0, P1, P2, B1, and B2 subsites are 
coloured in green, red, yellow, cyan, and pink. 
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3.4.2.2 dUMP recognition by PL3 
In the structure of PL3·dUMP complex, the presences of the nucleotides at the 
P1 catalytic sites of the PL3 proteins were observed from the electron density 
maps (Figure 3.46). The phosphate groups of the four ligands have full 
occupancy (1.0) whereas the maximum occupancy for the nucleoside moieties 
is ~0.6, which are observed in dUMP-B and -C (bound to molecules B and C 
respectively). The difference in occupancy between different moieties of dUMP 
is possibly a result of the catalytic sites of the proteins being occupied partially 
by phosphate ions from the crystallisation solution, and partially by dUMP 
molecules.  
 
Figure 3.46. Close view of the P1 catalytic subsite of PL3·dUMP complex (chain B) in 
stereo view. The dUMP ligand is shown as stick model with 2Fo-Fc electron density map 
contoured at 1.0σ. 
 
In the structure of PL3·dUMP complex, three of the ligands (dUMP-A to -C) 
adopt the C3'-exo conformation and only dUMP-D adopts the favoured C3'-
endo conformation (Moodie and Thornton, 1993) (examples of sugar puckers 








Figure 3.47. Conformations of nucleic acid sugar pucking. (a) Sugar ring pucker showing 
the endo (above) and exo (below) conformations of the 5-membered furanose sugar with 
the nucleotide base extended above the reference plane. Arrows indicate the atom that is 
puckered, and the direction of puckering. Figure was adapted from “DNA Structure: 
Alphabet Soup for the Cellular Soul” (Ho and Carter, 2011); (b) Examples of the C2'-
exo/-endo, as well as C3'-exo/-endo conformations. Figure was adapted from “Lehninger 
Principles of Biochemistry, 5
th
 Edition” (Nelson and Cox, 2008). 
 
The four dUMP ligands interact with corresponding PL3 molecules in a similar 
pattern: the uracil base is in the B1 subsite, and the phosphate group locates in 
the P1 subsite (Figure 3.48). Potential hydrogen bonds were observed between 
the uracil base and Thr-44 and Lys-119; the ribose and Gln-11, Lys-40, Asn-43, 
and Phe-117; and the phosphate with Arg-7, His-12, His-116, and Phe-117 
(Figure 3.49-3.50, Table 3.21-3.22). None of the interactions observed in the 
four molecules are identical. The less well-defined electron density of the 
nucleoside moieties caused by their partial occupancies may contribute to such 
differences. Higher resolution data from crystals grown in the same condition or 
growing crystals in a PO4
3-
 free crystallisation condition may improve the 
quality of the structure and provide us with more information on the 





Figure 3.48. Surface diagram of the three-dimensional structure of PL3·dUMP complex 
(chain B) with the subsites P0 (Lys-65), P1 (Gln-11, His-12, Lys-40, and His-116), P2 (Arg-7 
and Arg-10), B1 (Phe-42, Asn-43, Thr-44, and Phe-117), and B2 (Asn-66, Gln-68, Asn-70, 
and Glu-108) coloured in green, red, yellow, cyan, and pink respectively. Residues in the 
subsites as well as the dUMP-B ligand are shown in the stick representation. Carbon, 
nitrogen, oxygen, and phosphorus atoms of dUMP-B ligand are coloured in grey, blue, red 
and orange respectively.  
 
The interaction between Arg-7 and the phosphate group is worth mentioning, as 
it is part of the P2 subsite that should be interacting with the phosphate group of 
the second nucleotide (counting from 5' to 3', starting from the nucleotide 
binding to the B1 and P1 subsites) (Figure 3.36b). Similar interaction is also 
observed in the hRNase 4·dUp complex. A structure of PL3 in complex with a 
dinucleotide, such as 2'-deoxyuridylyl-3', 5'-adenosine (2'-dUpA), may shed 
light on whether Arg-7 is actually part of the P1 subsite in RNase 4 or such 




The crystal structure of PL3·dUMP complex has a total of two PO4
3-
 ions. One 
PO4
3-
 interacts with the side chains of Arg-31 and Arg-32 of molecule B while 
the other one is incorporated at the interface of molecule A and C by a water 
molecule and the side chains of four arginine residues (Figure 3.51, Table 3.23). 
Since PO4
3-
 ions are not required for the catalytic activity of PL3 and no similar 
interactions were reported for the structures of other of the RNase A 
superfamily members, the presence of PO4
3-
 ions in the crystal structure 






Figure 3.49. Details of the interactions at the catalytic site of 
PL3 molecule and dUMP in (a) chain A and (b) chain B. 
Nitrogen and oxygen atoms are coloured in blue and red; 
carbon atoms of the chain A, chain B of PL3 are coloured in 
green and pink; carbon atoms of dCMP-A and -B are 
coloured in grey. Water molecule is represented by sphere; 
potential hydrogen bonds are shown as dashed lines. 
 
 
Table 3.21. Potential hydrogen bonds between dUMP-A and -B ligands and chain A and chain B of wtPL3. 
dUMP atom PL3 residue Distance (Å) dUMP atom PL3 residue Distance (Å) 
dUMP-A dUMP-B 
O2 A Thr-44 OG1 2.65 O2 B Thr-44 OG1 3.02 
O4 A Lys-119 O 2.95
a
 O4 B Lys-119 O 2.97
a
 
O3' A Lys-40 NZ 2.51 O3' B Lys-40 NZ 2.96
a
 
 A Asn-43 OD1 3.29
a
 OP1 B Arg-7 NH1 2.49 
OP2 A Phe-117 N 3.00  B Arg-7 NH2 2.90 
 A His-12 NE2 3.16
a
 OP2 B Phe-117 N 2.84 
OP3 A Arg-7 NH1 3.02
a
  Water-71 O 2.71 
 A Arg-7 NH2 2.65
a
    
Potential hydrogen bonds shorter than 3.3 Å with D-H…A angle > 120° identified by HBPLUS (McDonald and Thornton, 1994) are shown. 
a 





Figure 3.50. Details of the interactions at the catalytic site of 
PL3 molecule and dUMP in (a) chain C and (b) chain D. 
Nitrogen and oxygen atoms are coloured in blue and red; 
carbon atoms of the chain C, chain D of PL3 are coloured in 
yellow and cyan; carbon atoms of dCMP-C and -D are 
coloured in grey. Water molecule is represented by sphere; 
potential hydrogen bonds are shown as dashed lines. 
 
 
Table 3.22. Potential hydrogen bonds between dUMP-C and -D ligands and chain C and chain D of wtPL3. 
dUMP atom PL3 residue Distance (Å) dUMP atom PL3 residue Distance (Å) 
dUMP-C dUMP-D 
O4 C Lys-119 O 3.00
a
 O4' D Phe-117 O 2.93
a
 
O3' Water-20 O 2.78 OP1 D Phe-117 O 3.22
a
 
O5' C Gln-11 NE2 3.28 OP2 D Arg-7 NH1 2.85 
 Water-20 O 2.68  D Arg-7 NH2 3.18 
OP1 C Arg-7 NH1 2.78 OP3 D His-12 NE2 2.85 
 C His-116 ND1 2.71  D Phe-117 N 2.88 
OP2 C His-12 NE2 2.77  Water-77 O 2.84 
 C Phe-117 N 2.95    
 Water-73 O 2.70    
OP3 C Phe-117 O 3.24
a
    
Potential hydrogen bonds shorter than 3.3 Å with D-H…A angle > 120° identified by HBPLUS (McDonald and Thornton, 1994) are shown. 
a 






Figure 3.51. Details of the interactions between phosphate 
ion and the PL3 molecule in (a) chain B and (b) chain A and 
C. Nitrogen, oxygen, and phosphorus atoms are coloured in 
blue, red and orange respectively; carbon atoms of the 
chain A, chain B, chain C of PL3 are coloured in green, pink 
and yellow respectively. Water molecule is represented by 
sphere; potential hydrogen bonds are shown as dashed lines. 
 
 
Table 3.23. Potential hydrogen bonds between PO4
3-
-1 and the chain B of the wtPL3 protein, as well as PO4
3-
-2 and the chain A and C of the wtPL3 protein. 
PO4
3-
-1 atom PL3 residue Distance (Å) PO4
3-
-2 atom PL3 residue Distance (Å) 
O1 B Arg-32 NH2 2.76 O1 Water-56 O 2.73 
O2 B Arg-31 NH1 2.74 O2 A Arg-32 NH2 3.16 
 B Arg-31 NH2 3.04  C Arg-31 NH1 3.17 
 B Arg-32 NE 2.91 O3 A Arg-31 NH2 2.74 
 B Arg-32 NH2 3.29  A Arg-31 NH1 3.23
a
 
O3 B Arg-31 NH2 2.80  C Arg-31 NH2 2.33 
    C Arg-32 NE 3.27 
    C Arg-32 NH2 2.92 
   O4 A Arg-31 NH1 2.70 
    A Arg-32 NE 2.84 





3.4.2.3 Comparison of ligand recognition by PL3 with that by hRNase4 and 
RNase A 
Comparisons between PL3·dUMP and hRNase 4·dUp complexes 
Terzyan et al. (1999) reported a complex structure of hRNase 4·dUp (2'-
deoxyuridine 3'-phosphate) along with the free structure of hRNase 4 to shed 
light on the structural basis for the substrate specificity. In the structure of 
hRNase 4·dUp complex, Arg-7, His-12, Thr-44, Phe-117 are involved in 
hydrogen bonding with dUp either directly or via a water network (Figure 3.52, 
3.53). Potential hydrogen bonds are observed between the same residues in PL3 
and dUMP; however, different atoms on dUMP are involved in the interactions. 
The reason for the difference could lie in the different positions of the 
phosphate group of dUp and dUMP (Figure 3.52, 3.53).  
 
 
Figure 3.52. In the structures of hRNase 4·dUp (PDB: 2RNF; Terzyan et al., 1999) and 
PL3·dUMP complexes, residues Arg-7, His-12, Thr-44, and Phe-117 of PL3 interact with 
the ligand in different ways. (a) Comparison between the interactions in the hRNase 
4·dUp complex and chain A of the PL3·dUMP complex; (b) comparison between the 
interactions in the hRNase 4·dUp complex and chain B of the PL3·dUMP complex. 
Nitrogen and oxygen atoms are coloured in blue and red respectively; carbon atoms in the 
structures of hRNase 4·dUp, chain A and chain B of PL3·dUMP complexes are coloured in 
grey, green and pink respectively. Potential hydrogen bonds are shown as black dashed 
lines for hRNase 4·dUp complex, green and pink dashed lines for chain A and chain B of 








Figure 3.53. In the structures of hRNase 4·dUp (PDB: 2RNF; Terzyan et al., 1999) and 
PL3·dUMP complexes, residues Arg-7, His-12, Thr-44, and Phe-117 of PL3 interact with 
the ligand in different ways. (a) Comparison between the interactions in the hRNase 
4·dUp complex and chain C of the PL3·dUMP complex; (b) comparison between the 
interactions in the hRNase 4·dUp complex and chain D of the PL3·dUMP complex. 
Nitrogen and oxygen atoms are coloured in blue and red respectively; carbon atoms in the 
structures of hRNase 4·dUp, chain C and chain D of PL3·dUMP complexes are coloured 
in grey, yellow and cyan respectively. Potential hydrogen bonds are shown as black 
dashed lines for hRNase 4·dUp complex, yellow and cyan dashed lines for chain C and 
chain D of the PL3·dUMP complex respectively. 
 
The interaction between Arg-101 and the dUp observed in the hRNase 4·dUp 
structure, however, is not observed in the structure of PL3·dUMP: although the 
O4 atom of dUMP is pointing towards the side chain of Arg-101, they are 
distanced too far apart (> 4 Å) for a hydrogen bond to form (Figure 3.54a, 
3.54b). The O4 atom of dUMP is interacting with the main chain oxygen of 













Figure 3.54. In the structures of hRNase 4·dUp (PDB: 2RNF; Terzyan et al., 1999) and 
PL3·dUMP complexes, the dUp/dUMP ligands are held by different residues. (a) Arg-101 
of hRNase 4 forms a hydrogen bond with the dUp ligand, whereas Arg-101 in chain A and 
B of the PL3·dUMP complex are distanced too far apart from dUMP for a hydrogen bond 
to form; (b) Arg-101 in chain C and D of the PL3·dUMP complex are also too far from 
dUMP to form hydrogen bonds; (c) dUp interacts with Gly-119 of hRNase 4 via H2O-345, 
where as dUMP ligands in chain A, B, and C of PL3 interact with Lys-119 directly via 
hydrogen bonds. Nitrogen and oxygen atoms are coloured in blue and red respectively; 
carbon atoms in the structures of hRNase 4·dUp, chain A, B, C and D of PL3·dUMP 
complexes are coloured in grey, green, pink, yellow and cyan respectively. Potential 
hydrogen bonds are shown as black dashed lines for hRNase 4·dUp complex, green, pink, 
yellow and cyan dashed lines for chain A, B, C and D of the PL3·dUMP complex 
respectively. 
 
Terzyan et al. (1999) proposed that the bulky side chain of Phe-42 of hRNase 4 





N3 atom of the dUp molecule. The same side chain conformation of Phe-42 is 
observed in the structures of free PL3, and molecules A, C, and D of PL3·dUMP. 
Interestingly, the side chain of Phe-42 in molecule B points away from Asp-80, 
presenting a different conformation, and yet dUMP is still bound to the B1 
active site of molecule B (Figure 3.55). Since the B1 subsite of molecule B is at 
the interface of molecules B and C, it is likely that such packing of molecules 
helps molecule B to hold dUMP-B in its B1 subsite even when Phe-42 is in a 
different conformation. 
 
Figure 3.55. The different orientation of Phe-42 in chain B (pink) of the PL3·dUMP 
complex compared with those in the hRNase 4·dUp complex (grey) (PDB: 2RNF; Terzyan 
et al., 1999) as well as chain A (green), C (yellow), and D (cyan) of the PL3·dUMP complex. 
 
The effect of crystal packing on the conformation of Phe-42 of the four 
molecules was examined in more details. Phe-42 of molecules B and D are at 
the interface with different regions of molecule C within the ASU (Figure 
3.56a). In molecule B, the side chain of Phe-42 is held away from Asp-80 
(Figure 3.55) by the side chain carbon atoms of Arg-41 (of molecule B) via van 
der Waals interactions (Figure 3.56b). Unlike Arg-41 of molecules A, C, and D 
which are pointing away from Phe-42 (Figure 3.56c, 3.57b, 3.58b), the side 
chain of Arg-41 in molecule B forms hydrogen bonds with Cys-57 and Glu-112 
in molecule C, thus folds towards and interacts with Phe-42 (Figure 3.56b). At 
the interface between molecules C and D, however, Phe-42 of molecule D is 
free from the attractions of Arg-41 of molecule D, which hydrogen bonded with 







Figure 3.56. Within one ASU of the PL3·dUMP complex, the conformation of Phe-42 in 
chain B is affected by crystal packing whereas the conformation of Phe-42 in chain D is 
not. (a) The four molecules of the PL3·dUMP complex in the ASU with the interfaces 
involving Phe-42 in chain B and chain D marked as “A” and “B” respectively; (b) Close 
view of the interface near Phe-42 in chain B (pink) and chain C (yellow) of the PL3·dUMP 
complex. Cys-57 and Glu-112 in chain C form hydrogen bonds with Arg-41 in chain B, 
which in turn attracts the side chain of Phe-42 and holds it in a different conformation; (c) 
Close view of the interface near Phe-42 in chain D (cyan) and chain C (yellow) of the 
PL3·dUMP complex. In chain D, the side chain of Arg-41 faces away from Phe-42, and 
hydrogen bonds with Thr-18, Val-78, and Ser-99 in chain C. Nitrogen and oxygen atoms 
are coloured in blue and red respectively; carbon atoms of chain B, C and chain D of the 







Phe-42 of molecules A and C are involved in the interfaces with molecules of 
other ASUs (Figure 3.57a, 3.58a). At the interface between molecule A and 
molecule C of another ASU (Figure 3.58a), neither Phe-42 nor Arg-41 of 
molecule A is in enough close proximity to interact with residues (Cys-57 to 
Thr-59, Gly-109, and Asn-110) of molecule C (Figure 3.58b).  
 
Similarly, at the interface between molecule C and molecule B of another ASU 
(Figure 3.58a), Arg-41 and Phe-42 of molecule C are too distanced from Glu-73 
to Val-76 of molecule B (Figure 3.58b). In both cases, the conformation of Phe-







Figure 3.57. The conformation of Phe-42 in chain A of the PL3·dUMP complex is not 
affected by crystal packing. (a) The four molecules of the PL3·dUMP complex in the ASU 
showing in cartoon form with one of the adjacent ASU (showing in ribbon form), whose 
chain C is at the interface with chain A of the original ASU; (b) Close view of the interface 
near Arg-41 and Phe-42 in chain A of the PL3·dUMP complex (green) and chain C in the 
adjacent ASU (cyan). Cys-57, Ser-58, Thr-59, Gly-109, and Asn-110 in chain C are near 
the interface; however, they are too distanced apart to interact with Arg-41 or Phe-42 in 
chain A. Nitrogen and oxygen atoms are coloured in blue and red respectively; carbon 










Figure 3.58. The conformation of Phe-42 in chain C of the PL3·dUMP complex is not 
affected by crystal packing. (a) The four molecules of the PL3·dUMP complex in the ASU 
showing in cartoon form with one of the adjacent ASU (showing in ribbon form), whose 
chain B is at the interface with chain C of the original ASU; (b) Close view of the interface 
near Arg-41 and Phe-42 in chain C of the PL3·dUMP complex (yellow) and chain B in the 
adjacent ASU (pink). Glu-73, Gly-74, Val-75, and Val-76 in chain B are near the interface; 
however, they are too distanced apart to interact with Arg-41 or Phe-42 in chain C. 
Nitrogen and oxygen atoms are coloured in blue and red respectively; carbon atoms of 








Comparisons between PL3·dUMP and RNase A·U5P complexes 
The cytosine preference of RNase A had led researchers to explore the 
possibility of using uridine-containing small molecules as RNase A inhibitors. 
Many crystal structures of RNase A complexed with natural and synthetic 
nucleotides have been solved, including the RNase A·U5P (uridine 5'-
phosphate) structure (PDB: 3DXG; Tsirkone et al., 2009). U5P and dUMP have 
a minimal conformational difference (the presence/absence of –OH group at the 
C2' position), therefore the structure of RNase A·U5P complex will be used in 
the comparison. 
 
Figure 3.59. The three-dimensional structure of RNase A·U5P complex (PDB: 3DXG; 
Tsirkone et al., 2009). Subsites P0 (Lys-66), P1 (Gln-11, His-12, Lys-41, His-119), P2 (Lys-7, 
Arg-10), B1 (Val-43, Asn-44, Thr-45, Phe-120, Ser-123), and B2 (Asn-67, Gln-69, Asn-71, 
Glu-111) are labelled and marked with different colours. Two U5P ligands are bound to 
the RNase A molecule. 
 
In the structure of RNase A·U5P complex, two U5P molecules (denoted U5P-A 
and U5P-B) bind to one RNase A molecule (Figure 3.59, 3.60). Only three 
potential hydrogen bonds are identified directly between U5P-A and His-12 and 
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Thr-45 of RNase A (Figure 3.60a), the corresponding residues in PL3 (His-12 
and Thr-44) are also involved in the interactions with dUMP ligand. However, 
more hydrogen bonds are observed between dUMP and PL3 (Figure 3.49-3.50, 
Table 3.20-3.21) than between U5P and RNase A (Figure 3.60a). This is not a 
surprise, since U5P is a less favoured ligand of RNase A.  
 
 
Figure 3.60. Interactions between (a) U5P-A and RNase A as well as (b) U5P-B and RNase 
A (PDB: 3DXG; Tsirkone et al., 2009). Carbon, nitrogen and oxygen atoms are coloured 
in brown, blue and red respectively. The U5P ligands and RNase A residues interacting 
with the ligands are shown as sticks, water molecules are shown as spheres, potential 
hydrogen bonds are shown as dashed lines. 
 
Unlike the various interactions observed between the phosphate groups of 
dUMP and PL3, there are no direct interactions between RNase A and the 
phosphate group of U5P-A. This is due to the fact U5P-B occupying the P1 and 
B2 subsites of RNase A (Figure 3.60b) forces the phosphate group of U5P-A to 





interactions (Figure 3.60a). Such interactions between the ligand and the B2 
subsite are not observed in the PL3·dUMP complex structure.  
 
With further biological functions being discovered for RNase 4 (Cocchi et al., 
2012; Li et al., 2013), it would be useful to study the interactions between this 
protein and cytosine-containing nucleotides kinetically and structurally, which 





3.4.3 Structure of PL3 D80A·dCMP complex 
3.4.3.1 Overall structure of PL3 D80A·dCMP complex 
The crystal structure of PL3 D80A·dCMP complex was determined at 2.6 Å 
resolution with four molecules in the ASU (Figure 3.61). The final model of the 
PL3 D80A·dCMP complex contains residues -1 – 119 in molecules A and B, 
residues 0 – 119 in molecules C and D, and 4 dCMP molecules. Ramachandran 
plot suggests that 95.1% of the residues in the structure of PL3 D80A·dCMP 
complex are in the most favourable regions with the remainder in the allowed 
regions (Figure 3.33 in Section 3.3.15.2).  
 
One hydrogen bond is identified between molecules A-C and B-D respectively 
(Table 3.24). Analysis of the possibility of the formation of biological dimers 
were performed using the PISA web server (Krissinel and Henrick, 2007). A 
CSS score of 0 for all potential dimers in the ASU suggests that the observed 
arrangement of the PL3 D80A·dCMP molecules is not biological.  
 
Figure 3.61. Arrangement of the four PL3 D80A·dCMP molecules in the ASU. dCMP 
ligands are shown in stick representation; The P0, P1, P2, B1, and B2 subsites are coloured 




Table 3.24. Potential hydrogen bonds at various dimer interfaces within the ASU of the 
PL3 D80A·dCMP structure. 
Hydrogen bond 
(donor – acceptor) 
Distance (Å) 
AVal-75 N – C Gly-67 O 3.23 
D Val-75 N – B Gly-67 O 3.22 
Potential hydrogen bonds shorter than 3.3 Å with D-H…A angle > 120° identified by HBPLUS 
(McDonald and Thornton, 1994) are shown. 
 
3.4.3.2 dCMP recognition by PL3 D80A 
In the structure of PL3 D80A·dCMP complex, the electron density maps of the 
dCMP nucleotides are well defined at the P1 catalytic subsites of the PL3 D80A 
proteins (Figure 3.62). Due to the initial high B-factors, the occupancies of the 
dCMP molecules were lowered (to 0.6 for dCMP-A and -B, 0.5 and 0.7 for the 
phosphate and nucleoside moieties of dCMP-C, and 0.3 for dCMP-D) so that 
they would have a similar B factor to those of the surrounding residues. 
 
Figure 3.62. Close view of the P1 catalytic subsite of PL3 D80A·dCMP complex (chain B) 
in stereo view. The dCMP ligand is shown as stick model with 2Fo-Fc electron density map 




Three dCMP ligands (dCMP-B to -D) are in the preferred C3'-endo 
conformation, and dCMP-A is in the O4'-endo conformation (Moodie and 
Thornton, 1993) (examples of sugar puckers are shown in Figure 3.47). Similar 
to the interactions between dUMP and PL3, the base moiety of the dCMP ligand 
locates in the B1 subsite of PL3 D80A, and the phosphate group is positioned 
near the P1 subsite (Figure 3.63).  
 
Figure 3.63. Surface diagram of the three-dimensional structure of PL3·dUMP complex 
(chain B) with the subsites P0 (Lys-65), P1 (Gln-11, His-12, Lys-40, and His-116), P2 (Arg-7 
and Arg-10), B1 (Phe-42, Asn-43, Thr-44, and Phe-117), and B2 (Asn-66, Gln-68, Asn-70, 
and Glu-108) coloured in green, red, yellow, cyan, and pink respectively. Residues in the 
subsites as well as the dUMP-B ligand are shown in the stick representation. Carbon, 
nitrogen, oxygen, and phosphorus atoms of dUMP-B ligand are coloured in grey, blue, red 
and orange respectively.  
 
The cytosine base of dCMP-A interacts with Lys-40 that belongs to the P1 
subsite (Figure 3.64, Table 3.25), whereas the base moiety of dCMP-B, -C and -
D interacts with Thr-44 that is part of the B1 subsite (Figure 3.65-3.67, Table 
3.25-3.26). The only interaction between the phosphate group of dCMP and PL3 
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D80A is observed in chain B: O1P of the phosphate group forms a hydrogen 
bond with His-116, one of the two catalytic His in the catalytic P1 subsite 
(Figure 3.65, Table 3.25). In both chains C and D, residues in the P1 subsite 
(His-12 of molecule C, and His-12 and Lys-40 of molecule D) interact with O2 
of the ribose of dCMP ligands (Figure 3.66-3.67, Table 3.26). There are a few 
potential hydrogen bonds identified between the nitrogen atoms of the dCMP 
molecules and the protein molecules; however due to the unusual D-H…A 






Figure 3.64. Details of the interactions at the catalytic site of PL3 D80A 
molecule and dCMP in chain A. Nitrogen and oxygen atoms are coloured in 
blue and red; carbon atoms of the chain A of PL3 D80A and dCMP-A are 
coloured in lime and grey respectively. Potential hydrogen bonds are shown as 
dashed lines. 
 
Figure 3.65. Details of the interactions at the catalytic site of PL3 D80A 
molecule and dCMP in chain B. Nitrogen and oxygen atoms are coloured in 
blue and red; carbon atoms of the chain B of PL3 D80A and dCMP-B are 
coloured in violet and grey respectively. Potential hydrogen bonds are shown 
as dashed lines. 
 
Table 3.25. Potential hydrogen bonds between dCMP-1 and -2 ligands and their corresponding PL3 D80A proteins. 
dCMP-A atom PL3 D80A residue Distance (Å)  dCMP-B atom PL3 D80A residue Distance (Å) 
O2 A Lys-40 NZ 2.61  O2 B Thr-44 N 2.53 
    O1P B His-116 NE2 2.85 





Figure 3.66. Details of the interactions at the catalytic site of PL3 D80A 
molecule and dCMP in chain C. Nitrogen and oxygen atoms are coloured in 
blue and red; carbon atoms of the chain C of PL3 D80A and dCMP-C are 
coloured in wheat and grey respectively. Potential hydrogen bonds are shown 
as dashed lines. 
 
Figure 3.67. Details of the interactions at the catalytic site of PL3 D80A 
molecule and dCMP in chain D. Nitrogen and oxygen atoms are coloured in 
blue and red; carbon atoms of the chain D of PL3 D80A and dCMP-D are 
coloured in teal and grey respectively. Potential hydrogen bonds are shown as 
dashed lines. 
 
Table 3.26. Potential hydrogen bonds between dCMP-3 and -4 ligands and their corresponding PL3 D80A proteins.  
dCMP-C atom PL3 D80A residue Distance (Å)  dCMP-D atom PL3 D80A residue Distance (Å) 
O2 C Thr-44 N 2.35  O2 D Thr-44 N 3.18 
O3' C His-12 NE2 3.16   D Thr-44 OG1 3.29 
    O3' D His-12 NE2 3.21 
     D Lys-40 NZ 2.57 
Potential hydrogen bonds shorter than 3.3 Å with D-H…A angle > 120° identified by HBPLUS (McDonald and Thornton, 1994) are shown.  
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3.4.3.3 Comparison of ligand recognition by PL3 D80A with that by PL3 
Site directed mutagenesis studies of PL3 reported by Hofsteenge et al. (1998a) 
revealed the importance of residue Asp-80 in the substrate specificity of the 
protein, and led us to begin the study of ligand recognitions by PL3 and PL3 
D80A mutant from a structural point of view. 
 
In the structure of PL3·dUMP complex, the dUMP ligand is bound to the PL3 
protein by at least 6 hydrogen bonds. However, only 2 to 4 hydrogen bond 
interactions are observed between dCMP ligand and PL3 D80A mutant. In all 
four dCMP molecules, the O2 atoms are all involved in hydrogen bonding, 
three of which with Thr-44, and the remainder with Lys-40.  
 
In the structure of PL3·dUMP complex, dUMP-B and -C have the highest 
occupancy, and PL3 molecules B and C have lower B-factors therefore are more 
stable than the other two molecules. However, since the side chain 
conformation of Phe-42 of molecule B is affected by crystal packing (see 
Section 3.4.2.3), molecule C of the PL3·dUMP complex structure will be 
referred to unless stated otherwise. Similarly, molecule C in the structure of PL3 
D80A·dCMP complex will be referred to, due to its higher stability and ligand 
occupancy. 
Comparison of the ligand-binding region of the structures of both PL3·dUMP 
and PL3 D80A·dCMP complexes (with hRNase4·dUp complex structure as a 
reference) revealed some differences in the side chain conformations of the 
residues in or near the B1 subsites (Figure 3.68). In the structures of PL3·dUMP 
and hRNase4·dUp complexes (carbon atoms coloured in yellow and pink 
respectively), the side chain of Arg-101 is hydrogen bonded with the side chain 
of Asp-80, and held more towards the B1 subsite, making Arg-101 more likely 
to interact with the =O group of uridine (as seen in the structure of the 
hRNase4·dUp complex). Also, in such conformation, the –NH2 group of Arg-
101 would strongly repulse the –NH2 group of a cytosine base. In contrast, in 
the PL3 D80A·dCMP complex structure (carbon atoms coloured in cyan), the 
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attraction of the side chain of Arg-101 from Asp-80 is lost due to alanine 
substitution, and the side chain of Arg-101 is positioned further away from the 
B1 subsite (Figure 3.68). This may reduce the repulsions that the –NH2 groups 
of Arg-101 would apply to the –NH2 group of the dCMP ligand, allowing the 
less favoured dCMP to occupy the B1 subsite. 
 
Another major difference observed between PL3 and PL3 D80A mutant is the χ1 
angle of His-116 (Figure 3.68). In the structure of PL3·dUMP complex, the χ1 
angle of His-116 of the four molecules ranges from -56.8° to -68.7°, while in all 
the other three structures we present here (structures of PL3, PL3 D80A, and 
PL3 D80A·dCMP), the χ1 angle of His-116 residues is between 158.8° and 
176.2°. The positive χ1 angle of His-116 is also observed in the structures of 
free hRNase 4 and hRNase 4·dUp complex (Figure 3.68), as well as the 
majority of structures of RNase A in complex with a mononucleotide ligand. 
Such dual conformation of the catalytic His-119 (RNase A numbering) have 
been reported (Richards and Wykoff, 1971; de Mel et al., 1994), and modelling 
studies have suggested that the two conformations His-119 of RNase A 





Figure 3.68. Stereo view of the ligand-binding regions of structures of PL3·dUMP, PL3 D80A·dCMP, and hRNase 4·dUp complexes (PDB: 2RNF; Terzyan et al., 
1999). Nitrogen, oxygen, and phosphorus atoms are coloured in blue, red, and orange respectively; carbon atoms are coloured in yellow for PL3 and dUMP, cyan 
for PL3 D80A and dCMP, and pink for hRNase 4 and dUp. Potential hydrogen bonds are represented by dashed lines, and are coloured in orange for the 




3.5 Future Work 
To date, we have successfully solved the structures of free porcine RNase 4 
(PL3), its D80A mutant, as well as two complex structures where PL3 and PL3 
D80A bind their preferred mononucleotide ligand, dUMP and dCMP 
respectively. These structures have shed some light on the protein-ligand 
interactions of PL3 and PL3 D80A mutant; however, the change of substrate 
specificity caused by the D80A substitution cannot yet be fully explained. If 
more time was available, we would like to use two types of non-hydrolysable 
ligands (Table 3.27), which can be either dinucleotides or in the form of 
oligonucleotides, to form complexes with PL3 and PL3 D80A. In theory, the 
pyrimidine base and its 3' phosphate group should interact with the B1 and P1 
subsites of PL3 respectively and the adenosine binds to the B2 subsite. These 
structures would allow us to further characterise the RNA recognition 
mechanism as well as the definitive role that Asp-80 plays in the substrate 
specificity of RNase 4.  
 
Table 3.27. Non-hydrolysable ligands for substrate specificity studies of PL3 and PL3 
D80A mutant. 





2'-deoxy-2'-fluoro uridylyl-3', 5'-adenosine 
(2'-F-dUpA) 
2'-deoxy-2'-fluoro cytidylyl-3', 5'-adenosine 
(2'-F-dCpA) 
 
Another approach would be to use longer oligonucleotides containing one or 
two repeats of dUpA/dCpA as ligands, so that these complexes would mimic 
the recognition of large RNA molecules by PL3 at some level. This would 
provide us with more knowledge on the interactions between the RNA and 
residues in different subsites of RNase, providing a better understanding of the 













Chapter 4. Molecular recognition of porcine 
ribonuclease 4 (PL3) by porcine 




4.1 Ribonuclease inhibitor, natural inhibitor of RNases 
Mammalian tissues express a potent proteinaceous inhibitor of the RNase A 
superfamily members. In 1952, Pirotte and Desreux first inferred the existence 
of such an inhibitor, from where started the extensive investigations on the 
nature (Roth, 1956; Roth, 1958a; Roth, 1958b; Roth, 1962; Shortman, 1961; 
Shortman, 1962) and distributions (Roth, 1962; Kraft and Shortman, 1970) of 
ribonuclease inhibitor (RI). Thanks to the novel method, which was based on 
the interactions between RNase and RI, developed in the late 1970s (Blackburn 
et al., 1977), the isolation of quantities of homogeneous RI could be achieved, 
which in turn brought the research of RI into the modern era.  
 
4.1.1 Primary structure of RI 
RI is an acidic protein with a molecular weight of approximately 50 kDa 
characterised by a high content of leucine and cysteine (Blackburn et al., 1977). 
To date, the primary structures of RI from pig (Hofsteenge et al., 1988), human 
(Lee et al., 1988; Schneider et al., 1988), and rat (Kawanomoto et al., 1992) 
have been determined by protein sequencing, and those of mouse, bovine, and 
chimpanzee RI were deduced from their complementary DNA (cDNA) 
sequences (Figure 4.1). These six proteins share a 60% sequence identity and an 
86% sequence similarity. RIs from pig, cow, rat, and mouse have 456 amino 
acid residues, whereas human RI (hRI) and chimpanzee RI have 460 residues, 
both possessing a four-residue N-terminal extension.  
 
Two interesting properties arose from the sequence analysis of RI.  Firstly, RI 
contains an unusually large number of cysteine residues that are in sulphydryl 
form that makes these proteins highly sensitive to oxidation (Fominaya and 
Hofsteenge, 1992). Secondly, RI is constructed almost entirely of leucine-rich 
repeats (LRRs). LRRs are sequences of 24-29 amino acids that contain leucine 
or another hydrophobic amino acid at constant positions. Such repeats have 
been identified in more than 100 proteins with a diverse range of functions, 
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including DNA repair, RNA processing, cellular growth and development, 
enzyme inhibition or activation, signal transduction, extracellular matrix 
interactions, control of neural circuit formation, and bacterial virulence (Kobe 
and Deisenhofer, 1994; Buchanan and Gay, 1996; Hothorn et al., 2011; She et 
al., 2011; de Wit and Ghosh, 2014). 
 
Figure 4.1. Comparison of the primary structures of human, chimpanzee, porcine, bovine, 
mouse, and rat RI. All sequences were taken from UniProtKB database. The multiple 
sequence alignment with a conservation scoring was performed using Clustal Omega 
EMBL-EBI online server (McWilliam et al., 2013; Sievers et al., 2011). Conserved residues 
are highlighted yellow. 
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4.1.2 Three-dimensional structure of RI and RI·RNase complexes 
To date, crystal structures have been determined for free porcine RI (pRI) 
(Kobe and Deisenhofer, 1993) (Figure 4.2) and a few RI·RNase complexes, 
including pRI with RNase A (Kobe and Deisenhofer, 1995; Kobe and 
Deisenhofer, 1996), hRI with hRNase 1 (Johnson et al., 2007), EDN (Iyer et al., 
2005), and ANG (Papageorgiou et al., 1997), bovine RI with RNase A, chicken 
RI with chicken RNase 1, and mouse RI with mouse RNase 1 (Lomax et al., 
2014) (Figure 4.3). 
 
pRI was the first LRR protein whose structure was ever determined. It revealed 
a novel non-globular supercoil in which 16 LRR units are symmetrically 
arranged into a horseshoe-like shape. The molecule has an overall dimension of 
70   62   32 Å, and an inner diameter of 21 Å. Each LRR unit contains a short 
β strand and a longer α helix; the β strands form a parallel β sheet in the inner 
space of the horseshoe whereas the α helices are exposed to the environment. 
The conserved residues in the LRRs are important for the structure of RI. The 
leucine residues in each unit form a hydrophobic core between the β strand and 
the α helix, and between the LRR units. The side chains of asparagine and 
cysteine residues at position 10 of the repeat are buried and form hydrogen 
bonds to the polypeptide backbone.  
 
Figure 4.2. Stereo view of the crystal structure of pRI (PDB: 2BNH; Kobe and 















Figure 4.3. Structural similarity of RNase·RI complexes. hRI·hRNase 1 (PDB: 1Z7X; 
Johnson et al., 2007), hRI·hEDN (PDB: 2BEX; Iyer et al., 2005), hRI·hANG (PDB: 1A4Y; 
Papageorgiou et al., 1997), pRI·RNase A (PDB: 1DFJ; Kobe and Deisenhofer, 1995), 
bRI·RNase A, chicken RI·RNase A-1, and mouse RI·RNase 1 (PDB: 4PEQ, 4PER, 3TSR 
respectively; Lomax et al., 2014) are shown. 
hRI·hRNase 1 
hRI·hEDN hRI·hANG 
chicken RI·RNase A-1 mouse RI·RNase 1 
 
pRI·bRNase A bRI·bRNase A 
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RI inhibits RNase by blocking the access of the substrate to the active site 
(Kobe and Deisenhofer, 1995), and such inhibition is observed in all 
determined RI·RNase complex structures (Figure 4.3). The protein occupies the 
central cavity of the inhibitor contacting its C-terminal region more closely. In 
all seven complexes, the interface is large, involving at least 26 residues of RI 
that cluster in three separate groups and 24-30 residues from the protein ligand, 
an example for both components of the RI·RNase complex are shown in Figure 
4.4. 
 
(a) Residues on pRI that 
are involved in the 
recognition of RNase A. 
The side chains of pRI 
residues are shown as 
sticks and coloured in 
black; the N- and C-
termini are labelled as N 
and C in violet; 
 
(b) RNase A residues 
that bind to pRI. The 
side chains of RNase A 
residues are shown as 
sticks and coloured in 
black; the N- and C-
termini are labelled as N 
and C in cyan.  
Figure 4.4. Cα backbone of (a) pRI and (b) RNase A with the side chains of the contact 
residues shown in black. Figures were generated using the complex structure of 






Structural studies revealed that the C-terminal region of RI (residues 433 to 460; 
hRI numbering) is involved in the interactions with the catalytic site residues of 
RNases (Gln-11, Lys-41, and His-119, RNase A numbering); and the other 
contacts are required to stabilise the complexes. Site-specific mutagenesis of 
this region showed that residues Tyr-434, Asp-435, Tyr-437, and Ser-460 
constitute a “hot spot” of binding energy (Chen and Shapiro, 1997; Chen and 
Shapiro, 1999). 
 
4.1.3 Rationale behind this study 
Preliminary analysis of pRNase 4 (PL3) recognition by human RI revealed a 17-
fold tighter binding than that of RNase A (Zelenko et al., 1994). Despite the 
fact that residues Gln-11, Lys-41, and His-119 (RNase A numbering), which 
contribute the major portion of the binding energy in the interactions with RI, 
are also present in PL3, it is difficult to provide an explanation for the tighter 




4.2 Modelling studies on PL3 recognition by pRI  
Modelling studies were carried out to gain some knowledge about the protein-
protein interactions between PL3 and pRI.  
 
4.2.1 Methodology 
Since the crystal structures of PL3 and pRI are both available, a model of the 
PL3·pRI complex structure was manually built in PyMol. Energy minimisation 
of the model was subsequently completed using the YASARA Energy 
Minimization Server (Krieger et al., 2009). Energy minimisation is a necessary 
step in computational modelling, as it corrects the geometrical relationships 
between the two proteins, allows the side chains to place themselves in more 




In the model of PL3·pRI complex structure, PL3 occupies the central cavity of 
pRI, making closer contact with the C-terminal region of the inhibitor (Figure 
4.5), similar to the other RNase A superfamily members.  
 
Figure 4.5. Stereo view of the energy minimised model of PL3·pRI complex. The N- and C- 




A simple analysis of the RNase A·pRI complex with the model generated for 
the PL3·pRI complex showed subtle differences in the orientation of side chains 
from the two protein complexes as shown in Figure 4.4 and Figure 4.6. 
However, a detailed three-dimensional structure of the complex is required to 












Figure 4.6. Cα backbone of (a) pRI and (b) PL3 
with the side chains of the contact residues shown 
in black. (a) Residues on pRI that are involved in 
the recognition of PL3. The side chains of pRI 
residues are shown as sticks and coloured in black; 
the N- and C-termini are labelled as N and C in 
violet; (b) PL3 Residues that bind to pRI. The side 
chains of PL3 residues are shown as sticks and 
coloured in black; the N- and C-termini are 






4.3 Towards the crystal structure of PL3·pRI complex 
To validate the computer model, the structural characterisation of PL3·pRI 
complex was pursued. Wild type PL3 and pRI were expressed and purified, and 
the purified proteins were used for the formation of the complex. 
 
4.3.1 Methods 
4.3.1.1 Expression and purification of wild type PL3 
The BL21C
+
(DE3)-RIPL-pET-46 EK/LIC-PL3 construct was used for the 
expression of wild type PL3. Optimised expression and purification protocols 
(Appendix II) were followed. 
 
4.3.1.2 Expression and purification of pRI 
The gene of pRI was carried by the ptRP vector in BL21(DE3) E. coli cells, 
which was obtained from our collaborator Dr Jan Hofsteenge from Basel, 
Switzerland. The protocol described by Kazakou (2008) was followed for the 
expression and purification of pRI. 
 
LB broth medium supplemented with 100 μg/ml ampicillin was inoculated with 
1% overnight culture, and incubated at 37 °C with shaking at 200 rpm until the 
cells had reached their late stationary phase, indicated by OD600 = 2.0. The cells 
were harvested by centrifuging at 15, 000 g (Beckman JLA10.500 rotor) and 
used to inoculate 1 L M9 minimal medium (1.5 g Pipes, 56.4 g minimal salt, 0.5 
ml Tween 20, 1 ml glycerol per 1 L M9 media). The culture was incubated at 
37 °C with shaking (200 rpm) for 6 hours before harvesting by centrifugation at 
15, 000 g (Beckman JLA10.500 rotor). The cell pellet from 0.5 L culture was 
monodispersed in 50 ml lysis buffer (20 mM Tris-HCl pH 7.5); cells were 
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ruptured by cell disruptor at 20, 000 psi. The lysate was centrifuged at 70, 000 g 
(Beckman JA 25.50 rotor) for 33 minutes (Kazakou, 2008).  
 
A 1 ml HiTrap NHS-activated HP column (GE Healthcare) was used to purify 
native pRI. The column was coupled with bovine pancreas ribonuclease A 
(RNase A) following instructions given in the manual of the column. The 
supernatant of cell lysate was loaded onto the column, which had been 
equilibrated with equilibration buffer (50 mM K3PO4 pH 6.4, 10 mM DTT, and 
1 mM EDTA). The column was re-equilibrated with the same equilibration 
buffer after protein loading, subsequently washed with wash buffer (50 mM 
K3PO4 pH 6.4, 10 mM DTT, 1 mM EDTA, and 1 M NaCl). pRI was eluted 
from the column with elution buffer (0.1 M Na acetate pH 5.0, 0.3 M NaCl, 10 
mM DTT, and 1 mM EDTA). Fractions with elevated UV trace were collected 
and dialysed against 2 L dialysis buffer (20 mM Tris-HCl pH7.5) at 4 °C 
overnight. The dialysed sample was analysed by SDS-PAGE electrophoresis 
(Kazakou, 2008). 
 
4.3.1.3 Complex formation of PL3pRI 
Purified pRI and PL3 were mixed in a 1:1.2 molar ratio in 20 mM Tris-HCl pH 
7.5, 20 mM DTT. The reaction mixture was incubated overnight at room 
temperature (Papageorgiou et al., 1997).  
 
4.3.1.4 Purification of PL3pRI complex by ion exchange chromatography 
The purification of PL3pRI complex was carried out by ion exchange 
chromatography with a 1 ml HiTrap Q Sepharose FF column (GE Healthcare). 
The PL3pRI sample prepared by overnight incubation was centrifuged at 70, 
000 g (Beckman 25.50 rotor) to remove any precipitate prior to purification, 
and subsequently loaded onto the HiTrap Q sepharose FF column which had 
been equilibrated with equilibration buffer (20 mM Tris-HCl pH 7.5). The 
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column was re-equilibrated with the same equilibration buffer, and the complex 
was eluted with an ascending NaCl gradient (0 to 0.4 M) in the equilibration 
buffer. Fractions with significant UV absorbance were collected and analysed 
by SDS-PAGE electrophoresis (Johnson et al., 2007). 
 
4.3.1.5 Purification of PL3pRI complex by size exclusion chromatography 
An alternative method of purifying PL3pRI complex was carried out using size 
exclusion chromatography. The PL3pRI complex sample prepared by overnight 
incubation was centrifuged at 70, 000 g (Beckman 25.50 rotor) to remove any 
precipitate prior to purification, and subsequently purified using a Superdex 200 
10/300GL size exclusion column (GE Healthcare) equilibrated with 20 mM 
Tris-HCl pH 7.5, 150 mM NaCl. Fractions with significant UV absorbance 




4.3.2 Results and discussion 
4.3.2.1 Expression and purification of pRI 
The protocol described in Section 4.3.1 (Kazakou, 2008)(Kazakou, 
2008)(Kazakou, 2008)(Kazakou, 2008)(Kazakou, 2008)(Kazakou, 
2008)(Kazakou, 2008) was followed for the expression and purification of pRI. 
The recombinant pRI protein was expressed in soluble form, and the RNase A 
affinity chromatography purification produced pure pRI (Figure 4.7). 





(a) Chromatogram of RNase A affinity chromatography 
purification of pRI; 
 
(b) 15% SDS-PAGE gel of purified pRI sample.  
Lane 1: low molecular weight marker (Sigma); 
Lane 2: pRI sample from RNase A affinity 
chromatography purification. 
 
Figure 4.7. Results of pRI purification by RNase A affinity chromatography. Sample 
collected from the elution step in the (a) RNase A affinity chromatography purification 
was (b) electrophoresed under non-reducing and denaturing conditions prior to staining 





4.3.2.2 Formation and purifications of PL3pRI complex 
The protocol described in Section 4.3.1.3 was repeated twice to produce two 
samples that would be purified by anion exchange chromatography and size 
exclusion chromatography respectively. Unexpectedly, precipitation was 
observed in both samples. The precipitation was removed by centrifugation and 
the soluble fractions were collected. 
 
One sample was purified by anion exchange chromatography as described in 
Section 4.3.1.4. Neither the chromatogram of the purification nor the SDS-
PAGE gel showed sign of protein presence (Figure 4.8), suggesting the 
precipitants contained both pRI and PL3. 
(a) (b) 
  




Lane 2: flow 
through of the 
loading step; 
Lane 3: flow 
through of the 
washing step; 
Lane 4: eluate. 
Figure 4.8. Results of Q-sepharose anion exchange purification of PL3pRI complex. (a) Q-
sepharose anion exchange purification of PL3pRI; (b) 15% SDS-PAGE gel of fractions 
from Q-sepharose anion exchange purification.  
 
Alternatively, the sample of PL3pRI complex was purified using size exclusion 
chromatography as described in Section 4.3.1.5. The chromatogram suggested 
that the sample consisted of three species, all of which were present at a low 
concentration (Figure 4.9a). The SDS-PAGE analysis of these three fractions 
however, suggested that no pRI was in the supernatant of the overnight-

















Figure 4.9. Results of size exclusion chromatography purification of PL3pRI complex. (a) 
Chromatogram of size exclusion chromatography purification of PL3pRI; (b) 15% SDS-
PAGE gel of fractions from size exclusion chromatography purification. Protein samples 
were electrophoresed under reducing and denaturing conditions prior to staining with 
Coomassie brilliant blue R-250. Only tagged PL3 protein was observed in the SDS-PAGE 
gel. 
 
This part of the work was carried out using the wtPL3 protein with the N-
terminal His-tag still attached. The fact that both complex samples showed 
precipitations after incubation, together with previous observations (made 
during my Master’s project) that the complex formation using a tag-free PL3 
purified from another construct did not result precipitation suggested that the N-
terminal tag of PL3 hindered the complex formation between PL3 and pRI. This 
led to the His-tag removal experiments of PL3. Due to lack of time, the complex 




4.3.3 Future Work 
The expression and purification protocols of pRI had been established; and 
quantities of pure pRI could be purified following these protocols. A new 
construct (BL21C
+
(DE3)-RIPL-pET-46 Ek/LIC-PL3) expressing PL3 with 
cleavable N-terminal His-tag had been prepared in this study. Expression and 
purification protocols of PL3 as well as the procedures for His-tag cleavage and 
subsequent purifications had been optimised; and pure untagged PL3 could be 
produced with good yield. The next step would be use the untagged PL3 protein 
to produce PL3pRI complex. Once the complex is formed and purified, 
crystallisation trials, structure determination and characterisation should follow, 




















The RNase A superfamily members are a group of pyrimidine-specific 
ribonucleolytic enzymes with a wide distribution cross the animal kingdom. 
RNase 4 is an interesting member of this family, as it presents some 
distinguishing features from the others. RNase 4 is the shortest and the most 
conserved RNase, and it has a strong uridine preference compared with the rest 
of the family. However, RNase 4 is not as extensively studied as its 
homologues EDN, ECP, and ANG, which all show additional biological 
functions such as neurotoxicity and angiogenic activity.  
 
Early kinetic and site-directed mutagenesis studies of porcine RNase 4 (also 
known as PL3) suggested the importance of residues Asp-80 and Arg-101 in the 
substrate specificity of RNase 4 (Hofsteenge et al., 1998a), which was 
supported by the crystal structures of hRNase 4 and its binary complex with 
dUp (Terzyan et al., 1999). In the structure of hRNase 4·dUp complex, the side 
chain of Arg-101 is positioned away from the molecule surface, folded inwards 
and directed to the B1 subsite, allowing hydrogen bonds to form with the ligand. 
Although Asp-80 does not form hydrogen bonds directly with the ligand, it was 
proposed that Asp-80 is forced to form a hydrogen bond with Thr-44 by the 
bulky side chain of Phe-42, and Thr-44 in turn interacts with the ligand. 
 
We used PL3 as a model to study the substrate recognition of RNase 4, and have 
solved four structures, namely PL3, PL3 D80A mutant, PL3·dUMP complex, 
and PL3 D80A·dCMP complex.  
 
Structural analyses show similarities in terms of protein-ligand interactions 
between PL3 and hRNase 4: hydrogen bonds are identified between the ligand 
and residues Arg-7, His-12, Thr-44, and Phe-117 of both proteins. Significant 
differences are also observed, such as the absence of hydrogen bonds between 
Arg-101 of PL3 and dUMP, and the interactions between dUMP and Gln-11, 
Lys-40, Asn-43, or Lys-119 of PL3 that are not identified between dUp and 
hRNase 4. Although we observed stabilisation effect of Arg-101 side chain by 
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Asp-80, we could not yet fully address the level of involvement of residues 
Asp-80 and Arg-101 in substrate recognition due to the high flexibility as well 
as the different positions of phosphate groups of the ligands used. In order to 
get a more realistic picture of ligand recognition and substrate specificity of 
RNase 4, we would need to use oligonucleotide ligands to produce protein-
ligand complex crystals. 
 
Compared with the PL3·dUMP complex, fewer hydrogen bonds are identified 
between the dCMP and PL3 D80A mutant. However, considering the size and 
thus the flexibility of the dCMP ligand, it is likely that additional hydrogen 
bonds could be formed between the nitrogen atoms of dCMP and the PL3 D80A 
protein. Since no structural information of PL3 and PL3 D80A mutant binding 
to the less favoured ligand (dCMP and dUMP respectively) is currently 
available, it is difficult to conclude whether the small number of hydrogen 
bonds between dCMP and D80A mutant is not enough for holding the ligand in 
the substrate-binding pocket. 
 
In the PL3 D80A·dCMP complex structure, the side chain of Arg-101 is free to 
move away from the B1 subsite in the absence of the side chain of Asp-80. It is 
likely that the increased distance between Arg-101 and the B1 subsite reduces 
the repulsions between the –NH2 groups of arginine and cytosine, allowing the 
B1 subsite to host the less favoured (by the wild type) dCMP ligand. Thr-44 
adopts the same conformation in PL3 and PL3 D80A mutant, suggesting Asp-80 
is not crucial in holding Thr-44 in the observed position. However, the side 
chain of Asp-80 is involved in a hydrogen-bonding network in the B1 subsite 
that is distorted in the D80A mutant, allowing the protein to bind the originally 
less-favoured cytidine ligand. 
 
The activities of members in the RNase A superfamily can be abolished by the 
cytosolic ribonuclease inhibitor (RI), a 50 kDa protein consisting of leucine-
rich repeats (LRRs) that arrange into a horseshoe-like shape. RI exists in many 
  
195 
animal species, and is involved in the regulation of cytoplasmic RNA level and 
protection of cells against unregulated RNase activity. RI binds to all the RNase 
A superfamily members, forming tight, reversible, one to one complexes. To 
date, several complex structures of RI·RNase from human, cow, chicken, and 
mouse have been determined, and all the structures revealed similar regions on 
the RNase molecules that are recognised by RI.  
 
With the crystal structure of PL3 being available, we could confirm the primary 
residues (Gln-11, Lys-41, and His-119 of RNase A) involved in RI·RNase 
interactions are also present in PL3. However, the tighter binding of PL3 to hRI 
than that of RNase A cannot be explained without a crystal structure of PL3·RI 
complex.  
 
Although we have not managed to produce the PL3·RI protein complex, we 
determined that any additional amino acid residues at the N-terminal of PL3, for 
example a fusion tag or a signal peptide, would hinder the complex formation. 
If more time was available, we should be able to produce and solve the 
structure of PL3·RI complex, which would contribute to a better understanding 
of protein-protein interactions. 
 
As D. C. Phillips and F. M. Richards stated in the preface of the book 
“Ribonuclease S”, “no structure-analysis is ever complete” (Richards and 
Wyckoff, 1973). Every new structure solved presents researchers with 
interesting features and raises more questions. With the four structures we 
present here, the collection of RNase structures is more complete, and 
additional information on substrate recognition of RNase 4 is available. We 
would like to study the structures of PL3 and PL3 D80A mutant in complex with 
non-hydrolysable ligands, as well as the PL3·RI protein complex, in order to 
further characterise the recognition of RNase 4 by its ligands as well as by RI, 
and provide some structural insight towards structure based drug design of 
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Appendix I – pET-46 Ek/LIC vector map 
The Novagen pET-46 Ek/LIC vector is a bacterial vector for ligation-
independent cloning (LIC) to express fusion proteins with an N-terminal 





Appendix II – Optimised expression and purification 
protocols of wild type PL3 from BL21C
+
(DE3)-RIPL-
pET-46 Ek/LIC-PL3 strain 
Construct BL21C
+
(DE3)-RIPL-pET-46 Ek/LIC-PL3 was prepared in this study 
and used to express and purify wild type PL3. TB (Terrific Broth) media 
supplemented with 100 μg/ml ampicillin was inoculated with 1% overnight 
culture of BL21C
+
(DE3)-RIPL-pET-46 Ek/LIC-PL3 cells, and incubated at 
37 °C with shaking at 200 rpm. Protein expression was induced by the addition 
of 1 mM IPTG to cells in the mid-exponential phase of growth (indicated by 
OD600 ≥ 0.6). The induced cells were further incubated at 16 °C with shaking at 
200 rpm for 16 hours, and harvested by centrifugation at 15, 000 g (Beckman 
JLA 10.500 rotor) for 10 minutes.  
 
Cells from 0.5 L bacterial culture were monodispersed in 50 ml lysis buffer (50 
mM Tris-HCl, pH 8.0) and ruptured using the TS Series Benchtop cell disruptor 
(Constant Systems Ltd., Daventry, Northants, UK) at 24,000 psi. The lysate 
was centrifuged at 39,000 g (Beckman JLA 25.50 rotor) for 20 minutes to 
harvest inclusion bodies. 
 
The inclusion body pellet was solubilised in 10 ml solubilisation buffer (7 M 
guanidine hydrochloride, 0.15 M reduced glutathione, 0.1 M Tris-HCl pH 8.0, 2 
mM EDTA) for 2 hours. The solubilised protein was separated from the solid 
matter by centrifugation at 70, 000 g for 30 minutes (Beckman JLA 25.50 rotor), 
and added dropwisely into 500 ml refolding buffer (0.5 M L-arginine, 0.6 mM 
oxidized glutathione) with gentle stirring. After the addition of the protein 




The PL3 protein was first purified by cation exchange chromatography. A self-
packed column with SP-Sepharose Fast Flow beads (GE Healthcare, UK) was 
equilibrated with equilibration buffer (50 mM Tris-HCl pH 8.0, 100 mM NaCl). 
Precipitated protein was removed from the refolding solution by centrifugation 
at 15, 000 g for 30 minutes (Beckman JLA 10.500 rotor); solubilised protein 
sample was diluted to 2.5 L with Milli-Q H2O and loaded onto the column. 
Subsequently the column was re-equilibrated with equilibration buffer (50 mM 
Tris-HCl pH 8.0, 100 mM NaCl). PL3 was eluted with an ascending NaCl 
gradient in equilibration buffer (from 0.1 M to 1.5 M NaCl). Fractions with 
raised UV trace were analysed by gel electrophoresis.  
 
The protein sample was further purified using reverse phase HPLC 
chromatography. A Jupiter C4 column (Phenomenex, USA) was used. The 
column was washed with 95% buffer B (HPLC-grade acetonitrile with 0.08% 
trifluoroacetic acid (TFA)) and equilibrated with 95% buffer A (degassed 
HPLC-grade H2O with 0.1% TFA) prior to protein loading. The column was re-
equilibrated with buffer A after the protein was loaded; and the protein was 
eluted with an increasing Buffer B concentration. Fractions with raised UV 
trace were pooled and lyophilised overnight. The lyophilised protein sample 
was dissolved in HPLC-grade H2O, and analysed by gel electrophoresis. 
 
 
